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Various studies have documented the alleviation of the symptoms of inflammatory 
disease associated with live helminth infection.  The advancement of proteomic 
techniques in tandem with the genomic characterisation of several hookworm species 
has enabled the investigation of individual molecules to be pursued.  Research 
subsequently described several excretory-secretory (ES) proteins exhibiting 
sequence homology to a family of mammalian proteins known as tissue inhibitors of 
matrix-metalloproteinases (TIMPs).  Several homologues of these TIMP-like proteins 
have now been described in human helminth parasite species.  With humans as a 
natural host, and with thousands of years of co-evolution, it is not unreasonable to 
suggest that TIMP-like proteins from hookworm species that primarily parasitise 
humans may not only reveal anti-inflammatory efficacy, but may indeed be better 
suited for development as potential human therapeutics.  This was a defining factor in 
the selection of Na-AIP-1, from the secretions of human hookworm Necator 
americanus, for further screening.  It is my hypothesis that Na-AIP-1 can act as an 
effective anti-inflammatory agent by inducing a regulatory immune environment.  As 
such, Na-AIP-1 presents as an excellent candidate for pre-clinical development as a 
novel biologic in the treatment of inflammatory bowel disease (IBD) and other 
inflammatory disorders, and this provides the basis of the research contained within 
this thesis.   
Na-AIP-1 was initially screened as an anti-colitic agent in the acute TNBS-induced 
model of murine colitis.  Further evaluation was then conducted in the more robust 
CD4+ CD25- adoptive transfer model of chronic murine colitis.  Immunological studies 
were performed in order to evaluate the effect of Na-AIP-1 administration on key 
leukocyte populations in healthy mice, identifying tissues and cellular phenotypes in 
which the protein localises to and associates with.  Finally, next generation sequencing 
was performed on colon tissue samples harvested from mice protected against 
chronic murine colitis by Na-AIP-1 administration. 
In the TNBS-induced model of acute chemically-induced colitis, prophylactic i.p. 
delivery of Na-AIP-1 protected against inflammatory pathology.  This was 
demonstrated across immunologically distinct murine strains, and appears dependent 
on the presence of CD11c+ cells.  In the T cell transfer model of murine colitis, 
v 
 
prophylactic i.p. delivery similarly was able to curtail inflammation, reducing the 
presence of inflammatory CD4+ T cells in the colon.  After injection into mice, Na-AIP-
1 predominantly associates with CD11c-expressing antigen-presenting cells in the 
lung and colon, which was associated with FoxP3+ cell population expansion at these 
sites. Transcriptional profiling of the colon tissue-specific immunomodulatory response 
induced by Na-AIP-1 in the T cell transfer colitis model revealed multiple anti-
inflammatory biological pathways that are shared with anti-IL-12/23p40 monoclonal 
antibody treatment.  However, Na-AIP-1 appeared to uniquely influence several 
biological processes, including the upregulation of fatty acid metabolism, the 
suppression of TGF-β signalling, and the downregulation of the coagulation cascade.   
These studies have for the first time validated the immunomodulatory capabilities of a 
recombinant human helminth-derived TIMP-like protein in suppressing inflammation 
in various murine strains and models of induced colitis. 
 
Commonly used abbreviations 
Abbreviation Definition 
A. caninum Ancylostoma caninum 
BAL bronchoalveolar lavage 
CD Crohn's disease 
CLP colonic lamina propria layer 
DC dendritic cell 
DSS dextran sulfate sodium 
EDTA ethylenediaminetetraacetic acid 
ES excretory/secretory 
EtOH ethanol 
HA human albumin 
hr hour 
IEL intraepithelial layer 
IBD inflammatory bowel disease 
kg kilogram 
L3 third stage larvae 
mAb monoclonal antibody 
min minute 
mg milligram 
MMP matrix metalloproteinase 
N. americanus Necator americanus 
PBS phosphate buffered saline 
PEC peritoneal exudate cells 
P. pastoris Pichia pastoris 
TcT adoptive T cell transfer  
Th1 Cd4+ T helper 1 
Th2 CD4+ T helper 2 
TIMP tissue inhibitor of matrix metalloproteinase  
TNBS 2,4,6-Trinitrobenzenesulfonic acid 
TREG T regulatory  
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Inflammatory bowel disease (IBD) is a blanket term describing Crohn’s disease (CD), 
ulcerative colitis (UC) and a small cluster of less common, but similarly idiosyncratic, 
autoimmune colitic conditions.  Escalating incidence in developing countries, 
combined with the existing prevalence of IBDs in westernised nations, has led to its 
emergence as a global disease of significant burden (Molodecky et al. 2012); in 
Australia alone, the economic costs associated with the management of this insidious 
disorder have skyrocketed to over $3 billion per year (PricewaterhouseCoopers 2013).  
Despite this, effective medical management of IBD remains elusive; whilst treatments 
exist, they are often poorly tolerated or minimally effective, underlining a need for the 
development of novel treatment strategies.   
The recognition of an inverse correlation between autoimmune disease incidence and 
the prevalence of human parasitic infection has led to the suggestion that helminths 
might possibly be exploited as a therapeutic.  Multiple studies have described the 
potential efficacy of live parasitic helminth infection in alleviating symptoms of 
inflammation, in both human and animal models of disease (Correale and Farez 2011, 
Fleming et al. 2011, McSorley et al. 2011, Navarro et al. 2016).  Consequently, there 
is interest in identifying potential immunomodulatory proteins secreted by helminths, 
which could be produced as a safer and more acceptable alternative to live worm 
therapy. 
The studies outlined within this thesis explore the pre-clinical development of a unique 
candidate molecule isolated from the secretions of the anthropophilic hookworm 
Necator americanus (Na-AIP-1), and its potential application as a novel anti-
inflammatory biologic in the treatment of IBD.  Section 1.1 gives background to the 
pathology of IBD, and current pathways for the treatment and management of this 
condition.  In section 1.2, the rationale and evolution of helminth therapy in the 
treatment of inflammatory disease is explored.  The scope of this thesis is described 




1.1 Inflammatory Bowel Disease 
1.1.1 Clinical Manifestation 
Emerging most commonly in early adulthood, IBDs are chronic, refractory disorders 
that are classified in accordance with the nature of their respective immunological and 
pathological features. Ultimately, the disorders are characterised by hyper-responsive 
inflammatory reactions and compromised epithelial barrier integrity (Clayburgh et al. 
2004, Xavier and Podolsky 2007, Bradford et al. 2012).  Clinically, IBDs present with 
episodic bloody diarrhoea, rectal bleeding, abdominal pain, fever, fatigue and weight 
loss. Periods of active disease can be accompanied by extra-intestinal manifestations; 
commonly cutaneous or rheumatic, although ocular, metabolic and renal involvement 
is also documented (Baumgart and Sandborn 2007, Levine and Burakoff 2011, 
Vavricka et al. 2015). 
UC, as the name suggests, is limited exclusively to the colon.  Disease activity can be 
pancolitic or restricted to a specific segment of colonic tissue.  Whilst relatively 
superficial in comparison to CD, exacerbation of inflammatory activity generates 
multiple, clearly defined lesions, producing a distinctive pockmarked appearance.  
Advances in both diagnostics and management have reduced morbidity rates for UC; 
however, in frequently relapsing patients, the likelihood of repeated severe attacks 
combined with a heightened propensity to colorectal malignancies results in colectomy 
being performed in approximately 20% of those diagnosed (Waterman et al. 2015) 
Inflammation in CD is distinguishable by the transmural, serpiginous nature of the 
lesions (Figure 1.1), which can present at any point of the digestive tract from mouth 
to anus.  Significant activity in the tissue of the colon and ileum occurs in the majority 
of patients (Abraham  and Cho 2009, Jostins et al. 2012).  As the disease progresses, 
strictures and fistulae commonly feature, and as such surgical intervention to avoid 
obstruction is necessary in around 75% of patients over their lifetime (Bernstein et al. 
2010, Baumgart and Sandborn 2012).  Given the systemic nature of the disorder 
however, this is not a curative measure, and CD is now generally considered to be the 





Figure 1.1: Colonoscopy imagery illustrating the ulceration characterising the 
two main subtypes of IBD.  Normal colon from a healthy subject (A).  In contrast, 
deep serpiginous ulceration (B) is a feature of CD whereas UC can be recognised by 




The evolution of genome-wide association studies has enabled the identification of a 
raft of gene alleles which are associated with an increased susceptibility to IBD.  Single 
nucleotide polymorphism-bearing candidate genes may be correlated specifically with 
either CD or UC, or both (Error! Reference source not found.).  The functionality of 
said genes are various but largely associated with innate mucosal defence; although, 
genes affiliated with immune cell recruitment, antigen presentation, T and B cell 
regulation, cell migration and autophagy are also implicated (Khor et al. 2011, 
Christophi et al. 2012). In CD, diminished or erroneous expression of the Muc1 and 
Muc19 genes (Buisine et al. 1999, Franke et al. 2010) compromises the mucin layer 
of the epithelium.  This, in combination with a reduction in the expression of tight 
junction proteins encoded by Cldn5 and Cldn8 (Zeissig et al. 2007), increases bowel 
wall permeability and enables the infiltration of the lamina propria with luminal 
antigens, initiating inflammation (Baumgart and Sandborn 2012).  Conversely, in UC, 
mucin disruption is more likely precipitated by flawed Muc2 transcription (Tytgat et al. 
1996, Ordas et al. 2012).  Epithelial cells are corrupted by the over expression of pore-
forming protein claudin-2 tight junction protein (Das et al. 2012), and basement 
membrane vulnerability instigated by a deviation in the Lamb1 gene (Anderson et al. 
2011, Ordas et al. 2012). A more complete understanding of the specific domains and 
variations which correlate most strongly with the susceptibility to these disorders will 
follow as bioinformantic techniques and reference databases continue to evolve. 
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Table 1.1:  Genetic and environmental factors implicated in IBD pathogenesis. 
Genetic alleles Environmental triggers 
CD-specific UC-specific pan-specific 
Nod2 Card11 Card9 Infection 
Hla Park7 Ccl20 Diet 
Mst1 Nfkb1 Xbp1 Appendectomy 
Atg16l1 Muc2 Il23r NSAIDs 
Muc1 Lamb1 Stat1 Dysbiosis 
Muc19 Arpc2 Jak2 Stress 
(Cho 2008, Khor et al. 2011, Jostins et al. 2012, Wallace et al. 2014, Liu et al. 2015) 
 
1.1.3 Immunology 
Initial insights painted UC as strictly mimicking a CD4+ T helper 2 (Th2) effector cell 
driven response, and CD that of CD4+ T helper 1 (Th1) (Fuss et al. 1996, Parronchi 
et al. 1997, Heller et al. 2002).  Cellular and cytokine profiling has however revealed 
a more complex immunological milieu, featuring innate, adaptive and regulatory 
immune association, and further underlining the dichotomy between CD and UC 
(Table 1.2).   
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Table 1.2: Cytokines and transcription factors implicated in IBD pathogenesis 
 
(Xavier and Podolsky 2007, Baumgart and Sandborn 2012, Nemoto and Watanabe 
2012, Yamamoto-Furusho et al. 2016) 
 
In CD, the failure of the epithelial barrier and subsequent antigenic intrusion of the 
lymphocyte-rich lamina propria instigates an immune response dominated by Th1 
IFNγ secreting cells (Figure 1.2).  Over-secretion of IL-12 by antigen-presenting 
macrophages and dendritic cells drives the adaptive immune component of CD; a 
finding supported by the increased level of lamina propria IL-12 detected in CD 
patients.  IL-12 promotes Th1 cell differentiation, and further stimulates their 
production of pro-inflammatory cytokines IFNγ and TNF.  Acute-phase response 
mediator IL-6, and IL-17, a pro-inflammatory cytokine additionally involved in 
monocyte/macrophage recruitment, are also present in elevated concentrations.  UC 
is also characterised by epithelial barrier deterioration, albeit by differential 
mechanisms. Presentation of commensal microbiota antigens activates non-classical 
CD1b-restricted NKT cells (Bendelac et al. 2007), a phenotypically unique lymphocyte, 
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exhibiting characteristics of both innate NK cells and adaptive T cells (Fuss et al. 
2004).  The activated NKT cells then go on to release high levels of IL-13, 
compromising epithelial cells by both triggering apoptosis pathways and increasing 
formation of the claudin-2 protein (Strober and Fuss 2011, Das et al. 2012).  At this 
point a further divergence from the cytokine profile observed in CD has been noted; 
most strikingly, an elevation in IL-5 but not in IFNγ, leading to the initial hypothesis of 
UC being a Th2-governed condition.  However, data collated and reviewed by Strober 
and Fuss (2011) and further by Geremia et al. (2014) confirms the conspicuous 
absence of IL-4 which is traditionally heavily expressed by these cells, leading to a 
reclassification of UC as an ‘atypical Th2-like condition’.  Surprisingly, and in conflict 
with previously published studies (Fuss et al. 1996, Fuss et al. 2004) there have been 
reports of ex-vivo culturing of biopsies from UC and CD patients showing no difference 
in IFNγ (Rovedatti et al. 2009) or IL-13 concentrations (Bernardo et al. 2012, Geremia 
et al. 2014) between the conditions, or in some cases, when compared to healthy 
controls. This further highlights the inability to cleanly classify CD and UC as mere 





Figure 1.2:  The mechanisms of development of colitic inflammation in IBD.    In 
CD, reduced mucus and corrupted tight junction proteins lead to an influx of antigens 
to the lamina propria, instigating a Th1-like response. In UC however, a flawed mucus 
layer and perforation of the epithelial layer are responsible for the antigenic 
stimulation, and the immune response more closely resembles that of the Th2 subset. 
 
The discovery of the Th17 T cell subset, and its characterisation as a major effector 
cell in the autoimmune landscape, instigated an evolution in the understanding of IBD 
immunology.  IL-6, dominant in CD and UC cytokine profiles, promotes Th17 T cell 
differentiation to the IL-17a secreting subtype, mediated via the RORγt transcription 
factor (Manel et al. 2008).  Indeed, IL-17 expression has been found to be elevated in 
patients suffering from CD & UC (Fujino et al. 2003, Towne et al. 2012, Neurath 2014).  
 
 9 
Interestingly, studies conducted in animal models of CD instead implies an abundance 
of the IL-23 cytokine; a heterodimeric inflammatory mediator which shares the IL-12b 
(p40) sub-unit, and accordingly can be targeted by anti-IL-12 antibodies (Towne et al. 
2012, Neurath 2014). This becomes clinically relevant with the discovery that IL-23 
instigates the skewing of Th17cells towards the IFNγ-producing pro-inflammatory 
phenotype, and importantly, suppresses expression of FoxP3, the hallmark of anti-
inflammatory regulatory T (TREG) cells.  Without the influence of IL-23, Th17cells adopt 
an IL-10 secreting phenotype, which encourages the expression and expansion of 
CD4+ FoxP3+ TREG cell populations (McGeachy et al. 2007) ( 
Figure 1.3).  Accordingly, whilst it is clear the Th17 subset of cells plays a role in the 
induction and maintenance of inflammation in IBD, there has been conjecture over 
whether this is in the role of an inflammatory effector cell, or in the suppression of the 
TREG subset.  When considering however the presence of Th17 cells and cytokines in 
UC, coupled with the distinct lack of IFNγ, it appears clear that its influence, at least in 
this condition, is in the quelling of FoxP3 expression.  
 
 
Figure 1.3:  Cytokine-driven modulation of Th17 cell phenotype.  In the context of 
IBDs, an abundance of IL-6 and IL-23 secretion by antigen presenting cells skews 
Th17 differentiation towards a pro-inflammatory phenotype.  In their absence, the 
pleitropic Th17 cell can adopt characteristics which encourage the regulation of an 
anti-inflammatory environment. 
 
1.1.4 Treatment Pathways 
No curative intervention for IBD exists at this time.  Current treatment protocols focus 
on the alleviation of symptoms associated with active inflammation, and the 
maintenance of periods of remission.  Pharmaceutical treatments broadly fall into five 
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categories - anti-inflammatories, immunosuppressives, antibiotics, probiotics and 
biologics - which may be delivered exclusively, or in combination, dependent on the 
individual (Bressler et al. 2015, Regueiro et al. 2016). 
 
1.1.4.1 Anti-inflammatory drugs 
Aminosalicylate (ASA) drugs sulfasalazine, mesalazine, olsalazine or balsalazide are 
used the first line in the management of mild to moderate active IBD, showing 
particular efficacy in the maintenance of remission in UC (Nielsen and Munck 2007, 
Baumgart and Sandborn 2007, Mattar et al. 2011). Although the mechanism of action 
has not as yet been fully elucidated, it is known that these drugs selectively target 
gastrointestinal mucosa (Podolsky 2002, Carter et al. 2004). Whilst nonsteroidal anti-
inflammatory drugs (NSAIDs) are largely efficacious in the treatment of inflammation, 
as a class of drugs they are generally evidenced to contribute to poor gastric outcomes 
when consumed on a regular basis.  Documented adverse effects include gastric 
discomfort, ulceration and bleeding (Fries et al. 1991), in addition to a disruption in 
renal and cardiovascular homeostasis (Kawada et al. 2012).  Indeed, a review 
conducted by Nielsen and Munck (2007) found data revealing 30% of patients 
undertaking treatment with sulfasalazine reporting adverse effects, and, remarkably, 
up to 80% of male patients also showing evidence of semen abnormalities.  Later 
formulations improved tolerability (Kruis et al. 2009, Sandborn et al. 2009), and 
accordingly mesalazine remains the cornerstone in treatment and maintenance 
regimes for moderate UC (Triantafillidis et al. 2011, Baumgart and Sandborn 2012).  
More recent data has brought into question any efficacy of mesalazine in the control 
of CD (Lim et al. 2016). 
 
1.1.4.2  Immunosuppressive drugs 
Immunosuppressive drugs which inhibit the proliferation of lymphocytes and activation 
of inflammatory pathways, including azathioprine, methotrexate, cyclosporine and 
tacrolimus, are regularly utilised in moderate to severe active IBD (Gionchetti et al. 
2017).  These drugs are used in conjunction with, or after the failure of, conventional 
ASA treatment. Delivered orally or intravenously, immunosuppressive drugs play a 
significant role in the induction and maintenance of remission in difficult to treat 
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refractory colitis, particularly in CD (Baumgart and Sandborn 2012, Zenlea and 
Peppercorn 2014).  The capacity of this treatment methodology to reduce 
inflammation however is countered by the patients’ subsequent vulnerability to 
opportunistic infection and neoplastic development, in addition to the nephrotoxicity, 
leukopaenia, seizures and anaphylaxis which can arise from the medium to long term 
use of steroidal anti-inflammatory drugs.  Accordingly, in a clinical setting, 
discontinuance of immunosuppressive therapy due to adverse events is reported in 
up to 25% of patients, in addition to the 30% of individuals for whom these drugs will 
not be effective (Triantafillidis et al. 2011, Meyer et al. 2015).  
 
1.1.4.3 Antibiotics 
Whilst displaying limited capability to induce remission when employed as a primary 
therapeutic strategy (Sutherland et al. 1991, Steinhart et al. 2002, Su et al. 2015), 
clinical guidelines recommend the use of antibiotics as an adjunct for the treatment of 
infections and septic toxicities arising from fistulising IBD (Nitzan et al. 2016). 
However, given the recognition of intestinal dysbiosis as a trigger to disease activity 
(Loh and Blaut 2012, Wallace et al. 2014), a more complex role for antibiotics in the 
modulation of the microbiome, and therefore the maintenance of remission, has been 
proposed (Kerman and Deshpande 2014).  The long-term use of antibiotics in the 
management of IBDs is however tempered by the evolving issue of antibiotic 
resistance, and meta-analyses which suggests paediatric antibiotic use may prompt 
an early onset of IBD in susceptible individuals (Hviid et al. 2011, Ungaro et al. 2014).  
Further systemic negative outcomes associated with prolonged antibiotic use include 
soft tissue damage, neurotoxicity, cardiotoxicity, hepatotoxicity and gastrointestinal 
disturbance (Bertino and Fish 2000, Knorr et al. 2008, Sarna et al. 2013, Nitzan et al. 
2016).  An increased vulnerability to Clostridium difficile infection, an intestinal 
infection associated with especially poor outcomes in IBD sufferers, has also been 






The modulation of commensal microbiota as a therapy, using probiotics, has been 
explored since the identification of several specific bacterial species/strains which 
appear to be associated with the induction of inflammatory disease activity when 
present in abundance (Willing et al. 2010, Chassaing and Darfeuille-Michaud 2011, 
Nagalingam and Lynch 2012, Comito and Romano 2012, Norman et al. 2015).  The 
rationale behind probiotic treatment applies the hypothesis that the supplementation 
of beneficial, protective microbial strains will competitively inhibit pathogenic strains, 
restoring intestinal homeostasis and prolonging periods of remission (Jonkers and 
Stockbrügger 2003, Sartor 2004).  Pilot studies have confirmed tolerability of varying 
microbial formulations (Kruis et al. 2004, Miele et al. 2009), however clinical trial data 
remains sparse.  In recent reviews, the current consensus appears to support the 
benefit of strains of Bifidobacterium, Lactobacillales and non-pathogenic E. coli as an 
adjunct to remission maintenance in UC, with no current data to support any efficacy 




Recent advances in biotechnology have seen the development of biologic drugs; 
monoclonal antibodies which bind to the molecules involved in inflammatory pathways 
and inhibit their activation/proliferation. First generation biologics approved for use in 
IBD targeted TNFα (infliximab, adalimumab, certolizumab and golimumab) and 
integrins (natalizumab and vedolizumab). The contemporary nature of these drugs 
means there is limited long term data, nor is there any head-to-head study comparing 
efficacy and tolerability between all formulations, but several meta-analyses have 
been published.  The consensus supports the use of anti-TNFα and anti-integrin 
agents in the induction and maintenance of remission in CD (Stidham et al. 2014a, 
Hazlewood et al. 2015, Danese et al. 2015) and UC (Reinisch et al. 2012, Stidham et 
al. 2014b), albeit with unanimity in the selection of the most effective formulation. A 
second wave of biologics is currently in development; tofacitinib, targeting the 
JAK/STAT pathway, has shown efficacy in the induction of remission in UC (Danese 
et al. 2015, Sandborn et al. 2017), however trials recorded significant cardiovascular 
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events (including fatal aortic dissection) and multiple cases of melanoma occurring in 
treated individuals (National Library of Medicine US 2016).  Ustekinumab, an 
IL12/23p40 antibody, has been beneficial in CD but again recorded a high proportion 
of both serious and minor adverse events in clinical trials (National Library of Medicine 
US 2014).  Accordingly, whilst these biologic drugs show competence as a rescue 
therapy, they are currently indicated for use when the patient has not responded to, or 
is unable to tolerate, conventional treatments (Carter et al. 2004, Bernstein et al. 2010) 
 
1.1.4.6 Cellular therapies 
Borrowing from transplant medicine, the use of cellular therapies as a treatment for 
autoimmune colitis and its comorbidities is now being explored.  This sophisticated 
concept follows a disease-modifying approach, in the hopes of bypassing the adverse 
effects and lack of efficacy often observed in traditional pan-immunosuppressive 
therapies.  The adoptive transfer of mesenchymal stem cells (MSCs) in the treatment 
of anal fistulae in CD has been proposed.  MSCs have long been understood to play 
a role in in immune regulation, by way of the induction of t cell anergy, the promotion 
of TREG proliferation and an enhancement in tissue repair (Glennie et al., 2005).  
Studies have confirmed the tolerability of this method and, whilst the molecular 
mechanism of action has not been defined, fistulae remission rates were significantly 
higher at 12 months when compared to placebo (Panés et al., 2018).  Despite this, 
MSC-treated individuals reported a high number of adverse events, including 
abscesses and proctalgia, and concerns over the longer term pro-tumorigenic 
influence of MSCs remain.  An alternate approach involves the in vivo enhancement 
of TREG populations.  To that end, these therapies are designed to either directly 
stimulate the expansion of native TREGS, or involve the reinfusion of modified donor 
TREGS, in order to inhibit the activation of effector T cells (Fantini and Monteleone, 
2017, Roth-Walter et al., 2020).  Studies involving the adoptive transfer of antigen-
specific TREGS targeting autoantibody producing B cells (Blat et al., 2014) and over-
expressed mucosal antigens (Elinav et al., 2009) have both reported compelling 
therapeutic capabilities in murine models of colitis.  Factors including a wide variation 
in both yield and surface receptor presentation between human TREG donors and the 
high technical costs involved in manufacturing the antigen-specific TREGS have limited 




1.1.4.7 Surgical intervention 
Surgical intervention is recommended in individuals with fistulising or obstructive IBD, 
when toxic complications arise, or when pharmaceutical therapies have failed to 
manage the symptoms of disease.  The World Gastroenterology Organisation has 
reported that surgery becomes necessary in up 75% of CD sufferers, and 30% of those 
diagnosed with UC (Bernstein et al. 2010); figures which are supported by meta-
analysis of available data (Carter et al. 2004, Bennis and Tiret 2012, Yu et al. 2016).  
Whilst total or partial colectomy remedies localised colitis, it is ineffective in controlling 
extra-intestinal manifestation of IBD, and therefore not considered curative.  Surgical 
management is not without complication; pouchitis, pelvic sepsis, faecal incontinence 
and diarrhoea are common (Ba'ath et al. 2007, Shung et al. 2015), and up to 70% of 
individuals require surgical reintervention within 15 years (Hwang and Varma 2008).  
Further complications, inherent to the formation of a stoma and including localised 
ischemia, bowel obstruction, and retraction, prolapse or herniation of the stoma site, 
are also to be considered (Kim and Kumar 2006). 
 
Whilst this demonstrates the existence of a variety of treatment options for the 
induction and maintenance of remission in both UC and CD, it also highlights the 
issues of inconsistent efficacy, and the concomitant adverse effects which come as a 
consequence of said interventions.  As such, the motivation to discover novel 
therapeutic strategies for IBD is high.   
 
1.1.5 Aetiology and the “old friend” hypothesis 
In a systematic review of data conducted by Molodecky et al. (2012), a clear pattern 
of increased prevalence of IBD in industrialised nations emerged, with a further 
revelation of increasing incidence not only in these urbanised regions, but also in 
developing countries where previously both incidence and prevalence rates had 
remained relatively low. This is supported by data provided from studies conducted in 
India (Desai and Gupte 2005, Ray 2016), China (Zhai et al. 2016), Croatia (Lakatos 
and Lakatos 2006, Pezerovic et al. 2014) and Latin America (Barreto et al. 2010, 
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Yamamoto-Furusho et al. 2017), where aspects of diet, lifestyle and sanitation have 
changed dramatically within a generation.   
The hygiene hypothesis published by Strachan (1989) shaped initial theories 
regarding this association between IBD incidence and global urbanisation.  Strachan 
speculates that modern hygiene practices and the resultant decrease in infection 
transmission would lead to a lower demand for the Th1 subset of immune cells, which 
are active during bacterial and viral invasion.  Instead, T cell differentiation would be 
preferentially skewed towards the pro-allergenic Th2 subset, and the resultant 
imbalance would increase the likelihood of allergen hypersensitivity and unregulated 
Th2 activation (Strachan 1989).  The simplistic view of competing Th1/Th2 profiles 
was soon contradicted by the profile of immune-mediated inflammatory disorders 
including rheumatoid arthritis (Simon et al. 1994), type 1 diabetes and multiple 
sclerosis (MS) (Liblau et al. 1995). 
Following these developments, Rook and Brunet (2005) revisited the hygiene 
hypothesis and presented their own reinterpretation: the ‘old friend’ hypothesis.  This 
theory, whilst also citing the changes to modern standards of living as being heavily 
influential in the development of these immune-modulatory disorders, further 
expanded on this rationale.  The ‘old friend’ hypothesis proposes reduced contact with 
primordial microorganisms, including parasitic helminths and mycobacteria, as 
influencing immunity by way of the regulation of immune cell activity, rather than via 
Th1/Th2 cell differentiation.  Since Palaeolithic times, and throughout the evolution of 
the mammalian immune system, humans have been inevitably and continuously 
exposed to certain environmental and microbial organisms.  As a persistent 
inflammatory response would be detrimental to the human host, these microorganisms 
were recognised and largely tolerated by the host immune system.  Mechanistically, 
this hypothesis revolves around a heightened proliferation of CD4+ FoxP3+ (TREG) 
cells, which fulfil the role of suppressing the activity of immune effector cells and 
subsequently can quell inflammation.  The co-existence of humans with primordial 
microorganisms developed into mutualistic symbiosis, with TREG proliferation and 
activation being largely driven by interaction with these “old friends”.  The industrial 
revolution and the subsequent progression to higher standards of living all but 
eradicated contact with many of these microorganisms in urbanised nations.  
Accordingly, without their instigation, TREG-driven modulation of response is reduced 
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and inappropriate immune activity occurs (Rook et al. 2013).  Interestingly, a 
comparison of the prevalence of soil-transmitted helminthiases and the incidence of 
IBD illustrates an inverse correlation between the two (Figure 1.4), lending weight to 
the ‘old friend’ hypothesis and raising suggestion of a possible negative association 
between IBD and helminthiases.  
 
 
Figure 1.4: Comparison of the geography of IBD incidence (IBD) and human soil-
transmitted helminthiases (STH) prevalence.  Comparison of the geography of IBD 
incidence (IBD) and human soil-transmitted helminthiases (STH) prevalence. Areas 
shaded in red in the left panel signify moderate to high incidence of IBD (Molodecky 
et al. 2012, Ng et al. 2017).  Areas shaded in red in the right panel indicate countries 
where infection with soil-transmitted helminths is considered endemic (World Health 
Organisation 2016). 
 
1.2  Helminth Therapy 
The suppression of inflammatory responses in human parasitic infections has been 
the subject of much investigation.  Up-regulation of IL-10-secreting TREG cells has been 
documented during both in vivo animal experiments of helminth infection (Elliott et al. 
2008, Wilson et al. 2005, Layland et al. 2010) and in vitro assays utilising hookworm 
secretions (Cuellar et al. 2009).  There is also suggestion of further immunoevasive 
mechanisms in anthropophilic helminths, including macrophage driven diminished T 
cell reactivity via selective up-regulation of programmed death ligand 1 (Smith et al. 
2004, Smith et al. 2007), and skewed antigen presentation, by way of co-stimulatory 
molecule suppression (Fujiwara et al. 2009).   
Naturally, from this the possibility of utilising helminths as therapeutics in inflammation-
based disorders arose.  Studies conducted in MS patients harbouring intestinal 
parasites showed a significant reduction in disease activity when compared over time 
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to uninfected counterparts (Correale and Farez 2007, Correale and Farez 2011, 
Fleming et al. 2011).  Feary et al. (2010) reported a trend towards improved airway 
responsiveness when harbouring established N. americanus infection.  A clinical trial 
involving sufferers of Celiac Disease (CeD), a gastrointestinal condition also mediated 
by immune dysregulation, additionally illustrated compelling outcomes when utilising 
helminths in the reduction of gluten-induced inflammatory cytokine responses and 
stabilised intestinal immunopathology (McSorley et al. 2011, Croese et al. 2015).  
These results, whilst not definitive, are encouraging and confirmed safe tolerability of 
the parasites during a diseased state. In considering these results in conjunction with 
the current evidence of the evolution of autoimmune IBD in modern society, a valid 
research hypothesis has arisen: that helminth therapy may be effective in the 
treatment of inflammatory GI diseases. 
 
1.2.1 Experimental helminth infection in the treatment of IBD 
One of the earliest studies testing the hypothesis that helminth exposure could be 
beneficial in IBD was conducted using a mouse model of disease by Elliott et al. 
(2002); interestingly, prior to the current depth of understanding of T cell classification 
and activity, and preceding Rook and Brunet’s seminal paper outlining their ‘old friend’ 
hypothesis.  However, the results and conclusions put forward by Elliott et al. (2002) 
give the first indications of a new perspective on the origin of autoimmune 
inflammatory disorders.  Experimental mice were administered intraperitoneal 
injections of Schistosoma mansoni ova on days 0 and 10 of the treatment period, then 
rectally administered Trinitrobenzenesulfonic acid (TNBS) on day 14, inducing Th1-
modulated inflammation of the colon considered to present a clinical profile suitably 
mimicking that seen in human CD (Scheiffele and Fuss 2002).  The results of this 
study indicated significantly lower pathology and mortality in mice receiving TNBS that 
were exposed to the schistosome eggs, compared with those treated with TNBS 
alone.  Cytokine analysis conducted post necroscopy led to the hypothesis that a Th2 
response to the S. mansoni ova curbed colonic inflammation, although the authors 
conceded the absence of an increase in Th2 cytokine IL-4.  Elevated IL-10 production 
was observed in mice administered S. mansoni eggs and TNBS, and not in those 
receiving TNBS alone, nor in those receiving eggs alone or healthy control mice. 
 
 18 
Similar principles were followed in original research by Summers et al. (2005a); in this 
study, live Trichuris suis ova were administered to a cohort of 29 human patients with 
active CD.  Whilst this exercise was undertaken primarily to determine the safety of T. 
suis ova administration in those suffering from CD, the results nonetheless reported a 
significant decrease of the CD activity index in over 79% of participants at week 24.  
This same research team subsequently reported on the efficacy of infection with T. 
suis ova in a population of UC patients; again, no adverse events were reported, and 
43.3% of participants reported a reduction in disease activity (Summers et al. 2005b).  
It should be noted that recent completion of phase II clinical trials confirmed the safety 
of this treatment method but reported no clinically relevant effect over 12 weeks in 
individuals with mild to moderately active IBD (Scholmerich et al. 2017). 
Subsequent research outlined an alternate solution for one of the barriers to live 
helminth infection in humans; namely, the lack of maturation and replication in the 
human host, which necessitates frequent reinfection.  An innovative open label study 
conducted by Croese et al. (2006) utilised the Necator americanus hookworm, which 
is known to survive for long periods within the human host.  This study demonstrated 
that CD patients safely tolerated inoculation with the larvae of this anthropophilic 
helminth.  In addition to adequately establishing infection in 100% of the participants, 
a decline in cumulative CD activity scores was also documented.  Similar studies 
exploring the therapeutic potential of N. americanus infection in the treatment of 
asthma were able to replicate the demonstrated safe tolerability of low dose infection 
by this N. americanus (Mortimer et al. 2006, Feary et al. 2010), however the clinical 
efficacy of human hookworm in asthma was not conclusive. 
Daveson et al. (2011) expanded on this concept by conducting a clinical trial in which 
healthy adult CeD patients were inoculated with N. americanus larvae.  In this double-
blind, placebo-controlled phase 1b/2a clinical trial, the protective properties of N. 
americanus were assessed by inducing an autoimmune inflammatory event.  This was 
achieved by way of a heavy 16 gram/day gluten challenge, conducted once 
colonisation by N. americanus was established.  Histopathological assessment of 
duodenal biopsies showed no significant difference in mucosal damage between the 
control and hookworm-infected groups, although a non-significant trend towards 
reduced damage was detected in the hookworm-infected group.  No significant 
differences were detected between groups in the number of circulating immune cells 
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which secrete the pro-inflammatory IFNγ cytokine.  Furthermore, no significant 
differences in clinical symptoms in response to the heavy gluten challenge were 
identified between groups.  Despite these findings, negative outcomes for the N. 
americanus treatment group were less severe than those of the control group, albeit 
not to a level of statistical significance.  Interestingly, at the end of the experimental 
period, all test participants declined anthelminthic treatment. 
A follow-up study to this clinical trial was conducted by McSorley et al. (2011).  This 
investigation involved the infection of seven of the control cohort from the study 
conducted by Daveson et al. (2011) with N. americanus larvae.  Upon maturation of 
the hookworms in the gut, the seven participants again underwent a gluten challenge 
identical to that of the previous trial, and the results were compared to their previous 
data.  Again, no significant difference in the severity of symptoms experienced by the 
participants was detected, however there was a significant decrease in the amount of 
IFNγ and IL-17 secreted by cells from gut biopsies from hookworm-infected patients 
compared to controls after gluten challenge (McSorley et al. 2011). 
Optimisation of the experimental protocol by Croese et al. (2015) resulted in a dramatic 
improvement in results.  In this study, candidates from the Daveson et al. (2011) study 
that were adherent to a gluten free diet in the management of their CeD symptoms 
were once again colonised by N. americanus.  For this study, the infective dose was 
increased from 15 to 20 third stage larvae (L3).  Furthermore, rather than commencing 
the gluten challenge at 16 g per day as per previous convention, gluten exposure was 
initiated at 1 mg per day then gradually increased to 50 mg per day, and finally 3 g per 
day, with a view to desensitise the immune system to the antigens triggering the 
autoantibody response.  This was also suggested to more closely reflect the 
inadvertent consumption of gluten by a diet-managed CeD patient.  
This study produced remarkable outcomes.  The villous height to crypt depth ratio, 
auto-antibody titres and celiac symptom index (CSI) score (in which test subjects self-
assessed the occurrence of CeD symptoms such as bowel habits and episodes of 
gastrointestinal pain) were utilised to gauge the level of inflammatory pathology 
induced by the gluten exposure.  The results indicated no significant difference 
between the pre-trial levels of these parameters, and those recorded upon completion 
of the initial 24-week gluten challenge (Croese et al. 2015), indicating that gluten intake 
by these CeD sufferers was remarkably well tolerated.  This gives some suggestion 
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that helminth infection helped to promote a state of immunological tolerance to the 
ingested gluten (Figure 1.5). 
 
 
Figure 1.5:  Results of research conducted by Croese et al. (2015).  Gluten 
challenge suggests live infection with N. americanus induces a state of immunological 
tolerance to the ingested gluten, illustrated by a reduction in IFNγ expression (A) and 
a concurrent increase in CD4+ FoxP3+ cells (B).  Results are presented as mean ± 
SEM.  p = 0.05, **p = 0.01.   
 
The research design in the reviewed literature has limitations, and this is particularly 
conspicuous in trials involving human participants.  At times participants were required 
to rate the severity of their own symptoms (Summers et al. 2005a, Summers et al. 
2005b, Croese et al. 2006, Croese et al. 2015) which is undeniably subjective and 
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does not account for any placebo effect.  Furthermore, in some of these studies 
participants continued to take any immunosuppressant medications that had been 
prescribed by their healthcare provider, making it difficult to definitively attribute the 
clinical outcome exclusively to helminth therapy. However, as acknowledged by the 
authors, for the most part these experiments were primarily proof of concept pilot 
studies to establish whether live infection could be safely tolerated in individuals with 
active IBD. 
The use of helminths as a form of therapeutic administration, whilst safe, presents 
several barriers.  As noted by Summers et al. (2005a), T. suis ova, whilst not causing 
disease, will only afford a human host a period of brief colonisation, making reinfection 
a frequent necessity.  Larval hookworm colonisation also produced symptoms 
associated with increased gastric motility, including pain, diarrhoea, vitamin deficiency 
and increased flatulence in some subjects, for up to 16 weeks’ post-inoculation 
(Daveson et al. 2011, Croese et al. 2015).  The concept of hosting a colony of live 
parasites may also not be palatable to some individuals.   
In the intervening years, several breakthroughs were made with regards to the 
understanding of the immunological pathways regulating IBD; perhaps of greatest 
importance was the identification and characterisation of both TREG and Th17 as 
individual subsets of T cells, and a greater knowledge of the cross-regulation between 
activated effector T cells.  This enabled research strategies from a more molecular 
perspective. 
 
1.2.2 Secreted molecules from helminths in the treatment of IBD 
With the benefit of previous research having validated the concept of helminth therapy, 
some of the complexities involved in the exposure methodology were able to now be 
addressed (Reardon et al. 2001, Elliott et al. 2002, Khan and Collins 2004).  The 
pitfalls of infecting people with live helminths were specifically highlighted, and it was 
noted that despite the apparent efficacy, numerous hurdles complicated its 
widespread adoption as a valid anti-inflammatory therapy.  Accordingly, the use of 
excretory/secretory products (ES) from anthropophilic helminth species that are 
adapted to survival in humans became a prospective alternative.   
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Infection of mice with live S. mansoni was shown to alleviate the pathology associated 
with TNBS colitis (Elliott et al. 2002), so Ruyssers et al. (2009) accordingly tested the 
efficacy of soluble somatic proteins from this helminth in the same disease model.  
Given the promise that experimental hookworm infections had shown in open label 
trials for treating CD and CeD (Croese et al. 2006, Croese et al. 2015), Ruyssers et 
al. (2009) in parallel also tested the ES proteins secreted by the canine hookworm 
Ancylostoma caninum, to investigate whether beneficial effects were restricted to 
distinct helminth phyla. When comparing the TNBS-induced colitis group against the 
group subsequently treated with S. mansoni proteins, the treated group showed 
significantly reduced macroscopic inflammation and myeloperoxidase activity.  Mice 
treated with A. caninum ES products also experienced similar levels of protection 
against inflammatory insult (Figure 1.6).  
 
 
Figure 1.6:  Effect of S. mansoni proteins (SmSWP) and A. caninum ES products 
(AcESP) in TNBS colitis.  Macroscopic inflammation score (A-B) and 
myeloperoxidase activity (C-D) of colon tissue in TNBS-treated mice.  Data presented 
as mean ± SEM. *p = 0.05, significantly different from the control-PBS group; #p = 




The post-necropsy cytokine profiles of the mice that had been administered helminth 
proteins indicated a transition from the pro-inflammatory Th1 and Th17 response 
towards a regulatory response, characterised by an upregulation of IL-10 and TGF-β.  
Accordingly, this ground-breaking study illustrated not only an effective potential 
alternative to live helminth infection, but also that positive outcomes were observed 
utilising proteins secreted by parasitic worms of different phyla.  
Alternate models of murine chemical colitis have been utilised to study the effects of 
helminth ES products on colon inflammation (Table 1.3).  One of the most frequently 
used approaches is to induce colitis via the consumption of drinking water in which 
dextran sulfate sodium (DSS) had been dissolved.  DSS-induced colitis develops less 
rapidly than TNBS-induced colitis.  Whilst initially both models produce a Th1-
mediated colitis, mimicking CD in humans, DSS-induced colitis traditionally shifts to a 
Th2-regulated disease model, and is generally considered a more typical reflection of 
UC (Alex et al. 2009). Unlike Ruyssers et al. (2009) who used ES products from a 
canine hookworm, Cançado et al. (2011) used both ES products and a somatic extract 
from Ancylostoma ceylanicum, a hookworm that readily completes its life cycle in both 
dogs and humans. Clinical indicators of disease throughout the experimental period 
were significantly lower in mice that were fed DSS and received intra-peritoneal 
injections of hookworm proteins than control mice that were fed DSS and injected with 
PBS. However, no significant differences were noted in the post-necropsy 
macroscopic scoring of inflammation between these groups.  Mice that received 
hookworm proteins had a significant reduction in Th1 cytokines, but surprisingly, there 
was no corresponding increase in the regulatory cytokine IL-10 as had been previously 




Table 1.3: Helminth ES molecules and their efficacy in murine models of colitis 




A. caninum AcESP * Therapeutic TNBS 
Reduced disease activity.  




C. sinensis rCsStefin-1 Therapeutic DSS 
Reduced disease activity.  
Decreased IFNγ, TNFα, IL-
17.  Increased IL-10. 
Jang et al. 
(2011) 
A. ceylanicum AcES * Prophylactic DSS 
Reduced disease activity.  
Decreased TNFα.   
Cançado et 
al. (2011) 
A. simplex rAs-MIF Prophylactic DSS 
Reduced disease activity.  
Decreased IFNγ, IL-6, IL-13.  
Increased IL-10. 
Cho et al. 
(2011) 
T. spiralis rTsP53 Prophylactic TNBS 
Reduced disease activity.  
Downregulated TNFα, IL-6 
mRNA.  Upregulated IL-10 
mRNA. 
(Du et al. 
2011) 
A. caninum AcESP * Prophylactic DSS 
Reduced disease activity.  
Increased IL-4, IL-10. 
Ferreira et 
al. (2013) 
B. malayi rBmAsnRS Therapeutic TcT 
Reduced disease activity.  
Increased IL-10. 
Kron et al. 
(2013) 
T. spiralis TsAES * Prophylactic DSS 
Reduced disease activity.  
Decreased IFNγ, IL-6, IL-17.  
Increased IL-10. 
Yang et al. 
(2014) 
A. viteae AvCystatin Prophylactic DSS 
Reduced disease activity.  
Decrease in MPO activity. 
Ziegler et al. 
(2015) 
B. malayi rBmCys Prophylactic DSS 
Reduced disease activity.  
Downregulated in IFNγ, 
TNFα, IL-17 mRNA.  
Upregulated IL-10 mRNA. 
Khatri et al. 
(2015) 
S. japonicum rSjcystatin Therapeutic TNBS 
Reduced disease activity.  
Decreased IFNγ.  Increased 
IL-4, IL-3, IL-10. 
Wang et al. 
(2016) 
S. japonicum rSj16 Prophylactic DSS 
Reduced disease activity.  
Decrease in MPO activity. 
(Wang et al. 
2017) 
A. caninum Ac-AIP-1 Prophylactic TNBS 
Reduced disease activity.  






rAl-CPI Prophylactic DSS Reduced disease activity. 
Coronado et 
al. (2017) 
A. viteae ES-62 Prophylactic 
DSS, 
TcT 






P28GST Therapeutic TNBS 
Reduced disease activity.  
Decrease in MPO activity. 
(Sarazin et 
al. 2018) 
N. brasiliensis NbEVs Prophylactic TNBS 
Reduced disease activity.  
Decreased IFNγ, IL-6, IL-17.  
Increased IL-10. 
Eichenberger 
et al. (2018) 
* crude ES product.  TcT: Adoptive T cell transfer model of colitis. 
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More recently, Ferreira et al. (2013) utilised the DSS-colitis model to comprehensively 
assess the impact of ES products harvested from A. caninum. When assessing the 
colonic pathology of DSS-colitis mice pre-treated with ES proteins, significantly 
reduced macroscopic and microscopic scores were recorded in comparison to mice 
that received DSS alone.  Both circulating cytokine profiles and those local to intestinal 
tissue in hookworm treated DSS colitis mice again displayed significant increases in 
pro-regulatory cytokine levels, accompanied by decreased levels of IFNγ and IL-17.  
Importantly, the upregulation of IL-10 was mirrored in mice receiving the hookworm 
proteins but not DSS, depicting a regulatory influence even in the absence of active 
disease.  Ferreira et al. (2013) showed that the major anti-inflammatory ES products 
of A. caninum (in the DSS model at least) were sensitive to denaturation, and therefore 
likely proteinaceous in origin. 
 
1.2.3  Future directions of research 
Immunology remains one of the most dynamic fields of modern medical science.  
Since the turn of the century, rapid advances in biotechnology have enabled the 
identification and characterisation of many new elements involved in the human 
immune response, and as such theories and preconceptions regarding the 
mechanisms at work and factors involved have also been forced to evolve.  As this 
analysis has illustrated, the theoretical base for the investigations into the use of 
helminths as a potential therapeutic, being the ‘old friend’ hypothesis, has remained a 
viable and plausible doctrine since first being proposed a decade ago; so much so that 
the research within has validated the hypothesis in almost every study, and further has 
been able to demonstrate an improvement in recorded markers of disease in the 
majority of investigations.  Indeed, other than in the results published by Cançado et 
al. (2011), where an up-regulation of TREG signifier IL-10 was not detected, cytokine 
profiles have remained remarkably consistent and suggest a similar mechanism of 
action regardless of helminth genus or indeed phylum. 
One particularly noticeable challenge to the progression of helminth therapy in IBD is 
a lack of consistency in experimental parameters, making comparisons in efficacy 
unrealistic; for example, in the contained publications the use of murine models with 
conflicting patterns of disease progression was noted, namely TNBS-induced versus 
 
 26 
DSS-induced colitis.  In fact, one review recently confirmed that over 65 murine models 
of IBD are in existence, with each representing a differing etiological or disease 
progression archetype (Mizoguchi 2012). 
It could also be argued that certain patterns of the administration of helminth-based 
intervention was questionable in its transferability as a treatment in human conditions.  
Helminth therapy administered prior to the induction of a state of inflammation (Elliott 
et al. 2002, Daveson et al. 2011) explores its utilisation as a prophylactic, whereas 
administration post-induction (Ruyssers et al. 2009) investigates employment as a 
curative intervention.  However, it is difficult to elucidate a rationale behind a study 
illustrating simultaneous administration of helminth therapy with a disease-inducing 
compound (Cançado et al. 2011), and what human situation or setting this represents. 
Moving forward, the consistent successes observed in published data, and our current 
understanding of the immunological milieu involved in autoimmunity, certainly implies 
that it is realistic to expect that helminth therapy can be effective in the treatment of 
IBD.  This ultimately requires a refinement in the direction of research in this field.  
Whilst the general mechanism by which helminth therapy addresses inflammation has 
been illustrated, the molecular function behind this activity has not.  That is to say, 
while it can be accepted that inflammation is being moderated by an up-regulation of 
IL-10 secreting TREG cells, exactly how this up-regulation is occurring is not yet clear.  
Accordingly, the identification, isolation and characterisation of the active molecules 
generating this response is essential.   
The advancement of proteomic techniques in tandem with the genomic 
characterisation of several hookworm species (Tang et al. 2014) enables the 
investigation of individual molecules to be pursued. Proteomic analysis of A. caninum 
ES products revealed the presence of over 200 different proteins, with homologies to 
a remarkable array of functional groups (Morante et al. 2017).  Research conducted 
by Cantacessi et al. (2013) described several ES proteins exhibiting sequential 
homology to a family of mammalian proteins known as tissue inhibitors of matrix-
metalloproteinases (TIMPs).  Unregulated activation of matrix-metalloproteinases has 
been shown to induce both chronic and acute inflammation; TIMPs pinpoint the agent 
triggering the inflammation cascade, and therefore their homologous counterparts 
became a logical candidate for the immunomodulatory behaviours described within. 
Somewhat surprisingly, functional assays revealed that despite sequence similarities 
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with mammalian TIMPs, these hookworm TIMP-like proteins did not display any 
matrix-metalloproteinase inhibitory activity (Cantacessi et al. 2013) 
Of the TIMP-like proteins identified by Cantacessi et al. (2013), Ac-AIP-2 
demonstrated a compelling suppression of airway inflammation in a murine model of 
asthma, and further showed evidence of the curtailment of human T-cell proliferation 
in an ex vivo environment (Navarro et al. 2016).  Similarly, Ac-AIP-1 has been shown 
to exert a potent anti-inflammatory effect in experimental murine colitis by establishing 
a robust pro-regulatory environment (Ferreira et al. 2017). 
Several homologues of these TIMP-like proteins have now been described in human 
helminth parasite species (Cantacessi et al. 2013). With humans as a natural host, 
and with thousands of years of co-evolution, it is not unreasonable to suggest that 
TIMP-like proteins from hookworm species that primarily parasitise humans may not 
only reveal anti-inflammatory efficacy, but may indeed be better suited for 
development as potential human therapeutics 
Whilst the mechanism of action behind the biological activity of the Ac-AIP-2 protein 
remains undetermined, sequence homology to this protein was a defining factor in the 
selection of Na-AIP-1, from the secretions of N. americanus, for further screening.   
 
1.3 Scope of thesis 
It is my hypothesis that Na-AIP-1 can act as an effective anti-inflammatory agent by 
inducing a regulatory immune environment.  As such, Na-AIP-1 presents as an 
excellent candidate for pre-clinical development as a novel biologic in the treatment of 
IBD and other inflammatory disorders, and this provides the basis of the research 
contained within this thesis.   
There were 3 aims explored in this thesis: 
Aim 1:  To assess the anti-colitic properties of Na-AIP-1 in the TNBS model of murine 
colitis under differing experimental parameters.   
Objective 1.1:  To assess whether Na-AIP-1 prophylactic vs. therapeutic 
intervention influences clinical indices and inflammatory responses. 
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Objective 1.2:  To investigate whether administering multiple doses of Na-AIP-
1 will potentiate its anti-colitic effect. 
Objective 1.3:  To investigate whether the anti-colitic effect of Na-AIP-1 is 
reproducible in an immunologically distinct murine strain. 
Aim 2:  To test the anti-colitic efficacy of Na-AIP-1 in the more immunologically robust 
T cell Transfer (TcT) model of murine colitis. 
Objective 2.1:  To conduct physiological, immunological and histological 
assessments to assess whether Na-AIP-1 offers protection against colitis. 
Objective 2.2:  To assess whether Na-AIP-1 prophylactic vs. therapeutic 
intervention influences clinical indices and inflammatory responses. 
Aim 3:  To describe the mechanism of action driving the anti-inflammatory influence 
of Na-AIP-1. 
Objective 3.1:  To conduct immunological assessment including flow cytometry 
to investigate the influence of Na-AIP-1 on in vivo immune cell populations, 
including cell phenotype, frequency and cytokine expression. 
Objective 3.2:  To induce colitis in genetically-modified murine strains to 
observe the influence of specific immune cell phenotypes on the anti-colitic 
performance of Na-AIP-1. 
Objective 3.3:  To conduct Next Generation Sequencing (NGS) to investigate 
the effect of Na-AIP-1 on the murine transcriptome during active disease. 
 
Chapter 2 reports on further results of recombinant Na-AIP-1 in the TNBS colitis 
model.  This objective of this chapter was to explore the anti-colitic performance of Na-
AIP-1 when altering experimental parameters such as the dosing regimen, 
experimental period and mouse strain. 
Chapter 3 explores the anti-colitic efficacy of Na-AIP-1 in a more immunologically 
robust, chronic murine model of colitis.  Colitis was induced in RAG-1 deficient mice 
(RAG KO) via adoptive transfer of CD4+ CD25- T cells.  Na-AIP-1 was delivered both 
as a prophylactic and therapeutic treatment, and the influence of delivery methodology 
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was also explored.  In addition to physiological assessment, the immunological 
consequence of Na-AIP-1 administration in colitic mice is also described. 
Chapter 4 characterises the in vivo immune response of Na-AIP-1.  Cellular uptake 
studies were conducted with fluorescent-labelled protein to examine how Na-AIP-1 
interacts with lymphocyte populations.  Loss of function studies in genetically-modified 
murine strains with induced colitis were conducted to display the influence of specific 
immune cell phenotypes on the anti-colitic performance of Na-AIP-1.   
Chapter 5 describes the alteration on colonic gene transcription in the CD4+ CD25- T 
cell transfer model of induced murine colitis, and the influence on such by prophylactic 
delivery of Na-AIP-1.  RNAseq was conducted on distal colon sections, and 
comparative analysis of differentially expressed genes was performed, comparing 
transcriptional modifications induced by Na-AIP-1 with that of positive and negative 
controls.  
These chapters contain unpublished data, that will be submitted for publication 
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Inflammatory bowel disease (IBD) is a blanket term describing Crohn’s disease (CD), 
ulcerative colitis (UC) and a handful of less common, but similarly debilitating, auto-
immune colitic conditions.  IBDs are chronic, refractory disorders which are classified 
in accordance with the nature of their respective immunological and pathological 
features; ultimately, the disorders are characterised by compromised epithelial barrier 
integrity and hyper-responsive inflammatory conditions.  An increase in the incidence 
of IBDs in developing countries, combined with their existing prevalence in 
industrialised nations, has led to its emergence as a global disease of significant 
burden (Molodecky et al. 2012).  However, effective medical management of IBD 
remains elusive; whilst treatments exist, they are often poorly tolerated or of limited 
effect, underlining a need for the development of novel treatment strategies.   
Various studies have documented the efficacy of live helminth infection in the 
alleviation of the signs and symptoms associated with inflammation in both human 
IBD, and animal models of colitic inflammation (Summers et al. 2005a, Croese et al. 
2006, Bager et al. 2010, Cho et al. 2012, Croese et al. 2015).  Despite being well 
tolerated, numerous hurdles complicate the adoption of live parasitic infection as a 
valid anti-inflammatory therapy.  As an alternative, the use of helminth-derived 
products began to be explored.  Motomura et al. (2008) examined the impact of 
prophylactic administration of Trichinella spiralis antigen on murine colitis induced by 
DNBS administration; a haptenizing agent which is structurally related to TNBS, and 
similarly invokes transmural inflammation and ulceration when delivered rectally 
(Wallace et al. 1995).  Exposure to T. spiralis antigen to the rectal mucosa five days 
prior to colitis induction significantly reduced macroscopic and histological indicators 
of pathology.  A concomitant upregulation of Th2 cytokines transforming growth factor 
β (TGF-β) and IL-13 in colon tissue was detected in the colon tissue of antigen-treated 
mice at termination.  In the DSS model of induced murine colitis, a cystatin secreted 
by Acanthocheilonema viteae was similarly reported to protect against colitic 
pathology, significantly reducing inflammatory index scores (Schnoeller et al. 2008).  
An escalation in IL-10, a cytokine responsible for Th2 modulation and TREG induction, 
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was found to be key in driving the anti-inflammatory effects of this secreted protein.  In 
a third study, Ruyssers et al. (2009) described the abatement of TNBS-induced colitis 
in mice treated with the excretory/secretory (ES) secretions from canine hookworm 
Ancylostoma caninum.  At termination, indicators of macroscopic inflammation and 
myeloperoxidase activity in the colons of A. caninum ES-treated mice showed 
significant abatement, accompanied by a reduction in the expression of pro-
inflammatory Th1 cytokines and a skewing towards a regulatory Th2 environment.  
Together, these early studies demonstrated the potential of therapeutic 
immunomodulation by helminth products in the absence of live parasitic infection. 
The characterisation of the transcriptomes (Cantacessi et al. 2010, Wang et al. 2010) 
and genomes of several hookworm species (Tang et al. 2014, Schwarz et al. 2015) 
has enabled deeper investigation into the components of the helminth secretome.  Of 
particular relevance, Cantacessi et al. (2013) were able to characterise secreted 
proteins homologous to a family of endogenous mammalian proteins known as tissue 
inhibitors of matrix-metalloproteinases (TIMPs).  TIMPs are inhibitors of matrix-
metalloproteinases (MMPs), enzymes that, with unregulated activation, can induce 
both chronic and acute inflammation at mucosal sites.  Although functional assays 
revealed a lack of MMP inhibitory activity, one of these TIMP-like proteins that is 
abundant in A. caninum ES products, and subsequently named Ac-AIP-2 for A. 
caninum Anti-Inflammatory Protein-2, was demonstrated by Navarro et al. (2016) to 
suppress airway inflammation in a murine model of asthma.  The homologous Ac-AIP-
1 protein was subsequently evidenced to suppress proinflammatory responses in a 
chemically-induced model of murine colitis (Ferreira et al. 2017).   
Also described by Cantacessi et al. (2013) were several homologues of these TIMP-
like proteins in helminths which primarily parasitise humans.  It is plausible that, with 
humans as a natural host, TIMP-like proteins from these species may not only display 
anti-inflammatory properties, but may be better adapted to modulate human immune 
function.  Accordingly, two potential TIMP-like proteins from the ES products of gut-
dwelling Necator americanus, one of the most common hookworms to parasitise 
humans, have been identified for further investigation.  Within this study, I describe 
and recombinantly reproduce two novel TIMP-like proteins isolated from the N. 
americanus secretome, Na-AIP-1 and NECAME_13168.  Furthermore, I investigate 
their efficacy in the abatement of inflammation in the 2,4,6-trinitrobenzenesulfonic acid 
 
 52 
(TNBS) acute model of murine colitis in BALB/c mice, and explored the therapeutic 
impact of differing dosage regimes. 
 
2.1 Materials and methods 
2.1.1 Proteins for recombinant expression 
TIMP-like proteins Na-AIP-1 and NECAME_13168, from the L3 infective stage of N. 
americanus, were identified by Cantacessi et al. (2013).  Briefly, genome data for N. 
americanus was analysed with known TIMP amino acid sequences from Homo 
sapiens (GenBank accession numbers XP_010392.1, NP_003246.1, P35625.1 and 
Q99727.1) and Ac-AIP-2 (EU523696.1) using BLASTp and InterProScan algorithms. 
TIMP-like proteins were then further assessed for an N-terminal signal peptide and 
netrin domain.  Netrin domains are central to TIMPs and contain the active site N-
terminal domain that confers MMP-inhibitory activity (Banyai and Patthy 1999). The 
hookworm TIMP-like proteins AceES-2 (Kucera et al. 2011) and Ac-AIP-2 (Navarro et 
al. 2016) display TIMP-like sequence and predicted structure, but lack defined 
residues involved in inhibition of MMP catalytic activity (Kucera et al. 2011, Cantacessi 
et al. 2013).  Secondary structural predictions were conducted using MOLMOL 2K.1 
(Koradi et al. 1996) and I-TASSER molecular graphics software (Yang et al. 2015).  H. 
sapiens TIMP-2 was the closest homologue with known structure and accordingly this 














Figure 2.1:  Comparison of amino acid sequence alignment and superposition 
of TIMP protein structures.  Necator americanus Na-AIP-1 (W2TPY4), 
NECAME_13168 (W2SWZ9), Homo sapiens TIMP-2 (P16035; PDB code 1BR9), 
Ancylostoma ceylanicum Excretory-secretory protein 2 (AceES-2; (Q6R7N7, PDB 
code 3NSW) and Ancylostoma caninum Ac-AIP-2 (B1Q143).  Superposition of Na-
AIP-1 on H. sapiens TIMP 2 superimposed over residues 81-115 and 95-129 
respectively (i).  Superposition of NECAME_13168 (W2SWZ9) on H. sapiens TIMP 2 
superimposed over residues 81-100 and 96-115 respectively (ii).  Superposition of 
AceES-2 (Q6R7N7, PDB code 3NSW) on H. sapiens TIMP-2 superimposed over 
residues 83-100 and 101-118 respectively (iii).  Na-AIP-1 and NECAME_13168 were 
modelled using Modeller and I-TASSER. 
 
2.1.2 Preparation of recombinant protein 
cDNA sequences corresponding to the open reading frames (ORFs) were cloned 
without signal peptides (Na-AIP-1 residues 18 to 139; NECAME_13168 residues 18 
to 134) into the EcoRI and XbaI sites of the pPIC-Zalpha plasmid (Invitrogen).  
Recombinant proteins had stop codons removed to allow the proteins to be translated 
in-frame with the C-terminal c-myc and hexahistidine tags to aid in detection and 
purification.  Recombinant proteins were expressed via secretion using the yeast 
Pichia pastoris.  Recombinant proteins were isolated from the yeast culture 
supernatant using immobilised metal ion affinity chromatography (IMAC) on an ÄKTA 
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FPLC chromatography system with a 5 mL HisTrap excel nickel column (GE 
Healthcare Life Sciences).  Endotoxin removal was conducted using an EndoTrap® 
HD Endotoxin Removal System (Hyglos) according to the manufacturer’s instructions.  
Yeast culture of 500 mL produced a yield of recombinant Na-AIP-1 of 47.4 mg with an 
endotoxin concentration of 0.74 EU/mg protein, and a yield of recombinant 
NECAME_13168 of 11.4 mg with an endotoxin concentration of 3.73 EU/mg protein 
(after endotoxin removal). 
 
2.1.3 Animals and TNBS-induced colitis 
Male BALB/c mice and SJL/Jarc, aged 5-7 weeks and weight-matched, were obtained 
from Animal Resources Centre (Murdoch, Australia) and allowed to acclimatise for 7 
days before the commencement of the experimental period.  Mice received autoclaved 
food and water ad libitum, and were maintained in pathogen-free conditions in a 
temperature-controlled room with a 12-hr light/dark illumination cycle.  Experiments 
were approved by the James Cook University Animals Ethics Committee under Ethics 
Approval numbers A2012 and A2379 and conducted in accordance with National 
Health and Medical Research Council Australian Code for the Care and Use of 
Animals for Scientific Purposes (8th Edition, 2013) and in compliance with the 
Queensland Animal Care and Protection Act, 2001 (Act No.64 of 2001). 
Colitis was induced via intra-rectal injection of 100 µL 1.5 mg TNBS in 50% EtOH in 
BALB/c mice, and 50 µL 1.5 mg TNBS in 50% EtOH in SJL/Jarc mice, as described 
elsewhere (Cobos Caceres et al. 2017).  Briefly, mice were anaesthetised via intra-
peritoneal (i.p.) injection of 6.25% ketamine/0.625% xylazine solution, administered in 
sterile PBS at 200 µL per mouse.  Sedated mice each received intra-rectal 
administration of 100 µL of TNBS/EtOH as per group assignment, via careful insertion 
of a flexible catheter (Gauge 20G× 11/4”, I.D. 0.80× 32 mm) with lubricant gel into the 
colon 4 cm proximal to the anus.  Mice were inverted (head down) for ~2 min prior to 
being returned to their cage to minimise leakage.  TNBS administration was conducted 
on day zero of the experimental period.  Mice were sacrificed via CO2 asphyxiation.
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2.1.4 Treatment administration 
Mice were randomly divided into treatment groups of five per cage.  Groups Na-AIP-1 
and NECAME_13168 received 1 mg/kg of purified recombinant protein, as indicated.  
Group HA (negative control) received 1 mg/kg of purified, non-immunogenic 
recombinant human albumin (HA), expressed and purified in P. pastoris under 
identical conditions to the hookworm proteins, as indicated (Low and Wiles 2016).  
Group PBS (vehicle control) received 200 uL of sterile PBS vehicle, as indicated. 
Group αIL12/23 (positive control) received 1 mg of InVivoMAb purified anti-mouse IL-
12/IL-23p40 (clone C17.8) antibody (BioXcell) on day -1 (Neurath et al. 1995). All 
treatments were administered via i.p. injection, prepared with PBS to a final volume of 
200 μL.  The recombinant protein dosage level of 1 mg/kg and route of delivery was 
determined in consideration with results from similar studies (Ruyssers et al. 2009, 
Navarro et al. 2016).   
 
2.1.5 Clinical and macroscopic disease scores 
Mice were assessed daily for clinical signs of disease and scored using criteria 
adapted from Ruyssers et al. (2009).  Piloerection and lethargy, diarrhoea, and rectal 
thickening/bleeding were graded according to severity from 0 (absent) to 2 (severe), 
to a maximum cumulative total score of 6.  At necropsy, colons were removed, flushed 
with PBS and assessed for length and macroscopic signs of disease utilising criteria 
adapted from Ruyssers et al. (2009).  Adhesion, oedema, and thickening were graded 
according to severity from 0 (absent) to 2 (severe), and ulceration was graded from 0 
(absent) to necrosis (3), to a maximum cumulative total score of 9.  Any deviations 
from these scoring rubrics have been noted where applicable. 
 
2.1.6 Histological analysis of distal colon tissue 
Distal colon tissue was harvested in 1 cm sections and fixed in 4% formalin overnight, 
whereupon tissue was transferred to 70% EtOH.  Embedding of tissue in paraffin, 
haematoxylin and eosin (H/E) staining and photomicrography was conducted at the 
histology unit of QIMR Berghofer Medical Research Institute (Brisbane, Australia) or 
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the Advanced Analytical Centre, James Cook University (Cairns, Australia).  Images 
were examined for visible changes and blinded scoring conducted.  Tissue sections 
were scored on a scale of 0-5 for each of the following parameters; (1) epithelial 
pathology (crypt elongation, hyperplasia, and erosion), (2) mural inflammation and (3) 
oedema for an overall maximal total histology score of 15. 
 
2.1.7 Statistical Analyses 
All groups n = 5 unless otherwise stated.  All data are presented as mean ± SEM.  
Statistical analyses were conducted using GraphPad Prism 6 software.  Comparisons 
between all groups were conducted using unpaired, one-way ANOVA (Holm Sidak) 
unless otherwise specified. Comparisons between individual groups were performed 
by unpaired, two-way Mann-Whitney U tests (Holm Sidak), vs. negative/vehicle 




All mice treated with Na-AIP-1, HA and PBS attained 100% survival until completion 
of the experiment.  Of mice treated with NECAME_13168, two (40%) were euthanised 
at day 6 on ethical grounds due to the severity of colitis. 
 
2.2.2 Prophylactic delivery of recombinant Na-AIP-1 limits clinical signs of 
TNBS-induced acute colitis in BALB/c mice. 
First, I examined the potential efficacy of Na-AIP-1 and NECAME_13168 in a 8-day 
model of acute TNBS-induced colitis.  Mice received i.p. injections of Na-AIP-1, 
NECAME_13168 or HA on days -1, 2 and 5.  Mice were challenged twice by intra-
rectal administration of TNBS on days 0 and 6, and sacrificed at day 8.  Mice treated 
with HA suffered 9.2% (3.1 ± 1.2g) weight loss within 48 hrs of TNBS administration, 
and did not recover to baseline weight for the remainder of the experimental period 
(Figure 2.2A).  Delivery of Na-AIP-1 mitigated colitis-induced weight loss, with weight 
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loss limited to the first 24 hr after TNBS delivery (4.8%; 0.5 ± 0.3 g), and recovery to 
100% baseline weight by day 3.  Differences reached statistical significance at days 4 
(p = 0.008), 5 (p = 0.02), 7 (p = 0.02) and 8 (p = 0.008).  Consistent with protection 
against weight loss, mice treated with Na-AIP-1 also exhibited significantly reduced 
clinical indicators of disease compared to HA-treated mice (Figure 2.2B). These 
protective effects of Na-AIP-1 mirrored or surpassed those of the positive control-
treated mice (αIL12/23). NECAME_13168 did not confer protection against weight loss 
or clinical signs of disease (Figure 2.2A-B). Together, these data suggest that Na-AIP-
1, but not NECAME_13168, appears to be highly efficacious at preventing onset of 
TNBS-induced colitis. 
 
Figure 2.2:  Prophylactic delivery of recombinant Na-AIP-1 limits clinical signs 
of TNBS-induced acute colitis in BALB/c mice. Mice received intraperitoneal 
injections of Na-AIP-1, N_13168, HA or αIL12/23 on days -1, 2 and 5.  Mice were 
challenged twice by intra-rectal administration of TNBS on days 0 and 6. Body weight 
(A) and clinical signs of disease (B) were measured daily.  Data are presented as 
mean ± SEM.  Comparisons were conducted using one-way ANOVA (Holm-Sidak).  
Naïve group included for comparison purposes only.  * p ≤ 0.05, significantly different 
from HA negative control group; ** p ≤ 0.01, significantly different from HA negative 
control group.  *** p ≤ 0.001, significantly different from HA negative control group.  
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Experiment was performed in duplicate; representative results from a single 
experiment are shown.  
2.2.3 Prophylactic delivery of recombinant Na-AIP-1 limits inflammatory 
pathology of the colon in BALB/c mice administered TNBS. 
I next examined the effect of Na-AIP-1 and NECAME_13168 on macroscopic and 
histological pathology in the colon upon the termination of the 8-day TNBS experiment.  
Length of colon at termination is applied as a measure of inflammatory pathology; the 
HA group presented with a 5.4% reduction in colon length (6.4 ± 0.2 cm) when 
compared to the αIL12/23 group (6.7 ± 0.3 cm) and mice receiving NECAME_13168 
(6.7 ± 0.2 cm).  Delivery of Na-AIP-1 preserved colon length (p = 0.008; 7.6 ± 0.2 cm) 
despite TNBS administration (Figure 2.3A).  After colon length measurement, 
macroscopic scoring of inflammatory pathology was conducted.  Mice receiving 
αIL12/23 (3.4, ± 1.0) displayed a significantly reduced score in comparison to the HA 
group (p = 0.04; 7.2, ± 1.1).  Treatment with Na-AIP-1 afforded a highly significant 
protection against macroscopic inflammatory injury (p = 0.008; 0.2, ± 0.2) (Figure 
2.3B).  Histologically, mice treated with HA displayed considerable morphological 
corruption, with diffuse transmural lymphocytic infiltration and villous, goblet cell and 
crypt destruction.  Mice receiving Na-AIP-1 displayed a complete preservation of 
colonic tissue, with minimal loss of goblet cells and an intact epithelium, sub mucosa 
and muscularis (Figure 2.3C-D).  Photomicrography and scoring representative of 
mice receiving NECAME_13168 images imply some minimal mitigation of injury when 
compared with the HA group; however, the mortality of 40% of the initial experimental 
group at day seven and the impact this has on the power of the provided statistical 




Figure 2.3: Prophylactic delivery of recombinant Na-AIP-1 limits inflammatory 
pathology in BALB/c mice with TNBS-induced acute colitis. Caecum and colon 
were removed at termination (A), and assessed for length (B) and macroscopic 
pathology (C).   Blinded histological scoring of inflammatory pathology (D).  H&E 
stained distal colon sections (E).  Annotations on HA image indicate inflammatory 
pathology, including areas of diffuse villus destruction and crypt loss (black arrow), 
dense lymphocytic infiltration of the lamina propria (white arrow) and thickening of the 
muscularis layer (blue arrow).   Data are presented as mean ± SEM.  Comparisons 
were conducted using two-way Mann Whitney T-test (non-parametric).  * p ≤ 0.05, 
significantly different from HA negative control group; ** p ≤ 0.01, significantly different 
from HA negative control group. Experiment was performed in duplicate; 
representative results from a single experiment are shown. 
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2.2.4 Single administration of recombinant Na-AIP-1 limits clinical and 
inflammatory pathology when delivered prophylactically or therapeutically 
within 24 hrs of TNBS challenge in BALB/c mice. 
In order to examine whether Na-AIP-1 is able to confer similar anti-colitic effects when 
delivered therapeutically in established colitis, I utilised a 3-day TNBS model.  Mice 
received a single i.p. injection of PBS (negative control; n = 2) on day -1, or Na-AIP-1 
on day -1, 1 or 2.  Mice were challenged by intra-rectal administration of TNBS on day 
0, and sacrificed at day 4.  As expected, mice receiving PBS experienced a dramatic 
and continuing loss of weight, with minimal resolution.  Mice receiving a single 
administration of Na-AIP-1 prophylactically at day -1 or therapeutically at day 1 
showed a persistent trend towards a reduction in colitis-induced weight loss, which 
was not replicated in the group receiving Na-AIP-1 at day 2 (Figure 2.4A).  Similarly, 
mice treated with Na-AIP-1 at days -1 and day 1 also exhibited a non-significant trend 
towards reduced clinical indicators of disease (Figure 2.4B) in comparison to the PBS 
group.  This is consistent with colon length and macroscopic inflammatory damage 
assessed at termination (Figure 2.4C-D).  Delivery of Na-AIP-1 therapeutically at day 
2 did not confer protection from TNBS-induced colitis.  This data suggests Na-AIP-1 
may be most efficacious when delivered prior to the onset of inflammation, rather than 




Figure 2.4: Recombinant Na-AIP-1 limits inflammatory pathology when delivered 
within 24 hrs of induction of acute TNBS colitis in BALB/c mice. Mice received 
intraperitoneal injections of Na-AIP-1 or PBS on day -1, day 1 or day 2.  Mice were 
challenged by intra-rectal administration of TNBS on day 0. Body weight (A) and 
clinical signs of disease (B) were measured daily.  Caecum and colon were removed 
at termination, and assessed for length (C) and macroscopic inflammatory damage 
(D).   Data are presented as mean ± SEM.  Multiple measure comparisons were 
conducted using a two-way RM ANOVA (Holm-Sidak).  Single measure comparisons 
were conducted using a one-way Mann Whitney T-test (non-parametric).   
Representative results from a single experiment are shown.  
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2.2.5 A combined prophylactic and therapeutic dosing regimen can potentiate 
the anti-inflammatory properties of Na-AIP-1 in SJL/JArc mice with TNBS-
induced acute colitis.    
I then wanted to assess whether combining prophylactic and therapeutic dosing would 
enhance the anti-inflammatory effect of Na-AIP-1, whilst also testing the efficacy in an 
immunologically distinct murine strain.  SJL/JArc mice are an inbred albino strain with 
naturally elevated circulating T cells, making them particularly susceptible to the 
induction of TNBS colitis (Scheiffele and Fuss 2002, Animal Resources Centre 2019).  
Mice received a single prophylactic i.p. injection of PBS (negative control) or Na-AIP-
1 on day -1, or two doses of Na-AIP-1 (days -1 and 1) (all groups n = 8).  Mice were 
challenged by intra-rectal administration of TNBS on day 0, and sacrificed at day 3.  
Mice receiving PBS lost weight daily until termination, at which point they presented 
at 22.5% (4.1 ± 0.4 g) below baseline weight (Figure 2.5A).  In contrast, mice treated 
with Na-AIP-1 displayed a mitigation of weight loss within 48 hrs of TNBS 
administration which was strongest in the group receiving two doses, and reached 
statistical significance on day 3 (p ≤ 0.001).  Similarly, mice receiving the combined 
regimen received lower clinical pathology scores, although this did not reach statistical 
significance (Figure 2.5B).  Interestingly, whilst mice receiving Na-AIP-1 experienced 
a conservation in colon length, only the single dose group achieved statistical 
significance in comparison to the PBS group (single dose p = 0.002; two doses p = 
0.1) (Figure 2.5C).  This is in contrast to the combined prophylactic and therapeutic 
delivery of Na-AIP-1 correlating with a greater reduction in the macroscopic indicators 
of inflammatory damage at termination (p = 0.03, compared to single dose p = 0.6) 
(Figure 2.5D).  These results suggest a combined dosing regimen may increase 




Figure 2.5:  A combined prophylactic and therapeutic dosing regimen 
potentiates the anti-inflammatory properties of Na-AIP-1 in SJL/JArc mice with 
TNBS-induced acute colitis.   Mice received intraperitoneal injections of Na-AIP-1 or 
PBS on day -1 only, or days -1 and 1.  Mice were challenged by intra-rectal 
administration of TNBS on day 0. Body weight (A) and clinical signs of disease (B) 
were measured daily.  Caecum and colon were removed at termination, and assessed 
for length (C) and macroscopic inflammatory damage (D).  Data are presented as 
mean ± SEM.  Multiple measure comparisons were conducted using a two-way RM 
ANOVA (Holm-Sidak).  Single measure comparisons were conducted using a one-
way Mann Whitney T-test (non-parametric).  *p ≤ 0.05, significantly different from PBS; 
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**p ≤ 0.01, ***p ≤ 0.001, significantly different from PBS.  Representative results from 
a single experiment are shown. 
 
2.3 Discussion 
Multiple studies have described the potential efficacy of live parasitic helminth infection 
in alleviating symptoms of inflammation, in both human and animal models of disease 
(Summers et al. 2005b, Croese et al. 2006, Smith et al. 2007, Sutton et al. 2008, 
McSorley et al. 2011, Correale and Farez 2011). Consequently, there is interest in 
identifying potential immunomodulatory proteins secreted by helminths, which could 
be produced as a safer and more acceptable alternative to live worm therapy.  Animal 
and ex-vivo studies involving the Ac-AIP-2 hookworm protein describe compelling anti-
inflammatory properties, despite the mechanism of action behind the biological activity 
remaining undetermined (Navarro et al. 2016).  TIMP-like homolog Ac-AIP-1, also 
isolated from the A. caninum secretome, has displayed similar potency in the TNBS-
induced model of colitis, with immunological studies suggestive of pro-regulatory 
response induction (Ferreira et al. 2017). The high degree of sequence homology 
shared by Na-AIP-1 and NECAME_13168 with Ac-AIP-1 justifies their recombinant 
production and screening for anti-colitic properties.  Additionally, during the transition 
of hookworm larvae from the free-living to the parasitic L3 stage of the life cycle, 
mRNAs encoding for Na-AIP-1 and NECAME_13168 are significantly upregulated 
(Cantacessi et al. 2013), indicating a role in the early phases of host-parasite 
interactions.   
The TIMP-like morphology of these various ES proteins lends further weight to their 
potential role in the regulation of inflammation.  Mammalian MMPs, and the TIMPs 
that govern their activity, have been evidenced to play a role in both CD and UC and 
as such have been suggested as a potential drug target (Jakubowska et al. 2016, 
Kuroda et al. 2019).  MMPs are a large family of enzymes that target and degrade 
components of the extracellular matrix, and are heavily engaged during a number of 
inflammatory conditions.  In contrast, TIMPs represent a group of multifunctional 
extracellular proteins that effectively regulate tissue remodelling by acting as an MMP 
inhibitor, and are distinguished by an N-terminal netrin domain (NTR).  This NTR 
module is characterised by a cysteine rich motif, which forms a number of disulphide 
bridges, giving the domain its distinctive morphology (Banyai and Patthy 1999).  It is 
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at this N-terminal site that MMP binding occurs, inhibiting catabolic activity.  A delicate 
balance between the presence MMP and TIMP molecules must be maintained to 
achieve intestinal homeostasis; under-expression of TIMPs can lead to uncontrolled 
inflammatory pathology, whereas an over-abundance can induce excessive fibrosis.  
As such, MMP/TIMP dysregulation correlates with both the pathogenesis of IBDs 
(Silosi et al. 2014, Lucafò et al. 2019) and the fistulising pathologies associated with 
longer term disease progression (Latella et al. 2015, Carbone et al. 2018).   
Studies of MMP/TIMP dysregulation involving different murine models of chemically- 
induced colitis have been conducted.  In the TNBS-induced model of colitis, blockade 
of pro-inflammatory Th17 responses by both anti-IL-17 monoclonal antibodies (Li et 
al. 2019) and thalidomide (Chen et al. 2019) attenuated inflammatory pathology; a 
significant downregulation in several MMPs was noted in both studies.  In the DSS-
induced model of chemical colitis, TIMP-1 knock-out mice displayed an increase in the 
severity of inflammation in the short term, but a reduction in colitic fibrosis as the 
condition became chronic (Breynaert et al. 2016).   Interestingly, findings published by 
de Bruyn et al. (2017) disputed the role of MMP-9 in colitic pathogenesis, an MMP 
which is routinely upregulated in human IBD and considered a leading potential drug 
target.  A comparison of both DSS- and TNBS-induced colitis in MMP-9 knock-out 
mice showed no improvement in inflammation compared to WT mice.  Accordingly, 
whilst it is unclear whether MMP/TIMP dysregulation is an instigator or a consequence 
of chemically-induced murine colitis, a downregulation in MMP enzymes is correlated 
with a reduction in inflammatory pathology. 
Several NTR domain-containing proteins outside of the TIMP family have also been 
demonstrated to influence immune activity.  Secreted frizzled-related proteins are a 
family of proteins involved in the signal transduction controlling cell proliferation and 
migration (Liang et al. 2019).  An upregulation in members of the secreted frizzled-
related protein family is associated with enhanced survival in colorectal cancer 
patients, suppressing cell proliferation and inducing apoptosis, via manipulation of the 
Wnt signalling pathway (Liu et al. 2019).  Human complement proteins C3, C4 and C5 
similarly bear the NTR motif (Thai and Ogata 2003).  These members of the 
complement cascade are associated with the instigation of innate immune responses 
to antigenic stimulation (C3, C4) and the formation of the membrane attack complex 
(C3, C5), representing both the classical and alternate activation pathways.  
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Interestingly, both of these protein families bear the NTR motif at the C-terminal, and 
bear minimal sequential homology to TIMPs (Banyai and Patthy 1999, Thai and Ogata 
2003, Liang et al. 2019).  In contrast, the location and sequence of the NTR motif in 
helminth-derived molecules is highly conserved in comparison to mammalian TIMPs.  
Yet, the helminth-derived homologs bear no correspondence in the C-terminal domain 
sequence, and do not appear to confer direct MMP inhibition (Cantacessi et al. 2013).  
As such, and until such time as a mechanism of action can be elucidated, these novel 
molecules are considered TIMP-like proteins. 
In the studies presented in this chapter, I have provided experimental data from the 
TNBS-induced model of murine colitis as proof-of-concept validation that treatment 
with the hookworm-derived ES molecule Na-AIP-1 can confer protection against 
inflammatory pathology.  TNBS-colitis in BALB/c mice is characterised by severe and 
acute weight loss, accompanied by piloerection, bloody diarrhoea, a reduction in colon 
length and ulceration of the colonic mucosa.  However, treatment with Na-AIP-1 
mitigated both the clinical and macroscopic indicators of disease; this is most dramatic 
in the 8-day experimental model in which Na-AIP-1 treated mice outperformed the 
positive control in each of the assessed key indicators of inflammatory disease.  
Furthermore, my data suggests that a single 20 μg i.p. administration of Na-AIP-1 can 
induce a trend towards the reduction in pathology if delivered within a 24 hr window 
either side of inflammatory insult.  No such trend is observed if Na-AIP-1 delivery is 
limited to 48 hrs post-TNBS administration, intimating the mechanism of Na-AIP-1 
action lies in the prevention of the development of inflammation, rather than the repair 
of damage in established inflammation.   
A combined regimen of treatment both 24 hrs pre- and post-TNBS administration 
appears to potentiate the protective influence of Na-AIP-1, significantly reducing 
macroscopic indicators of colitic damage at termination.  Importantly, this was 
demonstrated in SJL/JArc mice; an inbred murine strain that display a particularly 
intense inflammatory response to TNBS administration.  The increased susceptibility 
of this murine strain demonstrates the strength of Na-AIP-1 in the induction of an anti-
inflammatory environment in an even more acute state of inflammatory challenge.  In 
contrast to this, mice treated with NECAME_13168 experienced significant morbidity 
prior to the conclusion of the experimental period.  As such, it becomes difficult to 
assign value to the differences between this group and the negative control group 
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recorded on day seven and day eight, with the limited sample size making it difficult to 
confirm whether this represents a meaningful trend.  In histological photomicrography 
representative of the remaining population of the NECAME_13168 group at the end 
of the experimental period, images imply some mitigation of injury when compared 
with the HA group, however given the high level of mortality in subsequent replication 
trials, I did not proceed with further screening of this molecule. 
Given these results, further research is recommended on the elucidation of the 
immunomodulatory environment inferred by Na-AIP-1.  Investigations describing 
cytokine and costimulation marker profiling and quantitation in the tissue of 
experimental mice will prove crucial in defining the mechanisms of action involved in 
the anti-inflammatory pathway. 
In conclusion, an inverse correlation between the incidence of parasitic worm infection 
in human populations and the prevalence of IBD and other inflammatory conditions 
led to the hypothesis that helminths could be utilised in the treatment of this subset of 
diseases.  These studies have demonstrated that recombinant Na-AIP-1, a protein 
derived from the genome of the hookworm N. americanus, ameliorates clinical and 
histological signs of colitic inflammation in a murine model of TNBS-induced colitis.  
An effective route of administration and dosing regimen has been established, with 
repeated dosing potentiating the anti-colitic effect.  The findings within suggest Na-
AIP-1 may be more effective as a prophylactic than a rescue therapy in active disease. 
Recombinant Na-AIP-1 is safely tolerated and scale up of molecule production is 
feasible.  This recombinant protein presents and excellent candidate for further 







ANIMAL RESOURCES CENTRE. 2019. Strains: SJL/JArc.  
https://www.arc.wa.gov.au/?page_id=1332. 
BAGER P, ARNVED J, RØNBORG S, WOHLFAHRT J, POULSEN L K, 
WESTERGAARD T, PETERSEN H W, KRISTENSEN B, THAMSBORG S, 
ROEPSTORFF A, KAPEL C & MELBYE M. 2010. Trichuris suis ova therapy for 
allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial. Journal of 
Allergy and Clinical Immunology [Online], vol. 125, no. 1, pp. 123-130.e123, viewed 
21 April 2015, doi: dx.doi.org/10.1016/j.jaci.2009.08.006. 
BANYAI L & PATTHY L. 1999. The NTR module: domains of netrins, secreted frizzled 
related proteins, and type I procollagen C-proteinase enhancer protein are 
homologous with tissue inhibitors of metalloproteases. Protein Sci [Online], vol. 8, no. 
8, pp. 1636-1642, viewed 15 October 2015, doi: 10.1110/ps.8.8.1636. 
BREYNAERT C, DE BRUYN M, ARIJS I, CREMER J, MARTENS E, VAN LOMMEL 
L, GEBOES K, DE HERTOGH G, SCHUIT F, FERRANTE M, VERMEIRE S, 
CEUPPENS J, OPDENAKKER G & VAN ASSCHE G. 2016. Genetic Deletion of 
Tissue Inhibitor of Metalloproteinase-1/TIMP-1 Alters Inflammation and Attenuates 
Fibrosis in Dextran Sodium Sulphate-induced Murine Models of Colitis. J Crohns 
Colitis [Online], vol. 10, no. 11, pp. 1336-1350, viewed 6 April 2020, doi: 10.1093/ecco-
jcc/jjw101. 
CANTACESSI C, HOFMANN A, PICKERING D, NAVARRO S, MITREVA M & 
LOUKAS A. 2013. TIMPs of parasitic helminths - a large-scale analysis of high-
throughput sequence datasets. Parasit Vectors [Online], vol. 6, no. 1, pp. 156, viewed 
11 March 2015, doi: 10.1186/1756-3305-6-156. 
CANTACESSI C, MITREVA M, JEX A R, YOUNG N D, CAMPBELL B E, HALL R S, 
DOYLE M A, RALPH S A, RABELO E M, RANGANATHAN S, STERNBERG P W, 
LOUKAS A & GASSER R B. 2010. Massively parallel sequencing and analysis of the 
Necator americanus transcriptome. PLoS Negl Trop Dis [Online], vol. 4, no. 5, pp. 
e684, viewed 20 October 2015, doi: 10.1371/journal.pntd.0000684. 
CARBONE F, BODINI G, BRUNACCI M, BONAVENTURA A, VECCHIE A, LIBERALE 
L, CRESPI M, BALDISSARRO I, DALLEGRI F, SAVARINO V, MONTECUCCO F & 
GIANNINI E G 2018. Reduction in TIMP-2 serum levels predicts remission of 
inflammatory bowel diseases. Eur J Clin Invest, 48, e13002 
CHEN H, XU H, LUO L, QIAO L, WANG Y, XU M, LI Y, ZHU P & YANG B. 2019. 
Thalidomide Prevented and Ameliorated Pathogenesis of Crohn's Disease in Mice via 
Regulation of Inflammatory Response and Fibrosis. Front Pharmacol [Online], vol. 10, 
no., pp. 1486, viewed 6 April 2020, doi: 10.3389/fphar.2019.01486. 
CHO M K, PARK M K, KANG S A, CHOI S H, AHN S C & YU H S. 2012. Trichinella 
spiralis Infection Suppressed Gut Inflammation with CD4(+)CD25(+)Foxp3(+) T Cell 
 
 69 
Recruitment. Korean J Parasitol [Online], vol. 50, no. 4, pp. 385-390, viewed 22 April 
2015, doi: 10.3347/kjp.2012.50.4.385. 
COBOS CACERES C, BANSAL P S, NAVARRO S, WILSON D, DON L, GIACOMIN 
P, LOUKAS A & DALY N L. 2017. An engineered cyclic peptide alleviates symptoms 
of inflammation in a murine model of inflammatory bowel disease. Journal of Biological 
Chemistry [Online], vol., no., pp., viewed May 22, 2017, doi: 
10.1074/jbc.M117.779215. 
CORREALE J & FAREZ M F. 2011. The impact of parasite infections on the course of 
multiple sclerosis. J Neuroimmunol [Online], vol. 233, no. 1–2, pp. 6-11, viewed 4 May 
2015, doi: 10.1016/j.jneuroim.2011.01.002. 
CROESE J, GIACOMIN P, NAVARRO S, CLOUSTON A, MCCANN L, DOUGALL A, 
FERREIRA I, SUSIANTO A, O'ROURKE P, HOWLETT M, MCCARTHY J, 
ENGWERDA C, JONES D & LOUKAS A. 2015. Experimental hookworm infection and 
gluten microchallenge promote tolerance in celiac disease. J Allergy Clin Immunol 
[Online], vol. 135, no. 2, pp. 508-516, viewed 7 May 2015, doi: 
10.1016/j.jaci.2014.07.022. 
CROESE J, O'NEIL J, MASSON J, COOKE S, MELROSE W, PRITCHARD D & 
SPEARE R. 2006. A proof of concept study establishing Necator americanus in 
Crohn’s patients and reservoir donors. Gut [Online], vol. 55, no. 1, pp. 136-137, viewed 
16 March 2015, doi: 10.1136/gut.2005.079129. 
DE BRUYN M, BREYNAERT C, ARIJS I, DE HERTOGH G, GEBOES K, THIJS G, 
MATTEOLI G, HU J, VAN DAMME J, ARNOLD B, FERRANTE M, VERMEIRE S, VAN 
ASSCHE G & OPDENAKKER G. 2017. Inhibition of gelatinase B/MMP-9 does not 
attenuate colitis in murine models of inflammatory bowel disease. Nat Commun 
[Online], vol. 8, no., pp. 15384, viewed 6 April 2020, doi: 10.1038/ncomms15384. 
FERREIRA I B, PICKERING D A, TROY S, CROESE J, LOUKAS A & NAVARRO S. 
2017. Suppression of inflammation and tissue damage by a hookworm recombinant 
protein in experimental colitis. Clin Transl Immunology [Online], vol. 6, no. 10, pp. 
e157, viewed 15 January 2018, doi: 10.1038/cti.2017.42. 
JAKUBOWSKA K, PRYCZYNICZ A, IWANOWICZ P, NIEWINSKI A, 
MACIORKOWSKA E, HAPANOWICZ J, JAGODZINSKA D, KEMONA A & 
GUZINSKA-USTYMOWICZ K. 2016. Expressions of Matrix Metalloproteinases (MMP-
2, MMP-7, and MMP-9) and Their Inhibitors (TIMP-1, TIMP-2) in Inflammatory Bowel 
Diseases. Gastroenterol Res Pract [Online], vol. 2016, no., pp. 2456179, viewed 6 
April 2020, doi: 10.1155/2016/2456179. 
KORADI R, BILLETER M & WÜTHRICH K. 1996. MOLMOL: A program for display 
and analysis of macromolecular structures. Journal of Molecular Graphics [Online], 




KUCERA K, HARRISON L M, CAPPELLO M & MODIS Y. 2011. Ancylostoma 
ceylanicum excretory-secretory protein 2 adopts a netrin-like fold and defines a novel 
family of nematode proteins. J Mol Biol [Online], vol. 408, no. 1, pp. 9-17, viewed 15 
October 2015, doi: 10.1016/j.jmb.2011.02.033. 
KURODA N, MASUYA M, TAWARA I, TSUBOI J, YONEDA M, NISHIKAWA K, 
KAGEYAMA Y, HACHIYA K, OHISHI K, MIWA H, YAMADA R, HAMADA Y, TANAKA 
K, KATO T, TAKEI Y & KATAYAMA N. 2019. Infiltrating CCR2(+) monocytes and their 
progenies, fibrocytes, contribute to colon fibrosis by inhibiting collagen degradation 
through the production of TIMP-1. Sci Rep [Online], vol. 9, no. 1, pp. 8568, viewed 6 
April 2020, doi: 10.1038/s41598-019-45012-6. 
LATELLA G, DI GREGORIO J, FLATI V, RIEDER F & LAWRANCE I C. 2015. 
Mechanisms of initiation and progression of intestinal fibrosis in IBD. Scand J 
Gastroenterol [Online], vol. 50, no. 1, pp. 53-65, viewed 6 April 2020, doi: 
10.3109/00365521.2014.968863. 
LI J, LIU L, ZHAO Q & CHEN M. 2019. Role of Interleukin-17 in Pathogenesis of 
Intestinal Fibrosis in Mice. Dig Dis Sci [Online], vol., no., pp., viewed 6 April 2020, doi: 
10.1007/s10620-019-05969-w. 
LIANG C J, WANG Z W, CHANG Y W, LEE K C, LIN W H & LEE J L. 2019. SFRPs 
Are Biphasic Modulators of Wnt-Signaling-Elicited Cancer Stem Cell Properties 
beyond Extracellular Control. Cell Rep [Online], vol. 28, no. 6, pp. 1511-1525.e1515, 
viewed 6 April 2020, doi: 10.1016/j.celrep.2019.07.023. 
LIU X, FU J, BI H, GE A, XIA T, LIU Y, SUN H, LI D & ZHAO Y. 2019. DNA methylation 
of SFRP1, SFRP2, and WIF1 and prognosis of postoperative colorectal cancer 
patients. BMC Cancer [Online], vol. 19, no. 1, pp. 1212, viewed 6 April 2020, doi: 
10.1186/s12885-019-6436-0. 
LOW B E & WILES M V. 2016. A Humanized Mouse Model to Study Human Albumin 
and Albumin Conjugates Pharmacokinetics. Methods Mol Biol [Online], vol. 1438, no., 
pp. 115-122, viewed 16 January 2017, doi: 10.1007/978-1-4939-3661-8_7. 
LUCAFÒ M, PUGNETTI L, BRAMUZZO M, CURCI D, DI SILVESTRE A, MARCUZZI 
A, BERGAMO A, MARTELOSSI S, VILLANACCI V, BOZZOLA A, CADEI M, DE 
IUDICIBUS S, DECORTI G & STOCCO G. 2019. Long Non-Coding RNA GAS5 and 
Intestinal MMP2 and MMP9 Expression: A Translational Study in Pediatric Patients 
with IBD. International journal of molecular sciences [Online], vol. 20, no. 21, pp. 5280, 
viewed 6 April 2020, doi: 10.3390/ijms20215280. 
MCSORLEY H J, GAZE S, DAVESON J, JONES D, ANDERSON R P, CLOUSTON 
A, RUYSSERS N E, SPEARE R, MCCARTHY J S, ENGWERDA C R, CROESE J & 
LOUKAS A. 2011. Suppression of inflammatory immune responses in celiac disease 
by experimental hookworm infection. PLoS One [Online], vol. 6, no. 9, pp. e24092, 
viewed 16 March 2015, doi: 10.1371/journal.pone.0024092. 
 
 71 
MOLODECKY N A, SOON I S, RABI D M, GHALI W A, FERRIS M, CHERNOFF G, 
BENCHIMOL E I, PANACCIONE R, GHOSH S, BARKEMA H W & KAPLAN G G. 
2012. Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With 
Time, Based on Systematic Review. Gastroenterology [Online], vol. 142, no. 1, pp. 46-
54.e42, viewed 13 April 2015, doi: 10.1053/j.gastro.2011.10.001. 
MOTOMURA Y, WANG H, DENG Y, EL-SHARKAWY R T, VERDU E F & KHAN W I. 
2008. Helminth antigen-based strategy to ameliorate inflammation in an experimental 
model of colitis. Clin Exp Immunol [Online], vol. 155, no. 1, pp. 88-95, viewed 6 April 
2020, doi: 10.1111/j.1365-2249.2008.03805.x. 
NAVARRO S, PICKERING D A, FERREIRA I B, JONES L, RYAN S, TROY S, LEECH 
A, HOTEZ P J, ZHAN B, LAHA T, PRENTICE R, SPARWASSER T, CROESE J, 
ENGWERDA C R, UPHAM J W, JULIA V, GIACOMIN P R & LOUKAS A. 2016. 
Hookworm recombinant protein promotes regulatory T cell responses that suppress 
experimental asthma. Sci Transl Med [Online], vol. 8, no. 362, pp. 362ra143, viewed 
1 November 2016, doi: 10.1126/scitranslmed.aaf8807. 
NEURATH M F, FUSS I, KELSALL B L, STUBER E & STROBER W. 1995. Antibodies 
to interleukin 12 abrogate established experimental colitis in mice. J Exp Med [Online], 
vol. 182, no. 5, pp. 1281-1290, viewed 25 August 2015, doi: 
http://www.ncbi.nlm.nih.gov/pubmed/7595199 
RUYSSERS N E, DE WINTER B Y, DE MAN J G, LOUKAS A, PEARSON M S, 
WEINSTOCK J V, VAN DEN BOSSCHE R M, MARTINET W, PELCKMANS P A & 
MOREELS T G. 2009. Therapeutic potential of helminth soluble proteins in TNBS-
induced colitis in mice. Inflamm Bowel Dis [Online], vol. 15, no. 4, pp. 491-500, viewed 
19 March 2015, doi: 10.1002/ibd.20787. 
SCHEIFFELE F & FUSS I J. 2002. Induction of TNBS colitis in mice. Curr Protoc 
Immunol [Online], vol. 49, no. 15.19, pp. 15.19.11 - 15.19.14, viewed 4 May 2015, doi: 
http://www.ncbi.nlm.nih.gov/pubmed/18432874 
SCHNOELLER C, RAUSCH S, PILLAI S, AVAGYAN A, WITTIG B M, 
LODDENKEMPER C, HAMANN A, HAMELMANN E, LUCIUS R & HARTMANN S. 
2008. A helminth immunomodulator reduces allergic and inflammatory responses by 
induction of IL-10-producing macrophages. J Immunol [Online], vol. 180, no. 6, pp. 
4265-4272, viewed Mar 15, doi: 10.4049/jimmunol.180.6.4265. 
SCHWARZ E M, HU Y, ANTOSHECHKIN I, MILLER M M, STERNBERG P W & 
AROIAN R V. 2015. The genome and transcriptome of the zoonotic hookworm 
Ancylostoma ceylanicum identify infection-specific gene families. Nat Genet [Online], 
vol. 47, no. 4, pp. 416-422, viewed 23 October 2015, doi: 10.1038/ng.3237. 
SILOSI I, BOLDEANU M V, MOGOANTA S S, GHILUSI M, COJOCARU M, BICIUSCA 
V, COJOCARU I M, AVRAMESCU C S, GHEONEA D I, SILOSI C A & TURCULEANU 
A. 2014. Matrix metalloproteinases (MMP-3 and MMP-9) implication in the 
pathogenesis of inflammatory bowel disease (IBD). Rom J Morphol Embryol [Online], 
 
 72 
vol. 55, no. 4, pp. 1317-1324, viewed 23 April 2015, doi: 
http://www.ncbi.nlm.nih.gov/pubmed/25611261 
SMITH P, MANGAN N E, WALSH C M, FALLON R E, MCKENZIE A N, VAN ROOIJEN 
N & FALLON P G. 2007. Infection with a helminth parasite prevents experimental 
colitis via a macrophage-mediated mechanism. J Immunol [Online], vol. 178, no. 7, 
pp. 4557-4566, viewed 4 May 2015, doi: http://www.ncbi.nlm.nih.gov/pubmed/17372014 
SUMMERS R W, ELLIOTT D E, URBAN J F, JR., THOMPSON R & WEINSTOCK J 
V. 2005a. Trichuris suis therapy in Crohn's disease. Gut [Online], vol. 54, no. 1, pp. 
87-90, viewed 13 April 2015, doi: 10.1136/gut.2004.041749. 
SUMMERS R W, ELLIOTT D E, URBAN J F, JR., THOMPSON R A & WEINSTOCK 
J V. 2005b. Trichuris suis therapy for active ulcerative colitis: a randomized controlled 
trial. Gastroenterology [Online], vol. 128, no. 4, pp. 825-832, viewed 24 April 2015, 
doi: http://www.ncbi.nlm.nih.gov/pubmed/15825065 
SUTTON T L, ZHAO A, MADDEN K B, ELFREY J E, TUFT B A, SULLIVAN C A, 
URBAN J F, JR. & SHEA-DONOHUE T. 2008. Anti-Inflammatory mechanisms of 
enteric Heligmosomoides polygyrus infection against trinitrobenzene sulfonic acid-
induced colitis in a murine model. Infect Immun [Online], vol. 76, no. 10, pp. 4772-
4782, viewed 26 September 2018, doi: 10.1128/iai.00744-07. 
TANG Y T, GAO X, ROSA B A, ABUBUCKER S, HALLSWORTH-PEPIN K, MARTIN 
J, TYAGI R, HEIZER E, ZHANG X, BHONAGIRI-PALSIKAR V, MINX P, WARREN W 
C, WANG Q, ZHAN B, HOTEZ P J, STERNBERG P W, DOUGALL A, GAZE S T, 
MULVENNA J, SOTILLO J, RANGANATHAN S, RABELO E M, WILSON R K, 
FELGNER P L, BETHONY J, HAWDON J M, GASSER R B, LOUKAS A & MITREVA 
M. 2014. Genome of the human hookworm Necator americanus. Nat Genet [Online], 
vol. 46, no. 3, pp. 261-269, viewed 9 May 2015, doi: 10.1038/ng.2875. 
THAI C T & OGATA R T. 2003. Expression and characterization of the C345C/NTR 
domains of complement components C3 and C5. J Immunol [Online], vol. 171, no. 12, 
pp. 6565-6573, viewed 6 April 2020, doi: 10.4049/jimmunol.171.12.6565. 
WALLACE J L, LE T, CARTER L, APPLEYARD C B & BECK P L. 1995. Hapten-
induced chronic colitis in the rat: Alternatives to trinitrobenzene sulfonic acid. Journal 
of Pharmacological and Toxicological Methods [Online], vol. 33, no. 4, pp. 237-239, 
viewed 01 August 2018, doi: https://doi.org/10.1016/1056-8719(95)00001-X. 
WANG Z, ABUBUCKER S, MARTIN J, WILSON R, HAWDON J & MITREVA M. 2010. 
Characterizing Ancylostoma caninum transcriptome and exploring nematode parasitic 
adaptation. BMC Genomics [Online], vol. 11, no. 1, pp. 1-19, viewed 23 October 2015, 
doi: 10.1186/1471-2164-11-307. 
YANG J, YAN R, ROY A, XU D, POISSON J & ZHANG Y. 2015. The I-TASSER Suite: 
protein structure and function prediction. Nat Methods [Online], vol. 12, no. 1, pp. 7-8, 








The anti-inflammatory properties of Necator 
americanus secreted protein Na-AIP-1 in adoptive T 
cell transfer colitis. 
 
 75 
3 The anti-inflammatory properties of Necator americanus 
secreted protein Na-AIP-1 in adoptive T cell transfer 
colitis. 
 
As our understanding of the nature of IBDs progress, it has become increasingly 
apparent that the induction and maintenance of periods of disease activity are 
dependent on a disruption to immune homeostasis.  Accordingly, the need for animal 
models which replicate the specific nature of this inflammatory condition becomes 
critical.  In the previous chapter, I was able to show the efficacy of Na-AIP-1 as an 
anti-colitic prophylactic in the TNBS model of murine colitis.  Whilst the acute and swift 
nature of the TNBS-induced colitis model is valuable in the initial screening of potential 
biologics, it is essential that animal models that are faithful to the human condition are 
utilised, especially when striving to understand the immune mechanisms driving the 
observed effects.  Delivered rectally in ethanol to assist in the breakdown of the mucus 
layer, TNBS is a haptenizing agent which induces an acute but transient immune 
response within 24 hr of delivery, characterised by severe weight loss, fatigue and 
bloody diarrhoea (Antoniou et al. 2016).  Whilst inflammation presents as primarily 
Th1-driven, characterised by the presence of high levels of IFNγ and IL-12, the limited, 
self-resolving nature of this model gives little insight into adaptive immune responses 
in a chronic condition.  As such, whilst useful for initial screening or assessing 
interventions to acute periods of disease activity, it is not possible to identify a human 
IBD to which this is a faithful depiction.  Similarly, the dextran sulfate sodium (DSS) 
model of colitis relies on chemical induction of transient colitic inflammation, of which 
weight loss and loose, bloody stools are a feature.  When added to the drinking water 
of mice, DSS progressively degrades the epithelial layer of the large intestine and 
erosive colitis develops within 7-14 days (Chassaing et al. 2014).  Whilst this disruption 
in barrier function is closer to the pathogenesis of human IBDs, inflammation presents 
with fundamental elements of Th1, Th17 and Th2 type responses, which is in stark 
contrast to the T cell specific nature of human IBDs (Kiesler et al. 2015).   
The adoptive T cell transfer model of murine colitis however represents an opportunity 
to examine the therapeutic effect of Na-AIP-1 in a disease-state which resembles 
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human CD in several key aspects.  The induction of transmural, pancolitic 
inflammation in immune-deficient mice receiving adoptive transfer relies upon aberrant 
T cell activation, in the presence of commensal microbiota (Ostanin et al. 2009).  This 
results in a chronic, Th1/Th17 driven inflammatory condition, typified by DC-mediated 
IL-12/23 secretion (Yang et al. 2020); consequently, anti-IL-12/23p40 antibodies are 
considered the preeminent positive control in this model (Yen et al. 2006).  Immuno-
compromised mice begin to exhibit clinical indicators of colitis 3-5 weeks after adoptive 
transfer of donor (WT) CD4+ T cells; traditionally slow, incremental weight loss is 
observed followed by loose stools, piloerection and fatigue, although these clinical 
indicators are not always present.  At termination, colon shortening and macroscopic 
injury may be observed, albeit not to the degree of the TNBS-induced model (Ostanin 
et al. 2009).  The chronic aspect of this model gives the advantage of demonstrating 
the impact of intervention on adaptive immune responses, and the selection of specific 
subtypes of CD4+ T cell for adoptive transfer permits a greater characterisation of the 
role of TREGS in this disease (Wirtz et al. 2007).  Unlike transient models of induced 
colitis, the ongoing sub-acute inflammation also enables an assessment of the longer-
term complications generated by fibrotic tissue remodelling.  Whilst it must be 
acknowledged that the pathogenesis of adoptive transfer-induced colitis - the 
disruption of T cell homeostasis in a leukopaenic host - is not characteristic of IBD, the 
established state of inflammation in this model however is reflective of human CD.  A 
further confirmation of the suitability of this model is indicated in comparative 
transcriptional studies, whereby 30 of 32 genes associated with IBD were altered in 
the adoptive transfer colitis model (te Velde et al. 2007).   In contrast, transcription of 
only 2 of these genes were modified in TNBS-induced colitis.  Accordingly, in these 
studies, I investigate the effect of prophylactic administration of Na-AIP-1 on CD4+ 
CD25- T cell transfer-induced colitis in immunocompromised mice, and begin 
preliminary investigations into the immunological landscape induced by Na-AIP-1 
administration.  Furthermore, I explore the impact of differing dosage strategies, 





3.1 Materials and methods 
3.1.1 Animals  
B6.SVJ129-Rag1 (RAG KO) and C57BL/6 mice, male and aged 5-7 weeks, were 
obtained from Animal Resources Centre (Murdoch, Australia) or Australian 
BioResources (Moss Vale, Australia) and allowed to acclimatise for 7 days before the 
commencement of the experimental period.  Mice received autoclaved food and water 
ad libitum, and were maintained in pathogen-free conditions in a temperature-
controlled room with a 12-hr light/dark illumination cycle.  Experiments were approved 
by the James Cook University Animals Ethics Committee under Ethics Approval 
numbers A2379 and A2571 and were conducted in accordance with National Health 
and Medical Research Council Australian Code for the Care and Use of Animals for 
Scientific Purposes (8th Edition, 2013) and in compliance with the Queensland Animal 
Care and Protection Act, 2001 (Act No.64 of 2001). 
 
3.1.2 Induction of colitis 
Colitis was induced in RAG KO mice using established protocols (Ostanin et al. 2009).  
Briefly, spleens were harvested from C57BL/6 WT donor mice into RPMI with 2% FBS 
on ice.  Spleens were gently homogenised into a suspension, passed through a 70 
μm strainer and incubated with red blood cell lysis buffer (Sigma-Aldrich) at room 
temperature for no longer than 5 min.  CD4+ cells were isolated by negative selection 
via magnetic separation, using the EasySep CD4+ T Cell Isolation kit (Stemcell 
Technologies) as per manufacturer’s instructions.  Enriched T cells were labelled with 
APC-conjugated anti-mouse CD4 (clone RM4-5; BD Biosciences) and FITC-
conjugated anti-mouse CD25 (clone AL-21; BD Biosciences) and sorted into CD4+ 
CD25- fractions on BDTM FACSAria III.  Each RAG KO mouse received 100 μL of PBS 
containing 4 x 104 purified CD4+ CD25- cells by i.p. injection on day 0.   
 
3.1.3 Treatment administration 
For prophylactic studies, group Na-AIP-1 received 1 mg/kg of purified recombinant 
protein, as indicated.  Group HA (negative control) received 1 mg/kg of purified HA, 
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expressed and purified in P. pastoris under identical conditions to the hookworm 
proteins, as indicated.  Group PBS (vehicle control) received 200 uL of sterile PBS, as 
indicated. Group αIL12/23 (positive control) received 1 mg of InVivoMAb purified anti-
mouse IL-12/IL-23p40 (clone C17.8) antibody (BioXcell) as indicated (Lindebo Holm 
et al. 2012). All treatments were administered via i.p. administration, prepared with 
PBS to a final volume of 200 μL.   
For therapeutic studies (n = 8 unless otherwise indicated), i.p. treated mice received 
either 1 mg/kg or 3 mg/kg (n = 7) of purified recombinant Na-AIP-1, prepared with PBS 
to a final volume of 200 μL twice per week from day 29 onwards.  PBS (vehicle control) 
received 200 uL of sterile PBS twice per week from day 29 onwards. Mice that 
received oral dosing received 5 mg/kg or 25 mg/kg of purified recombinant Na-AIP-1, 
prepared as an emulsion in olive oil (Bertolli Extra Virgin olive oil) to a final volume of 
200 μL, and delivered by gavage twice per week from day 29 onwards.  Group PBS-
OIL (vehicle control) received a PBS-olive oil emulsion of identical volume (39 μL PBS 
and 161 μL olive oil per dose) twice per week from day 29 onwards.  Group αIL12/23 
positive control mice received 1 mg of anti-mouse IL-12/IL-23p40 (clone C17.8) 
antibody i.p. either from day 0 (n = 4) or day 29 (n = 5) onwards.  Oral therapeutic 
studies were conducted in parallel with the i.p. therapeutic studies and these 
experiments shared positive control groups. 
The recombinant protein dosage levels were determined in consideration with results 
from previous studies in the TNBS model of murine colitis.  Mice were randomly 
divided into treatment groups of five per cage unless otherwise stated. 
 
3.1.4 Clinical and macroscopic disease scores 
Mice were weighed and assessed for clinical signs of disease twice weekly.  
Piloerection and lethargy, diarrhoea and colon thickening were graded according to 
severity from 0 (absent) to 2 (severe), to a maximum cumulative total score of 6.  For 
therapeutic studies, clinical observations were normalised to the date treatment 
commenced, and graphed as fluctuations from this normalised baseline.  At necropsy, 
colons were removed, flushed with PBS and assessed for length and macroscopic 
signs of disease.  Adhesion, oedema and thickening were graded according to severity 
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from 0 (absent) to 2 (severe), and ulceration was graded from 0 (absent) to 3 
(necrotic), to a maximum cumulative total score of 9.   
 
3.1.5 Histological analysis of distal colon tissue 
Distal colon tissue was harvested in 1 cm sections and fixed in 4% formalin overnight, 
whereupon tissue was transferred to 70% EtOH.  Histology was performed as outlined 
in section 2.1.6.  Images were examined for visible changes and blinded scoring was 
conducted.  Tissue sections were scored on a scale of 0-5 for each of the following 
parameters; (1) epithelial pathology (crypt elongation, hyperplasia, and erosion), (2) 
mural inflammation and (3) oedema for an overall maximal total histology score of 15. 
 
3.1.6 Flow cytometric analysis of colon tissue 
Phenotypic flow cytometry was conducted on isolated colon lamina propria layer (CLP) 
and intraepithelial layer (IEL) cells, which were prepared using established protocols 
(Weigmann et al. 2007, Couter and Surana 2016).  Briefly, 1 cm sections of colon were 
harvested from RAG KO mice during necropsy, flushed with PBS and collected into 
RPMI with 2% FBS on ice.  LPL were extracted from whole colon sections using 
extraction buffer (PBS, 5 mM EDTA, 2% FBS) and incubated with shaking (150 rpm) 
for 30 min at 37°C.  IEL were isolated from the remaining tissue using digestion buffer 
(RPMI, collagenase type 1: 200 units/mL, DNase type 1: 2000 units/mL) and incubated 
with shaking (150 rpm) for 30 min at 37°C.  The tissue was then gently homogenised 
into a suspension and passed through a 70 μm strainer.  Cells were labelled with 
V500-conjugated anti-mouse CD45.2 (clone 104; BD Biosciences) and V450-
conjugated anti-mouse CD4 (clone RM4-5; BD Biosciences).  Flow cytometry was 
conducted on a BDTM FACSAria III.    
Cytokine detection was conducted on whole colon tissue homogenate (500 µL PBS/1 
cm tissue) using a BDTM Mouse Inflammation Kit Cytometric Bead Array (CBA) (BD 
Biosciences), as per the manufacturer’s instruction.  Flow cytometry was conducted 




3.1.7 Statistical Analyses 
All groups were n = 5 unless otherwise stated.  All data are presented as mean ± SEM.  
Visualisation and analysis of CBA was conducted using FCAP ArrayTM software 
version 3.0.  Visualisation and analysis of flow cytometry data was conducted using 
FlowJoTM Software (for Mac) version 10.6.  Statistical analyses were conducted using 
GraphPad Prism 8 software.  Comparisons between all groups at multiple time points 
were conducted using unpaired, two-way ANOVA (Holm Sidak) unless otherwise 
specified. Comparisons between individual groups were performed by unpaired, two-
way Mann-Whitney U tests (Holm Sidak), vs. negative/vehicle control, unless 




All mice treated with Na-AIP-1, αIL12/23, HA and PBS attained 100% survival until 
experimental completion. 
 
3.2.2 Prophylactic administration of Na-AIP-1 limits clinical colitic pathology 
in RAG KO mice.  
The primary goal of this chapter was to determine whether the anti-colitic effect of Na-
AIP-1 in TNBS colitis could be replicated using both prophylactic and therapeutic 
administration in a chronic, immune-mediated model of gut inflammation.  RAG KO 
mice (n = 6 per treatment group) received donor CD4+ CD25- cells i.p. on day 0 of the 
experimental period.  Treatments were also established on day 0, and mice received 
Na-AIP-1 or HA twice per week to termination, or αIL12/23 once per week to 
termination, via i.p. injection.  HA treated mice showed clear evidence of established 
colitis by day 21, with a mean loss in body weight of -2.5% (0.6 ± 0.4 g) between days 
18 to 21, and a further mean loss of -4.8% (2.1 ± 0.6 g) between days 21 and 25 
(Figure 3.1A).  In contrast, mice treated with Na-AIP-1 consistently gained weight 
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during these periods, which by termination had reached p < 0.0001 (vs. HA-treated 
mice).  This trend was mirrored when scoring for clinical indicators of disease, which 
were recorded twice weekly from day 21 (Figure 3.1B).  At termination, colons of mice 
receiving HA (8.3 ± 0.1 cm,) were significantly shorter than the positive control group 
treated with αIL12/23 (11.5%; 9.4 ± 0.3 cm; p = 0.004) and the Na-AIP-1 treatment 
group (10.9%; 9.3 ± 0.3 cm; p = 0.04) (Figure 3.1C-D).  This data implies that Na-AIP-





Figure 3.1:  Prophylactic administration of Na-AIP-1 limits clinical pathology in 
colitic RAG KO mice.  Mice received adoptive transfer of 4 x 104 CD4+ CD25- T cells 
on day 0.  Na-AIP-1 and HA were administered via i.p. injection twice weekly from day 
0, or αIL12/23 once weekly from day 0.  Body weight (A) and clinical signs of disease 
(B) were measured twice weekly.  Colons were removed and measured at termination 
(C-D).  Data are presented as mean ± SEM.  Multiple measure comparisons were 
conducted using a two-way RM ANOVA (Holm-Sidak).  Single measure comparisons 
were conducted using a two-way Mann Whitney T-test (non-parametric).   * p ≤ 0.05, 
significantly different from HA negative control group; ** p ≤ 0.01, significantly different 
 
 83 
from HA negative control group.  **** p ≤ 0.0001, significantly different from HA 
negative control group.  Experiment was performed in triplicate; representative results 
from a single experiment are shown. 
 
3.2.3 Prophylactic administration of Na-AIP-1 limits inflammatory 
histopathology in RAG KO mice. 
Analysis of the histological pathology of the colon is considered to be the strongest 
indicator of inflammatory damage in the T cell transfer model of murine colitis (Ostanin 
et al. 2009).  Mice treated with HA displayed evidence of longitudinal epithelial 
hyperplasia, relatively dense leukocyte infiltration in the lamina propria, and a degree 
of goblet cell loss which is particularly striking when compared to mice treated with 
Na-AIP-1 (Figure 3.2).  Histopathology scores in mice receiving αIL12/23 (0, ± 0; p = 
0.004) and Na-AIP-1 (1.6, ± 1.2; p = 0.009) reflect a significant preservation of colonic 
architecture and minimal visible infiltration of the lamina propria or thickening of the 
muscularis.  A considerable divergence in scoring is apparent when comparing Na-
AIP-1 treated mice with the negative control group (8.8, ± 0.9).  This supports the 
premise that prophylactic i.p. delivery of Na-AIP-1 was able to supress inflammation 




Figure 3.2:  Prophylactic administration of Na-AIP-1 limits inflammatory 
histopathology in colitic RAG KO mice.  Caecum and colon were removed at 
termination, and assessed blinded for histological evidence of inflammatory pathology 
(A).  H&E stained distal colon sections (B). Data are presented as mean ± SEM.  
Comparisons were conducted using two-way Mann Whitney T-test (non-parametric).  
** p ≤ 0.01, significantly different from HA negative control group.  Representative 
results from a single experiment are shown. 
 
3.2.4 Prophylactic administration of Na-AIP-1 induces a protective environment 
in colitic RAG KO mice by reducing intestinal T cell frequency and limiting IFNγ 
expression. 
In order to begin to determine the nature of the changes induced by Na-AIP-1 
administration, phenotypic flow cytometry was conducted on pooled samples from 
each of the treatment conditions.  Live cells were identified by size and complexity, 
and lymphocytes determined by gating on CD45+ cells. Cells which were CD45+ 
CD4+ were classed as T cells.  Of lymphocytes present in the isolated IEL samples, 
43% were confirmed as T cells in the HA group (Figure 3.3A), which reduced to 23% 
in the αIL12/23 group.  Mice treated with Na-AIP-1 displayed a similarly reduced ratio 
with only 20% of leukocytes classified as T cells.  CLP samples indicate a dramatic 
reduction in T cells in mice treated with αIL12/23 (8%) and Na-AIP-1 (10%), in 
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comparison with mice receiving HA (41%).  Assessment of cytokines in whole colon 
tissue samples revealed IFNγ in all Na-AIP-1 and αIL12/23 treated mice was below 
detectable levels, but was present in high concentration in HA treated mice (6328, ± 
391.8 pg/g/mL) (Figure 3.3B).  Whilst not reaching statistical significance (p = 0.07 
vs. HA), there was also a trend towards an increase in IL-4 in the Na-AIP-1 group 
(Figure 3.3C).  Together, this data suggests that Na-AIP-1 administration results in a 





Figure 3.3: Prophylactic administration of Na-AIP-1 induces a protective 
environment in RAG KO receiving adoptive transfer of CD4+ CD25- cells mice 
by reducing intestinal T cell frequency and limiting IFNγ expression.  
Comparative analysis of intraepithelial cells (IEL) and lamina propria (CLP) from 
pooled distal colon sections (A).  Flow cytometry detection of IFNγ in whole colon 
tissue samples (B).  Detection of IL-4 by cytometric bead assay (C).  Data are 
presented as mean ± SEM.  Comparisons were conducted using two-way Mann 
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Whitney T-test (non-parametric).   * p ≤ 0.05, significantly different from HA negative 
control group.  Representative results from a single experiment are shown. 
 
3.2.5 Therapeutic intervention with Na-AIP-1 was ineffective in established 
colitis 
Having confirmed the potency of Na-AIP-1 as a prophylactic intervention in T cell-
mediated murine colitis, I then wanted to assess its efficacy as a rescue treatment in 
established colitis.  Accordingly, in this experiment treatment for all groups, excepting 
the αIL12/23 prophylactic group (administration started at day 0), commenced at day 
29 of the experimental period. Na-AIP-1 was also administered at two concentrations 
(1 mg/kg and 3 mg/kg) in order to account for this change in protocol. 
None of the therapeutic treatments administered from day 29 onwards were able to 
have a significant impact on colitis-induced weight loss, clinical indicators of disease 
or macroscopic signs of injury at termination (Figure 3.4A-C).  Histological analysis of 
distal colon tissue sections revealed that despite no improvement in the clinical scores, 
mice receiving therapeutic administration of αIL12/23 showed the least inflammatory 
damage, reaching statistical significance (p = 0.04, vs. PBS) (Figure 3.4D).  A lack of 
consistent results within the Na-AIP-1 treated groups means that whilst a number of 
mice showed no or minimal inflammatory damage, statistical significance was not 
reached.  Accordingly, i.p. delivery of Na-AIP-1 at concentrations of both 1 mg/kg and 







Figure 3.4:  Therapeutic intervention with Na-AIP-1 was ineffective in 
established colitis.  Mice received adoptive transfer of donor CD4+ CD25- T cells on 
day 0.  PBS or Na-AIP-1 were delivered via i.p. injection twice weekly from day 29 at 
a concentration of either 1 mg/kg (1) or 3 mg/kg (3).  αIL12/23 was administered i.p. 
once weekly from either day 0 (p) or day 29 (t).  Body weight (A) and clinical signs of 
disease (B) were measured twice weekly.  Colons were removed at termination and 
assessed for macroscopic pathology (C).  Blinded histological scoring of inflammatory 
pathology in H&E stained distal colon sections (D).  Data are presented as mean ± 
SEM.  Multiple measure comparisons were conducted using a two-way RM ANOVA 
(Holm-Sidak).  Single measure comparisons were conducted using a two-way Mann 
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Whitney T-test (non-parametric).   * p ≤ 0.05, significantly different from PBS vehicle 
control group; ** p ≤ 0.01, significantly different from PBS vehicle control group.  
Representative results from a single experiment are shown. 
 
3.2.6 Na-AIP-1 lacks oral activity when delivered as a therapeutic intervention. 
In order to assess whether the route of administration would impact on the efficacy of 
Na-AIP-1 as a rescue treatment in established colitis, an adoptive T cell transfer 
experiment was also conducted in mice receiving oral administration of Na-AIP-1.  
There was no improvement between orally dosed Na-AIP-1 groups and the negative 
control PBS-OIL group in any of the measured parameters (Figure 3.5A-D).  These 
results imply a lack of activity as a rescue therapy when Na-AIP-1 is delivered by oral 





Figure 3.5:  Na-AIP-1 lacks oral activity when delivered as a therapeutic 
intervention.  Mice received adoptive transfer of donor CD4+ CD25- T cells on day 
0.  Oral gavage of PBS or Na-AIP-1 at 5 mg/kg (5) or 25 mg/kg (25) were delivered 
twice weekly from day 29 as an emulsion in olive oil.  αIL12/23 was administered i.p. 
once weekly from either day 0 (p) or day 29 (t).  Body weight (A) and clinical signs of 
disease (B) were measured twice weekly.  Colons were removed at termination and 
assessed for macroscopic pathology (C).  Blinded histological scoring of inflammatory 
pathology in H&E stained distal colon sections (D).  Multiple measure comparisons 
were conducted using a two-way RM ANOVA (Holm-Sidak).  Single measure 
comparisons were conducted using a two-way Mann Whitney T-test (non-parametric).  
* p ≤ 0.05, significantly different from PBS vehicle control group; ** p ≤ 0.01, 
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significantly different from PBS vehicle control group.  Representative results from a 
single experiment are shown. 
 
3.3 Discussion 
In the selection of an animal model of disease for assessing the suitability of potential 
drug candidates, it is essential that the condition mirrors the human disease to which 
it corresponds.  The adoptive transfer model represents a colitis model which, unlike 
chemically-induced acute erosive models, replicates the chronic nature of human 
IBDs, and produces a similar histological and immunological profile (Kjellev et al. 
2006).  Traditionally, colitis induction was instigated by the transfer of CD4+ 
CD45RBhigh T cells to congenial immunocompromised mice; however, more recently 
the CD4+ CD25- adoptive transfer model has emerged as an alternative in which 
induction can be achieved more efficiently and with less variability.  Additionally, 
reconstitution with CD4+ CD25- ensure the presence of naïve T cells, and prevents 
the introduction of naturally occurring IL-10 expressing TREGS, which have prior been 
evidenced to quell colitic inflammation in mice (Mottet et al. 2003), and suppress 
activity associated with autoimmunity (Bala and Moudgil 2006).  
In this study I have demonstrated that Na-AIP-1 is able to induce potent suppression 
of inflammatory activity when delivered i.p. prior to, or during the onset, of CD4+ CD25- 
T cell transfer-induced murine colitis.  Throughout the experimental period, mice 
receiving prophylactic Na-AIP-1 demonstrated a resistance to colitis-induced weight 
loss, and further displayed very limited, if any, piloerection, rectal irritation or disruption 
to their stool consistency indicative of ongoing disease.  Terminal statistics and 
imagery confirmed minimal inflammatory injury in sampled tissues.  I also observed a 
corresponding reduction in pro-inflammatory T cell populations in the colon in Na-AIP-
1-treated mice.  Adjusting the administration strategy had a dramatic effect on the 
efficacy of Na-AIP-1 to exert an anti-colitic effect.  In established colitis, i.p. 
administration of Na-AIP-1, even at higher concentrations, appeared largely ineffective 
as a rescue treatment.  There was no visible impact on the clinical aspects of the 
disease of Na-AIP-1-treated mice prior to termination.  At termination, scoring of 
macroscopic colon injury revealed no consistent or statistically significant difference 
was recorded between treatment groups (Figure 3.4D).  When examining histological 
pathology, inconsistencies within treatment groups prevent any meaningful conclusion 
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from being drawn, and no statistical significance was reached.  Duplication of this 
protocol with an increased administration frequency could shed more light on the 
potential of the exploitation of Na-AIP-1 as a therapeutic biologic.  Direct enteric 
administration via oral gavage of Na-AIP-1, when administered at this frequency using 
olive oil as a vehicle, did not display any meaningful or consistent anti-colitic efficacy.  
Whilst it is acknowledged that a lack of regulatory influences enables colitic 
inflammation to perpetuate in this model, it is unclear without further investigation how 
prophylactic Na-AIP-1 is able to arrest the associated pathology.  This may be driven 
by an interference in T cell stimulation or motility, or Na-AIP-1 may be acting directly 
on T cells or on upstream processes involved in their activation, such as antigen 
presentation.  A reduction in T cells in both the IEL and cLP samples from Na-AIP-1-
treated mice was detected, yet at this stage it is unclear whether this is due to a direct 
or downstream inhibition of effector T cell trafficking, proliferation or survival, or a 
combination of all three.  There are several approaches to determining this.  Cell 
proliferation assays including BrdU labelling with fluorescence microscopy, or CFSE 
labelling with flow cytometry, can measure localised T cell expansion (Dock et al., 
2017).  Similar labelling and detection of apoptosis markers of gut-resident cells can 
be achieved via flow cytometry using Annexin V assays (Crowley et al., 2016); the 
comparison of which with peripheral T cells will clarify whether treatment with Na-AIP-
1 is preferentially activating programmed cell death pathways.  Expression of gut 
homing receptors CCR9 and integrin α4β7 may elucidate whether there is any impact 
on T cell transporting (De Calisto et al., 2012).   
One tantalising hint towards a potential mechanism is the upturn in IL-4 detected in 
mice receiving Na-AIP-1 which, whilst not reaching statistical significance, may still 
bear some biological relevance.  Human helminthiases are known to elicit a Th2 
immune response, characterised by an increase in IL-4 production, which acts via 
feedback loop to downregulate the Th1-associated responses we would expect to see 
in this model of experimental colitis, including the production of pro-inflammatory 
cytokines such as IFNγ (Anthony et al. 2007).  Accordingly, one could hypothesise 
that Na-AIP-1 may even act upon CD4+ NK1.1+ cells, stimulating the release of IL-4 
and promoting CD4+ differentiation to a Th2-like phenotype (Anthony et al. 2007).  
Interestingly, a role for NK cells in the mediation of T cell transfer colitis has been 
previously demonstrated (Fort et al. 1998).  Despite initially being suspected of 
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instigating and perpetuating inflammation via IFNγ secretion, NK cells were revealed 
to supress inappropriate effector cell responses to intestinal microbiota in the CD4+ 
CD45RBhigh colitis model.  In a similar adoptive transfer model, relying on 
reconstitution of RAG KO mice with purified CD4+ CD44- CD62L+ cells, Yamaji et al. 
(2012) demonstrated that mAb blockade of NK1.1+ cells exacerbated the onset of 
colonic inflammation.  The plausibility of NK cell involvement is strengthened by the 
characterisation of the influence of N. americanus secretions on this cellular subtype 
(Teixeira-Carvalho et al. 2008).  In vitro studies were able to demonstrate N. 
americanus significantly influenced the migratory and effector functionality of NK cells 
in response to their ES products.  Experimental analysis of the direct effects of Na-
AIP-1 on specific lymphocyte populations should be conducted in order to help 
elucidate the manner by which this molecule is able to subdue the onset of colitic 
inflammation. 
In conclusion, the results included within validate the anti-colitic properties of Na-AIP-
1 when administered as an i.p. injected prophylactic treatment in the CD4+ CD25- T 
cell transfer model of murine gut inflammation.  Preliminary results indicate Na-AIP-1 
reduces the frequency of CD4+ T cells at the site of insult, and curtails the production 
of pro-inflammatory Th1 cytokine IFNγ.  Similar dosing concentrations and regimens 
in established colitis have little positive effect, but there are potential implications that 
intensifying either (or both) of those criteria may enhance its potential as a rescue 
therapy in IBD.  This data parallels our preliminary findings in the TNBS-induced model 
of colitis and endorses further studies to examine the mechanism of action driving the 
anti-colitic effect of Na-AIP-1.  Furthermore, whilst several studies have been 
published detailing the potential of hookworm-derived products in the TNBS and DSS 
models of murine colitis (Ferreira et al. 2017, Eichenberger et al. 2018, Wangchuk et 
al. 2019), there are no reports of the effects of helminth ES-derivatives this more 
robust replication of human CD.  As such the studies contained within represent an 
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4 Characterising the immune cell response to Na-AIP-1 in 
mice
 
The validation of Na-AIP-1 as an anti-inflammatory agent in distinct murine strains and 
models of colitis reinforces its potential as a candidate for pharmacological 
development.  My studies to date have revealed that prophylactic i.p. administration 
of Na-AIP-1 induces a downregulation in colonic IFNγ-secreting CD4+ effector T cells 
during active intestinal inflammation, but the systemic influence on the immune 
system, and the mechanism driving such, remain undescribed.  Various modes of 
modulation of the human immune system by intestinal helminths, including N. 
americanus, have been described to date.  Evasion strategies employed by helminths 
during human parasitosis include inducing IL-10 and TGF-β upregulation to instigate 
FoxP3+ TREG proliferation (Flynn and Mulcahy 2008, Turner et al. 2008, Layland et al. 
2010), induction of DC tolerogenicity (Semnani et al. 2001, Segura et al. 2007), T cell 
anergy via macrophage-dependent mechanisms (Smith et al. 2004, Smith et al. 2007) 
and disruption of cell signalling pathways (Gao et al. 2013, Vukman et al. 2013).  The 
identification of various compounds being employed to accomplish this 
immunomodulation has granted the opportunity to describe some of the key molecular 
influences on individual leukocyte populations. 
Several studies have revealed distinct immune cell subpopulations that are targeted 
by immunomodulatory hookworm secreted proteins.  N. americanus-derived 
secretions have previously been shown to bind to human NK cells, manipulating IFNγ 
production (Teixeira-Carvalho et al. 2008).  Research later conducted by Tribolet et 
al. (2015) established that the Na-ASP-2 protein binds to human B cell surface 
proteins, influencing signalling pathways to inhibit effector B cell activation.  
Acanthocheilonema viteae secreted protein ES-62 similarly targets B cells by 
subverting TLR4 signalling, driving expansion of the IL-10 producing regulatory B cell 
(BREG) subset (Rodgers et al. 2014, Rodgers et al. 2015).  Ac-AIP-2, a TIMP-like 
protein secreted by A. caninum which shares a netrin-domain morphology with Na-
AIP-1, likewise induces an anti-inflammatory, regulatory immune setting and has 
displayed potent efficacy in a murine model of asthma (Navarro et al. 2016).  This 
molecule, upon capture by mesenteric CD11c+ CD103+ DCs, induces tolerogenicity, 
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which in turn drives CD4+ FoxP3+ TREG cell accumulation in the trachea and small 
intestine.  However, the mechanism of helminth immunomodulation is not limited to 
direct cellular binding.  A study by Osbourn et al. (2017) confirmed Heligmosomoides 
Polygyrus ES protein HpARi directly binds to extra-cellular IL-33 to prevent the 
initiation of allergic inflammation, and has also proved to be efficacious in a murine 
asthma model. The ability of helminths to target and influence functionally distinct 
leukocyte phenotypes via diverse mechanisms highlights their sophistication in 
manipulating host immunity.  Indeed, the recognition of diverse immunomodulatory 
mechanisms being employed concurrently by N. americanus makes the elucidation of 
the mechanism driving Na-AIP-1 activity all the more compelling. 
The studies contained within this chapter examine the effect of fluorescently tagged 
Na-AIP-1 administration on key leukocyte populations in healthy mice, identifying 
tissues and cellular phenotypes in which the protein localises to and associates with.   
 
4.1 Materials and methods 
4.1.1 Animals  
Male and female C57BL/6 mice and male BALB/c, aged 5-7 weeks, were obtained 
from Animal Resources Centre (Murdoch, Australia).  Male and female 
C57BL/6.CD11c.DTR aged 6+ weeks, were obtained from James Cook University 
Small Animal Facility (Townsville, Australia).  C57BL/6 Il10-GFP × FoxP3-RFP dual 
reporter mice (Wan and Flavell 2005, Kamanaka et al. 2006, Zhang et al. 2017) aged 
6+ weeks were obtained from the colony established at QIMR Berghofer Medical 
Research Institute (Brisbane, Australia).  All mice were allowed to acclimatise for 7 
days before the commencement of the experimental period.  Mice received autoclaved 
food and water ad libitum, and were maintained in pathogen-free conditions in a 
temperature-controlled room with a 12-hr light/dark illumination cycle.  Experiments 
were approved by the James Cook University Animals Ethics Committee under Ethics 
Approval numbers A2379 and conducted in accordance with National Health and 
Medical Research Council Australian Code for the Care and Use of Animals for 
Scientific Purposes (8th Edition, 2013) and in compliance with the Queensland Animal 
Care and Protection Act, 2001 (Act No.64 of 2001). 
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4.1.2 Na-AIP-1 labelling 
NAIP-647 was created using Alex FluorTM 647 Protein Labelling Kit (Molecular 
ProbesR).  Manufacturer’s protocol was optimised for use with 12-20 kDa proteins. 
 
4.1.3 Experimental treatments 
All treatments were administered via intra-peritoneal (i.p.) administration as indicated, 
prepared with PBS to a final volume of 200 μL. Mice were sacrificed via CO2 
asphyxiation. 
 
4.1.3.1 Cellular uptake study 
BALB/c mice were randomly allocated to treatment groups and received either PBS, 
Na-AIP-1 conjugated with Alexa Fluor 647 (NAIP-647; 1 mg/kg) or unlabelled Na-AIP-
1 (1 mg/kg; n = 3).  
 
4.1.3.2 CD11c.DTR experiment 
Male and female C57BL/6.CD11c.DTR (DTR) or C57BL/6 (WT) mice were randomly 
allocated to the various treatments, with an even split between sexes. All mice 
received 500 ng diphtheria toxin (Sigma-Aldrich) as indicated.  Groups HA (WT) and 
HA (DTR) (negative control) received 1 mg/kg of purified HA, expressed and purified 
in P. pastoris under identical conditions to the hookworm proteins (Low and Wiles 
2016), as indicated.  Groups Na-AIP-1 (WT) and Na-AIP-1 (DTR) received 1 mg/kg of 
purified recombinant Na-AIP-1 as indicated. Depletion of CD11c+ cells was confirmed 
by comparing CD3- CD19- CD11c+ MHCII+ cell frequency in the live mLN cells 




4.1.3.3 FoxP3 reporter experiment 
Male and female C57BL/6 Il10-GFP × FoxP3-RFP mice were randomly allocated to 
treatment groups, with an even split between sexes.  Group Na-AIP-1 (n = 6) received 
1 mg/kg of purified recombinant Na-AIP-1.  Group TNa (n = 4; negative control) 
received 1 mg/kg of recombinant Na-AIP-1 from the same batch, which had been 
denatured by trypsinising and boiling, in methods described elsewhere (Ferreira et al. 
2013).  Briefly, Na-AIP-1 was digested with 1 μg trypsin/μg protein (Sigma-Aldrich), 
incubated overnight at 37°C, and then heated at 95°C for 1 hr. 
 
4.1.4 Tissue collection and preparation 
Tissues were collected at termination and prepared for flow cytometric analysis using 
previously well-established techniques (Zhang et al. 2008, Ray and Dittel 2010, Van 
Hoecke et al. 2017).  Briefly, blood was collected into a heparin-containing tube, with 
cells pelleted by centrifugation and incubated with RBC lysis buffer (Sigma-Aldrich 
R7757) for 2 min at room temperature.  Bronchoalveolar lavage (BAL) was conducted 
by incision of the trachea and subsequent flushing of the lung using a 21 g needle 
attached to a 1 mL syringe containing pre-chilled sterile PBS.  Lavage was repeated 
to a total final collection volume of 3 mL per mouse.  Samples were kept on ice, with 
cells isolated by centrifugation.  Peritoneal exudate cells (PEC) were collected by 
insertion and flushing of the peritoneal cavity with a 21 g needle attached to a 3 mL 
syringe containing pre-chilled sterile PBS. Lavage was repeated to a total final 
collection volume of 7-9 mL per mouse.  Samples were kept on ice, with cells isolated 
by centrifugation.  Mesenteric lymph nodes (mLN) were collected into RPMI with 2% 
FBS on ice.  mLN were transferred to digestion buffer (RPMI, collagenase type 1: 200 
units/mL, DNase type 1: 2,000 units/mL) and incubated with shaking (150 rpm) at 37°C 
for 25 min, then gently homogenised into a suspension and passed through a 70 μm 
strainer.  Colon tissue (1 cm section, flushed with PBS) was collected into RPMI with 
2% FBS on ice, then transferred to tubes containing extraction buffer (PBS, 5 mMol 
EDTA, 2% FBS) and incubated with shaking (150 rpm) for 30 min at 37°C.  Samples 
were transferred to digestion buffer and incubated with shaking (150 rpm) at 37°C for 
25 min, then gently homogenised into a suspension and passed through a 70 μm 
strainer.  Colon suspensions were incubated with RBC lysis buffer for 5 min at room 
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temperature.  Spleens were collected into RPMI with 2% FBS on ice.  These were 
transferred to digestion buffer and incubated with shaking (150 rpm) at 37°C for 25 
min, then gently homogenised into a suspension and passed through a 70 μm strainer.  
Spleen suspensions were incubated with RBC lysis buffer for 5 min at room 
temperature. 
 
4.1.5 Flow cytometric analyses 
Cells were labelled with FITC-conjugated anti-mouse Ly6c (clone AL-21; BD 
Biosciences), PerCP5.5-conjugated anti-mouse CD11b (clone M1/70; BD 
Biosciences), PerCP5.5-conjugated anti-mouse EPCAM (clone G8.8; eBioscience), 
PE-conjugated anti-mouse MHCII (I-A/I-E) (clone M5/114.15.2; BD Biosciences), PE-
conjugated anti-mouse SiglecF (clone E50-2440; BD Biosciences), AF594-conjugated 
anti-mouse CD8a (clone 53-6.7; eBioscience), AF594-conjugated anti-mouse CD19 
(clone eBio1D3; eBiosciences), PE-Cy7-conjugated anti-mouse F4/80 (clone BM8; 
eBiosciences), v450-conjugated anti-mouse CD11c (clone HL3; BD Biosciences), 
AF700-conjugated anti-mouse CD45.2 (clone 104; BD Biosciences), APC-CY7-
conjugated anti-mouse CD3e (clone 145-2C11; eBiosciences), APC-conjugated anti-
mouse CD4 (clone RM4-5; BD Biosciences), V500-conjugated anti-mouse CD45.2 
(clone 104; BD Biosciences) and APC-Cy7-conjugated anti-mouse CD3e (clone 145-
2C11; eBioscience).  Total cellularity was calculated using AccuCheck Counting 
Beads (Molecular ProbesR) according to the manufacturer’s instruction.  Flow 
cytometry was conducted on a BD LSRFortessaTM X-20. 
 
4.1.6 TNBS-induced colitis 
Colitis was induced via intra-rectal injection of 100 µL 2.5 mg TNBS in 50% EtOH, as 
described elsewhere (Cobos Caceres et al. 2017).  Briefly, mice were anaesthetised 
via intra-peritoneal injection of 6.25% ketamine/0.625% xylazine solution, 
administered in sterile PBS at 200 µL per mouse.  Sedated mice each received intra-
rectal administration of 100 µL of TNBS/EtOH as per group assignment, via careful 
insertion of a flexible catheter (Gauge 20G× 11/4”, I.D. 0.80× 32 mm) with lubricant 
gel into the colon 4 cm proximal to the anus.  Mice were inverted (head down) for ~2 
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min prior to being returned to their cage to minimise leakage.  TNBS administration 
was conducted on days zero and seven of the experimental period.   
 
4.1.7 Clinical and macroscopic disease scores 
Mice were assessed daily for clinical signs of disease and scored using criteria 
adapted from Ruyssers et al. (2009).  Piloerection and lethargy, diarrhoea, and rectal 
thickening/bleeding were graded according to severity from 0 (absent) to 2 (severe), 
to a maximum cumulative total score of 6.  At necropsy, colons were removed, flushed 
with PBS and assessed for length and macroscopic signs of disease utilising criteria 
adapted from Ruyssers et al. (2009).  Adhesion, oedema, and thickening were graded 
according to severity from 0 (absent) to 2 (severe), and ulceration was graded from 0 
(absent) to necrosis (3), to a maximum cumulative total score of 9.  Any deviations 
from these scoring rubrics have been noted where applicable. 
 
4.1.8 Statistical Analyses 
All groups n = 5 unless otherwise stated.  All data are presented as mean ± SEM.  
Statistical analyses were conducted using GraphPad Prism 6 software.  Comparisons 
between all groups were conducted using unpaired, two-way ANOVA (Holm Sidak) 
unless otherwise specified. Comparisons between individual groups were performed 
by unpaired, two-tailed Mann-Whitney U tests (Holm Sidak), vs. negative/vehicle 
control, unless otherwise specified. Significance levels were set at a p value of ≤ 0.05. 
 
4.2 Results 
4.2.1 NAIP-647 can be detected in the lung, colon and peritoneal cavity after 
intra-peritoneal injection 
In order to determine the distribution of Na-AIP-1 in lymphoid organs and tissues after 
injection into mice, fluorescent-labelled recombinant protein was delivered to naïve 
mice via i.p. injection for 5 consecutive days. Mice were sacrificed 24 hr after the final 
injection.  Control mice received PBS vehicle only, or unlabelled Na-AIP-1 (serving as 
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the fluorescence-minus one control). NAIP-647 was strongly detected in BAL (22.6% 
of total live cells), and was also visible in colonic cells (0.52% of total live cells) (Figure 
4.1). As expected, these NAIP-647+ cells were not detected in the tissues of PBS or 
unlabelled Na-AIP-1-treated mice.  NAIP-647 was also detected in PEC samples 
(21.9% of total live cells), which was the site of injection.  Due to the high fluorescence 
intensity of NAIP-647 cells present in the PEC samples however, the excessive 
fluorescent brightness caused spill over into other channels and no further accurate 
analysis of NAIP-647+ PEC cell phenotype was possible.  NAIP-647 detection in blood 
(0.17%), spleen (data not shown, 0.14%,), and mLN (not shown, 0.02%) was minimal; 
as such these tissues were considered negative for Na-AIP-1 binding.  This data 
suggests IP injected Na-AIP-1 accumulates mostly in mucosal tissue sites such as the 




Figure 4.1:  NAIP-647 delivered by intra-peritoneal injection is detected in the 
lung and colon.  Mice received PBS, unlabelled recombinant Na-AIP-1 (1 mg/kg), or 
Na-AIP-1-Alexa Fluor 647 conjugate (NAIP-647; 1 mg/kg) via i.p. injection for 5 
consecutive days.  At day 6, mice were sacrificed and tissues collected and analysed 
by flow cytometry.  Plots have been gated on live singlet cells.  Data are presented as 
mean (SEM) frequency of NAIP-647+ cells in each condition. *p ≤ 0.05 vs. PBS, ****p 
< 0.0001 vs. PBS; one-way ANOVA Holm-Sidak.    Experiment was performed twice 
with representative results shown. 
 
4.2.2 NAIP-647 associates exclusively with CD45+ CD11c+ cells in the lung 
I assessed the phenotype of NAIP-647+ cells in BAL tissue.  Analysis of co-staining 
of NAIP-647 with other cell lineage markers indicated that NAIP-647+ cells were 
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uniformly highly positive for CD45 and CD11c, and predominantly SiglecF positive 
(Figure 4.2A). NAIP-647+ cells in the lung did not appear to be positive for the 
lymphocyte markers CD3, CD19 or CD8. Further analysis of the CD45+ CD11c+ 
NAIP-647+ subpopulation revealed characteristics consistent with alveolar 
macrophages (90% F4/80+ CD11b+), suggesting these cells are the predominant cell 





Figure 4.2:  NAIP-647 is predominantly associated with CD45+ CD11c+ cells in 
the lung BAL.  Mice received NAIP-647 via i.p. injection for 5 consecutive days.  At 
day 6, mice were sacrificed and bronchoalveolar lavage (BAL) collected and analysed 
by flow cytometry.  NAIP-647+ cells were isolated and assessed for co-expression of 
a panel of cell lineage markers.  Arrows indicate markers that were co-expressed on 
NAIP-647+ cells. (A).  Gating on NAIP-647+ CD45+ CD11c+ populations revealed 
phenotypic markers consistent with alveolar macrophages (F4/80+ CD11b+) (B).  
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Data are expressed as mean frequency in each quadrant.  Experiments were 
performed twice with representative results from one experiment shown. 
 
4.2.3 NAIP-647 is detected in leukocyte and epithelial cell populations in the 
colon 
When investigating the phenotype of the smaller population of NAIP-647+ cells in 
colon tissue samples, there was evidence of localisation with both haematopoietic 
CD45+ cells, but also CD45- cells (Figure 4.3A).  There was also evidence that NAIP-
647+ cells were co-staining with markers such as CD11b, F4/80, MHC-II and CD11c, 
suggestive of a macrophage- or dendritic like-cell. Further analysis of NAIP-647+ 
leukocyte (CD45+) populations via sequential gating revealed uptake of NAIP-647+ 
by two major distinct populations, including intestinal macrophage and dendritic cells 
(Bain and Schridde 2018). 
A substantial proportion of NAIP-647+ cells however were CD45- (Figure 4.3A-B).  
Analysis of CD45- NAIP-647+ cell population showed that 44.7% of these cells co-
stained with the epithelial cell marker EPCAM, while the remaining 56.3% could not 
be phenotyped with the cell markers used (Figure 4.3C).  Together, these results 
suggest that NAIP-647+ associates with multiple cell types within the colon, including 
APC subsets such as DCs and macrophages, but also non-haematopoietic cells, 







Figure 4.3:  NAIP-647 is detected in CD45+ leukocyte and CD45- epithelial cell 
populations in the colon.  Mice received Na-AIP-1-Alexa Fluor 647 conjugate (NAIP-
647) via i.p. injection for 5 consecutive days.  At day 6, mice were sacrificed and colon 
tissue collected and analysed by flow cytometry.  NAIP-647+ cells were assessed for 
co-expression of a panel of cell lineage markers.  Arrows indicate markers that were 
co-expressed on NAIP-647+ cells.  (A). NAIP-647+ CD45+ cells were subsequently 
profiled for macrophage (F4/80+ CD11b+) and DC markers (F4/80- CD11b+) (B). Data 
are expressed as mean frequency in each quadrant.  NAIP-647+ CD45- cells were 
gated and profiled for co-expression of the intestinal epithelial cell marker EPCAM (C).  
Experiments were performed twice; results from a single representative experiment 
are shown. 
 
4.2.4 Administration of Na-AIP-1 reduces colon tissue cellularity and affects B 
cell and neutrophil populations at mucosal sites 
Next, I wanted to examine whether administration of Na-AIP-1 influences the 
frequencies and total numbers of leukocytes within various organs of the immune 
system (lung BAL, colon, spleen, blood, peritoneal cavity and mesenteric LN).  
Administration of Na-AIP-1 did not affect the total cellularity, or the frequency or total 
numbers of various cell lineages in the mLN or spleen (Table 4.1). Na-AIP-1 
administration reduced the total cellularity in the colon compared to PBS control (p = 
0.003), with increases in B cell frequency (p = 0.02) and a trend toward increased 
colonic B cell numbers (p = 0.07).  Na-AIP-1 treatment significantly reduced neutrophil 
frequency in the BAL (p = 0.002), while increasing neutrophil frequency in the blood 
compared to PBS-treated mice (p = 0.006). Frequencies and total numbers of T cells, 
DCs and macrophages were not affected by Na-AIP-1 treatment in any organ studied. 
The outcome of this investigation indicates that even in the absence of inflammatory 
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Gated on live CD45+ cells. 
^BAL:  F4/80+ CD11b+ CD11c+.    
Data presented as mean (SEM). Comparisons conducted using two-way unpaired Mann Whitney. * p ≤ 0.05, ** p ≤ 0.01.  
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4.2.5 Targeted depletion of CD11c+ cells limits the anti-inflammatory influence 
of Na-AIP-1 
As Na-AIP-1 was detected in a high proportion of CD11c+ cells in the BAL and colon, 
I hypothesised that CD11c+ cells may be a biological target of this protein for exerting 
its immunosuppressive activity in colitis. Hence, I next wanted to investigate whether 
ablation of this CD11c+ population would inhibit the function of Na-AIP-1 in an 
inflammatory setting.  In order to test this, I utilised mice engineered to express a high-
affinity simian diphtheria toxin receptor on CD11c-bearing cells (CD11c-DTR), 
enabling targeted depletion of these cells by administration of human diphtheria toxin.  
Mice would be administered a 9 day TNBS protocol to assess if Na-AIP-1-mediated 
suppression of colitis required the presence of CD11c+ cells. Mice received 500 ng of 
diphtheria toxin on day -1, day 4 and day 8 to ensure consistent depletion of CD11c+ 
macrophage and dendritic cells. Recombinant Na-AIP-1 or HA treatment was 
delivered 24 hr prior and 24 hr post each TNBS challenge.  DC depletion was 
confirmed at termination (Figure 4.4A).  As expected, TNBS administration to WT 
mice and co-treatment with HA control resulted in rapid weight loss (Figure 4.4B) and 
increased clinical score (Figure 4.4C) that was slow to subside, and similar to that 
seen in CD11c+ cell-depleted DTR+ mice (Figure 4.4B-C). Also as expected, Na-AIP-
1 treatment of CD11c-sufficient WT mice resulted in rapid recovery from weight loss, 
and reduced clinical scores between day 5-6 post-TNBS compared to the control 
group, although low sample size prevented statistical significance. However, Na-AIP-
1 did not protect against weight loss and clinical disease in CD11c-depleted DTR mice 
(Figure 4.4B-C). These results were consistent with terminal colon length and 
macroscopic score parameters, which showed that Na-AIP-1 administration 
significantly protected against colon shortening (Figure 4.4D) and macroscopic 
disease (Figure 4.4E) in WT mice, but not in CD11c-depleted DTR mice. Visual 
inspection of the colons of the mice at termination highlighted the striking disparity 
between Na-AIP-1 (WT) and Na-AIP-1 (DTR) mice, with the latter showing high 
degrees of oedema and distal necrosis (Figure 4.4F).  This experiment was performed 
in triplicate; in one replication of the loss of function study, two Na-AIP-1 (DTR) and 
one HA (DTR) mouse were found deceased on day 8 of the experimental period due 
to severe colitis-induced wasting disease.  All other experiments attained 100% 
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survival until completion.  The outcome of these studies suggest Na-AIP-1 requires 






Figure 4.4:  Targeted depletion of CD11c+ cells limits the anti-inflammatory 
influence of Na-AIP-1 in TNBS colitis.  WT or CD11c-DTR mice received 
intraperitoneal injections of Na-AIP-1 or HA on days -1, 1, 6 and 8.  Mice were 
challenged twice by intra-rectal administration of TNBS on days 0 and 7.  CD11c+ 
cells were depleted by DT treatment on day -1, 4 and 8.  Depletion was confirmed by 
flow cytometry on live singlet mLN cells (A).  Body weight (B) and clinical indicators of 
disease (C) were measured daily.  Caecum and colon were removed at termination, 
and assessed for length (D) and macroscopic inflammatory damage (E).  Data are 
presented as mean ± SEM; * p ≤ 0.05 vs. Na-AIP-1 (WT).  Repeated measure 
comparisons were conducted using two-way ANOVA (Holm-Sidak); single measure 
comparisons were conducted using two-way unpaired Mann-Whitney.  Naïve group 
for comparison purposes only.  Experiment was performed in triplicate; representative 
results from a single experiment are shown. 
 
4.2.6 Na-AIP-1 administration in healthy FoxP3-RFP reporter mice induces 
CD4+ FoxP3+ cell proliferation in the lung, colon and peritoneal cavity 
The expansion of TREG populations and the subsequent suppression of inflammation 
by helminths has been well documented (Flynn and Mulcahy 2008, Turner et al. 2008, 
Layland et al. 2010).  Furthermore, studies imply effector molecules present in 
helminth secretions, including one which bears sequence homology to Na-AIP-1 and 
induces CD11c+ DC tolerogenicity, may be compelling this response (Grainger et al. 
2010, Navarro et al. 2016).  Accordingly, I wanted to determine whether Na-AIP-1 may 
similarly affect FoxP3+ cell populations.  In order to test this, dual IL-10/Foxp3 reporter 
mice (Zhang et al. 2017) received Na-AIP-1 or TNa (denatured Na-AIP-1, negative 
control) via i.p. injection for 5 consecutive days and were sacrificed on day 6. As the 
focus of this experiment was to analyse Foxp3-Treg populations, I did not investigate 
changes in IL-10 competent cells in the various tissues. The frequencies of CD4+ 
Foxp3+ cells in the blood and spleen were not affected by Na-AIP-1 administration 
(Figure 4.5). While CD4+ FoxP3+ cells are rare in the BAL, I did observe a significant 
increase in the frequency of these cells in Na-AIP-1-treated mice (p = 0.04). Similarly, 
Na-AIP-1 treatment resulted in significant increases in CD4+ FoxP3+ cell frequency 
in the PEC (p = 0.02), and a trend towards increases in the colon, which did not reach 
statistical significance (p = 0.07). This data is indicative of Na-AIP-1 promoting an 
expansion of TREGS, both at the site of injection and in mucosal tissues such as the 




Figure 4.5:  Na-AIP-1 administration in FoxP3-RFP mice is associated with 
expansion of CD4+ CD4+ FoxP3+ cells populations in the lung, colon and 
peritoneal cavity.  Mice received Na-AIP-1 (1 mg/kg, n = 6) or denatured Na-AIP-1 
(TNa; 1 mg/kg, n = 4) via i.p. injection for 5 consecutive days.  At day 6, mice were 
sacrificed, tissues collected and cells stained with anti-CD4 Abs and analysed by flow 
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cytometry for co-expression of Foxp3 RFP. Data are presented as mean (SEM). *p ≤ 
0.05, unpaired two-way Mann-Whitney. Results from a single experiment are shown. 
 
4.3 Discussion 
Previous studies have established that Na-AIP-1 is able to suppress inflammation in 
two distinct models of induced colitis, across multiple murine strains (sections 2.2 and 
3.2).  Identifying the cellular and molecular mechanisms by which Na-AIP-1 is able to 
exert its anti-inflammatory effects is key in harnessing and exploiting this novel protein 
as an anti-colitic therapy. In the present chapter, I evaluated the influence of Na-AIP-
1 on leukocyte populations in mice in order to identify any specific cellular targets for 
the protein, and downstream effects on immune cells in various organs. I have 
demonstrated that in healthy mice, Na-AIP-1 delivered to the peritoneal cavity is 
detectable at the site of injection, but also the lung and colon, where it is present 
primarily in/on CD11c+ macrophage and DC populations. While Na-AIP1 injection 
does not substantially change the immune cell repertoire in most organs, there did 
appear to be some tissue specific changes in B cells, neutrophils and Foxp3+ TREG 
populations. Depletion of CD11c+ cells in mice prevents the ability of Na-AIP-1 to exert 
its anti-colitic effects in the TNBS-colitis model. These findings suggest that APCs 
such as macrophage and DCs may be central for the function of Na-AIP1. 
There were several intriguing outcomes of these studies.  Most remarkably, greater 
than 20% of all cells isolated from the BAL were Na-AIP-1+, even though the protein 
was injected systemically via IP administration. There was evidence that Na-AIP-1 can 
also be detected in the colon (0.5% of cells), which fits with its anti-colitic activity, 
however the more striking result from the lung suggests that Na-AIP-1 may also be 
effective as an anti-inflammatory in the respiratory tract.  This is supported by the 
results of the FoxP3 reporter study, which showed that Na-AIP-1 expanded TREGS at 
this site.  Whilst curious, this pulmonary presence is perhaps not entirely unexpected.  
Previous transcriptomic analysis has determined that Na-AIP-1 mRNA is highly 
upregulated during the infectious L3 stage of the life cycle of N. americanus (Tang et 
al. 2014).  At this stage, N. americanus is a filariform larva which is able to penetrate 
the skin of a human host and travel throughout the circulatory system until it reaches 
the lungs, where larval migration across the alveolar wall occurs.  From here, the 
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larvae make their way to the gastrointestinal tract via the trachea (Jourdan et al. 2018).  
Accordingly, specificity for both pulmonary and gastrointestinal APCs by Na-AIP-1 
would certainly be an astute evolution of function.  In studies conducted by Navarro et 
al. (2016), multiple i.p. administrations of recombinant Ac-AIP-2 was similarly shown 
to generate a regulatory environment which caused strong suppression of OVA-
induced murine lung inflammation; however, capture of Ac-AIP-2 was only 
demonstrable in mesenteric CD11c+ DCs.  As such, the presence of Na-AIP-1 in BAL 
APCs after i.p. administration appears to be a unique development, unreported in 
other similar hookworm ES molecule studies.  
I have also demonstrated that treatment with Na-AIP-1 appears to induce pulmonary 
neutropaenia, with concomitant increases in circulating neutrophils, despite the 
absence of any active inflammation or infection.  In a study evaluating neutrophil 
recruitment in mice harbouring H. polygyrus, a similar yet non-significant trend towards 
neutropaenia in BAL samples was also visible when compared to naïve mice (Long et 
al. 2019).  The migration of helminth larvae across the alveolar surface has been 
confirmed to stimulate pulmonary neutrophil recruitment, causing a rapid and intense 
immune response designed to disable and expel the larvae (Chen et al. 2012).  
Bouchery et al. (2020) recently described a further mechanism of neutrophil 
immunomodulation by N. americanus, by way of the destruction of neutrophil 
extracellular traps (NETs) by a secreted deoxyribonuclease molecule.  Accordingly, 
an ability to influence or evade neutrophil populations is both advantageous to N. 
americanus, and not without precedent.  Critical to the instigation and maintenance of 
pulmonary inflammation, the increased presence of airway neutrophils has been 
shown to directly correspond with the severity of allergic asthma (Ray and Kolls 2017) 
and chronic obstructive pulmonary disease (Guillon et al. 2015), and correlates with 
an increased mortality in fibrotic pulmonary conditions (Lammertyn et al. 2017); in such 
conditions, Na-AIP-1 presents as an exciting new potential intervention which is 
worthy of further investigation.  Whilst examining the suitability of Na-AIP-1 as a 
therapeutic in these confounding conditions, the impact on pulmonary neutrophil 
populations must be thoroughly explored and understood, to ensure no detrimental 




As N. americanus is a gut-dwelling parasite and Na-AIP-1 shows anti-colitic effects, 
the suppression of pro-inflammatory immune responses in the peritoneal cavity and 
colon induced by Na-AIP-1 could perhaps be anticipated.  However, unlike what was 
observed in the lung, the presence of labelled Na-AIP-1 in colon tissue was not limited 
to APCs, or indeed to leukocytes.  A significant proportion of Na-AIP-1 positive cells 
in the colon were negative for CD45 expression, suggestive of a non-haematopoietic 
cell population. Of these potential cell subsets in this gate, I could only define one 
possible cell type, i.e. EPCAM+ cells that were presumably epithelial cells.  Without a 
more directed investigation, I was not able to confidently assign a precise phenotype 
to these subsets. EPCAM+ cells may be any range of colonic epithelial cell, including 
Paneth cells, goblet cells or tuft cells (Haber et al. 2017).  The identity of the CD45- 
EPCAM- cell population remains completely undefined.  It is possible these cells are 
mesenchymal stem cells, cells undergoing phenotypic transition, or epithelial cells in 
which Na-AIP-1 has inhibited EPCAM expression (Lampignano et al. 2017).  Murine 
parasitosis by Nippostrongylus brasiliensis, H. polygyrus and Tritrichomonas muris 
have all recently been reported to induce the proliferation of stem cells, and promote 
their differentiation into tuft cells (von Moltke et al. 2016, Howitt et al. 2016, Gerbe et 
al. 2016, Luo et al. 2019). Similarly, this may account for the CD45- populations 
observed here.  Tuft cells are one of several cell subtypes that are critical during the 
instigation and maintenance of the Th2 response to parasitic infection in humans 
(Howitt et al. 2016).  This unique chemosensory epithelial subset is able to detect the 
presence of intestinal parasites via bitter taste receptors, triggering the production of 
ILC2-activating alarmin IL-25 and driving expulsion of the parasite from the host (von 
Moltke et al. 2016).  Therefore, there is obvious benefit to N. americanus in 
manipulating tuft cell populations. 
The presence of Na-AIP-1 in both APC and epithelial cell populations in colon tissue 
raises further questions regarding the mechanism of action.  It is unclear at this stage 
whether the presence of Na-AIP-1+ APCs is specific and functional (i.e. receptor-
mediated), or a by-product of its recognition and subsequent uptake as a foreign 
antigen by professional antigen-presenting cells. Further, it is unclear whether the 
presence of Na-AIP-1+ cells at the various tissue sites is a consequence of passive 
diffusion of Na-AIP-1 throughout the body, or relocation of Na-AIP-1+ cells from the 
peritoneal site of injection to other tissues.  Elucidation of whether distribution is 
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transporter-mediated or passive is an important pharmacokinetic factor in the 
development of any new druggable compound.  Transporters are able to show tissue 
or cellular specificity, and as such a range of in vitro assays are able to assist in the 
determination of compound-transport binding (Krajsci 2013), which are then able to 
be verified in vivo in the various murine transport knock-out strains (Feng et al. 2014), 
or imaging studies (Tournier et al. 2018).  Receptor-ligand binding studies, including 
pull-down assays and protein arrays, will also aid in the determination of functional 
binding affinity.  Classical flow cytometric phagocytosis assays or confocal imaging, 
using fluorescently labelled protein, can determine whether NaAIP-1 remains surface 
bound, or is phagocytised and induced intra-cellular or intra-nuclear modifications 
(Smirnov et al., 2017, Yefimova et al., 2018). 
The TNBS-colitis experiment in mice with depleted CD11c+ cell populations implies 
that such cells are crucial in order for Na-AIP-1 to exert an anti-inflammatory effect.  
Whilst CD11c+ DCs are key in the instigation of effector cell response to pathogens, 
they are also able to act as a suppressive influence.  These tolerogenic dendritic cells 
(tDC) may be naturally occurring or induced, and whilst bearing identical phenotypic 
markers to standard DCs, they secrete retinoic acid and TGF-β, skewing naïve T cell 
differentiation towards the FoxP3+ regulatory phenotype and inducing pro-
inflammatory effector cell anergy (Gordon et al. 2014).  Tissue-resident DCs within the 
mLN and colon are particularly adept at inducing tolerance, and this is evidenced in 
the lack of inflammatory response to commensal microbiota in immunocompetent 
individuals (Uhlig and Powrie 2003, Gordon et al. 2014).  Studies conducted in multiple 
chemically-induced models of murine colitis have all demonstrated an association 
between CD11c+ DC/macrophage populations and the suppression of inflammatory 
pathology, by way of tolerogenic APC modulation of effector cells (Qualls et al. 2009, 
Matisz et al. 2017, Paiatto et al. 2018).  Therefore, when additionally considering the 
effect of Na-AIP-1 on CD4+ FoxP3+ cell populations, a plausible argument can be 
made for tDC-driven TREG induction.  To more definitively determine the effect of Na-
AIP-1 on CD11c+ cell populations, this experiment could be enhanced by including a 
more thorough cellular analysis at termination, such as that utilised by Navarro et al. 
(2016) when demonstrating the tolerogenicity induced by Ac-AIP-2.  Specifically, flow 
cytometric analysis and sorting of CD11c+ cells with markers to detect the expression 
of TGF-β and retinaldehyde dehydrogenase 2, a retinoic acid synthesis catalyst, would 
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identify tDCs in mLN and colon tissue.  The inclusion of resistin-like molecule α 
(RELMα) identifiers would further be able to identify any alternatively activated 
macrophage cells within the contingent of CD11c+ cells (Matisz et al. 2017).  Next 
generation sequencing of these colon tissues may further clarify transcriptional 
pathways which are being altered, and detect any upregulation of the aforementioned 
tolerogenic identifiers.  Further, introducing TREG identifiers and sampling at multiple 
timepoints will enable validation of FoxP3+ cell population expansions. This robust 
examination would verify that the modest, yet significant, differences in TREG 
populations within Na-AIP-1-treated mice within this study were not a consequence of 
technical issues with sample recovery or preparation. 
Also notable was the increase in the frequency of B cells in colon tissue when 
compared to the negative control, despite a considerable reduction in total cellularity 
in the colon.  However, I did not thoroughly classify whether these B cells were being 
recruited to this site, were proliferating locally, or whether the B cells exhibited 
differences in function, for example a regulatory B cell phenotype. There is evidence 
of donor parasite-induced regulatory B cells suppressing murine colitis in the absence 
of endogenous T or B cell populations, potentially involving a regulatory macrophage 
subtype.  Recently, Reyes et al. (2015) demonstrated such in a chemically-induced 
model of colitis in RAG KO mice.  In this particular study, colitis was induced using 
DNBS; a haptenizing agent which is structurally related to TNBS, and similarly invokes 
transmural inflammation and ulceration when delivered rectally (Wallace et al. 1995).  
Adoptive transfer of CD19+ B cells harvested from Hymenolepis diminuta-infected 
C57BL/6 (WT) mice ablated colitis in these studies, with detection of transferred B cell 
populations in the peritoneal cavity, colon, mLN and spleen of recipient RAG KO mice 
at termination.  These anti-colitic B cells were confirmed to be functionally distinct from 
IL-4 activated B cells, and reliant on F4/80+ macrophages to exert anti-colitic activity.  
Given the apparent affinity of Na-AIP-1 for macrophages, and indeed the lack of anti-
colitic efficacy in the absence of CD11c+ cells, this hypothesis may explain the results 
described within.  Further, it has been reported that B cells and CD4+ FoxP3+ TREG 
cells are effective in the suppression of inflammation in an alternate model of inducible 
murine colitis, by forming a ‘regulatory loop’ (Wang et al. 2015).  In this study, RAG 
KO mice received WT splenic B cells, which were able to supress DSS-induced colitis 
and encourage FoxP3+ population expansion, acting directly on these TREG cells by 
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way of a novel IL-10-independent mechanism.  Donor B cells instead acted via ligation 
of the glucocorticoid-induced tumour necrosis factor-related receptor (GITR).   GITR 
is highly expressed on the surface of TREG cells, and ligation is able to modulate 
regulatory cell activation and proliferation (Ephrem et al. 2013).  Wang et al. (2015) 
demonstrated that GITR ligation by splenic B cells was able to induce TREG-driven IL-
10 production; this in turn stimulated the secretion of an immunosuppressive 
immunoglobulin A isotype by B cells in the gut mucosa, attenuating colitic pathology.    
In order to elucidate the immunomodulatory processes induced by Na-AIP-1, and 
confirm any BREG involvement, repetition of the experiment described within this 
chapter with an optimised panel of phenotypic markers targeting specific subtypes of 
the cells of interest would be beneficial.  Verification of BREG involvement may also be 
characterised via loss of function studies, although in the absence of an identified 
specific BREG transcription factor it is not yet possible to generate a transgenic knock 
out mouse for this B cell subset (Quan et al. 2016). The differentiation to the regulatory 
B cell phenotype can originate from various B cell subtypes and appears dependent 
on the disease context; as such they may variously share surface markers with 
follicular, memory or plasma B cells (Blair et al. 2010, Iwata et al. 2011, van de Veen 
et al. 2013, Wang et al. 2015).  Initially, homozygous B6.muMt- mice, a transgenic B 
cell deficient murine strain, could assist in determining whether there is a causal link 
between B cells and Na-AIP-1 activity.  
In conclusion, within this chapter I have demonstrated that Na-AIP-1 appears to 
engage with CD11c+ cells soon after injection, and the presence of CD11c+ cells such 
as DCs and macrophages appears crucial to the anti-colitic mechanism of action. The 
downstream cellular effects of Na-AIP1 injection appear to involve expansion of B cells 
in the colon, and CD4+ FoxP3+ TREGs at mucosal tissue sites such as the lung and 
gut, suggesting a potential future direction of determining the benefit of Na-AIP-1 in 
the treatment of inflammatory or fibrotic disorders of the respiratory tract.  These 
findings highlight the compelling immunomodulatory abilities of Na-AIP-1; however, 
the involvement of several phenotypically distinct cellular subtypes prevents the 
identification of a definitive mechanism of action on the basis of these analyses.  
Further investigations, including analysis of transcriptional changes induced in target 
cells by Na-AIP-1, would be beneficial in identifying molecular and metabolic pathways 
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5 Characterising the effect of Na-AIP-1 on colonic gene 
expression in a murine model of colitis 
 
Previous chapters within this thesis have demonstrated that prophylactic delivery of 
Na-AIP-1 is able to inhibit the development of intestinal inflammation in both acute and 
chronic models of induced murine colitis.  Immunological studies suggested that the 
presence of CD11c+ antigen presenting cells (APCs) is critical for Na-AIP-1 to 
abrogate colon inflammation.  Further, repeated administration of this protein expands 
FoxP3+ TREG populations in mucosal tissue sites, together highlighting a potential 
cellular mechanism of how Na-AIP-1 may function in vivo.  However, a definitive 
molecular mechanism of action for Na-AIP-1 remains elusive. 
The evolution of transcriptomic analysis has enabled a greater understanding of the 
nature of colitic conditions, and the mechanisms involved in their pathogenesis and 
activity (Holgersen et al. 2015, Lin et al. 2018).  Next generation sequencing (NGS) 
also has the benefit of assisting to identify the physiological targets of drugs and 
compounds, by characterising the genes, processes and pathways which are 
transformed by its delivery (Gerits et al. 2016, Jardim-Perassi et al. 2019).  
Accordingly, the present chapter attempts to further characterise the mechanism 
behind the anti-colitic effect of prophylactic Na-AIP-1 administration, using NGS.   
The CD4+ CD25- adoptive transfer model of murine colitis is mediated by T cell-
mediated disruption of intestinal immune homeostasis, akin to the inflammatory status 
of human Crohn’s Disease (Holgersen et al. 2015).  My aim was to use RNAseq to 
focus on the transcriptional changes in the colon during the early stages of T-cell 
mediated colitis induction (3-4 weeks after T cell transfer) in mice treated with Na-AIP-
1 or PBS vehicle (Figure 5.1).  I also compared transcriptional changes in mice treated 
with the positive control anti-IL-12/23 monoclonal antibodies, where the mechanism of 
action is well established (Lindebo Holm et al. 2012, Castro-Mejía et al. 2016).  
Conserved genes and pathways between these anti-inflammatory interventions will be 
identified and examined for functional relevance.  Particular attention will be paid to 
modification of genes or pathways which are exclusive to Na-AIP-1 and differentiate it 




Figure 5.1:  Overview of analytical and computational processes.  RNA is 
extracted from colon samples and submitted to differential gene expression analysis.  
Differential expression profiles for anti-inflammatory interventions (αIL12/23 and Na-
AIP-1) will be assessed against the vehicle control (PBS vehicle).  Enrichment of 
differentially expressed genes will identify the biological processes associated with 




5.1.1 Mice and colitis study 
B6.SVJ129-Rag1 (RAG KO) and C57BL/6 mice, male and aged 5-7 weeks, were 
obtained from Animal Resources Centre (Murdoch, Australia) or Australian 
BioResources (Moss Vale, Australia) and allowed to acclimatise for 7 days before the 
commencement of the experimental period.  Mice received autoclaved food and water 
ad libitum, and were maintained in pathogen-free conditions in a temperature-
controlled room with a 12-hr light/dark illumination cycle.  Experiments were approved 
by the James Cook University Animals Ethics Committee under Ethics Approval 
numbers A2379 and A2571 conducted in accordance with National Health and 
Medical Research Council Australian Code for the Care and Use of Animals for 
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Scientific Purposes (8th Edition, 2013) and in compliance with the Queensland Animal 
Care and Protection Act, 2001 (Act No.64 of 2001).  Colitis was induced in RAG KO 
mice by adoptive transfer of CD4+ CD25- cells as described for previous studies 
(section 3.1.2).  Briefly, spleens were harvested from C57BL/6 WT donor mice into 
RPMI with 2% FBS on ice.  Spleens were gently homogenised into a suspension, 
passed through a 70 μm strainer and incubated with red blood cell lysis buffer (Sigma-
Aldrich) at room temperature for no longer than 5 min.  CD4+ cells were isolated by 
vehicle selection via magnetic separation, using the EasySep CD4+ T Cell Isolation 
kit (Stemcell Technologies) as per manufacturer’s instructions.  Enriched T cells were 
labelled with APC-conjugated anti-mouse CD4 (clone RM4-5; BD Biosciences) and 
FITC-conjugated anti-mouse CD25 (clone 7D4; BD Biosciences) and sorted into CD4+ 
CD25- fractions on BDTM FACSAria III.   Mice recieved 100 μL of PBS containing 4 x 
104 purified CD4+ CD25- cells by i.p. injection on day 0.  Group Na-AIP-1 (n = 8) 
received 1 mg/kg of purified recombinant protein.  Group PBS (vehicle control, n = 8) 
received 200 μL of sterile PBS, as indicated. Group αIL12/23 (positive control, n = 8) 
received 1 mg of InVivoMAb purified anti-mouse IL-12/IL-23p40 (clone C17.8) 
antibody (BioXcell) as indicated (Lindebo Holm et al. 2012). Naïve RAG KO (n = 2) 
did not receive donor T cells or treatment. All treatments were administered via i.p. 
administration, prepared with PBS to a final volume of 200 μL, twice per week from 
day 0 to termination.  Termination for RNAseq analysis was conducted when 100% of 
the PBS-treated cohort were exhibiting signs of colitis, including diarrhoea, lethargy 
and piloerection, at day 27.  At this time point, n = 4 were randomly selected from the 
PBS, αIL12/23 and Na-AIP-1 groups, and n = 1 from the naïve group.  The remaining 
cohort continued to be treated until termination at day 32, in order to monitor late stage 
disease progression.  Body weight and clinical scores were assessed twice per week 
(Figure 1.1).  Piloerection and lethargy, diarrhoea and colon thickening were graded 
according to severity from 0 (absent) to 2 (severe), to a maximum cumulative total 





Figure 5.2:  Clinical progression of adoptive transfer colitis.  Mice received 
adoptive transfer of 4 x 104 CD4+ CD25- T cells on day 0.  Na-AIP-1 and PBS were 
administered via i.p. injection twice weekly from day 0, or αIL12/23 once weekly from 
day 0.  Body weight (A) was measured twice weekly from day 0.  Clinical signs of 
disease (B) were measured twice weekly from day 17.  At day 27, indicated by the red 
arrow, 100% of the PBS cohort showed clinical indicators of colitis, and termination of 
the mice included in the RNAseq study was conducted.  The remaining cohort 
continued to be treated until termination at day 32, in order to monitor late stage 
disease progression.  Data are presented as mean ± SEM.  Comparisons were 
conducted using a two-way mixed-effects RM ANOVA (Holm-Sidak).  * p ≤ 0.05, 
significantly different from PBS negative control group.   
 
5.1.2 Tissue collection and RNA preparation 
At termination, colons were removed and cleaned in sterile PBS.  One cm sections of 
distal colon were collected into RNAlater (Sigma-Aldrich) on ice.  Total RNA was 
extracted from macerated whole colon tissue using the RNeasy Plus Mini Kit 
(QIAGEN) according to the manufacturer’s protocol and stored at -80°C. 
 
5.1.3 RNAseq pre-processing and analysis 
Sample pre-processing and analysis was performed by Australian Genomics 
Research Facility (AGRF, Melbourne, Australia). Samples were prepared using 
TruSeq Stranded mRNA Library Prep Kit (illumina) according to the manufacturer’s 
protocol.  Paired end sequencing to generate a read length of 150 bp was conducted 
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using NovaSeqS4.  Adapter sequence 'AGATCGGAAGAGC' was trimmed using 
Cutadapt version 1.91 (Martin 2011) and trimgalore version 0.5.0_dev (Babraham 
Bioinformantics 2020b).  Data integrity and quality control was done using FastQC 
(Babraham Bioinformantics 2020a). STAR version 2.7.0a (Dobin et al. 2013) was 
utilised for read alignment, with alignment to the murine reference genome mm10. 
 
5.1.4 Differential gene expression analysis 
Data normalisation, principle component analysis (PCA), log ratio vs. mean average 
plot (MA plot) and differential gene expression analysis was conducted using the 
consensusDE package in R (Waardenberg and Field 2019).  Data integration and 
alignment was conducted using the buildSummarised argument, with alignment to 
GRCm38.94 gtf file (ftp://ftp.ensembl.org/pub/release-94/gtf/mus_musculus/).  When 
assessing differentially expressed genes (DEGs), those with a log-fold change (LFC) 
of -0.5 to 0.5 were excluded; this cut-off was determined by assessment of MA plots 
for the analysis (Supplementary Figure 5.1), and with the consideration of levels 
required for lowly expressed genes to achieve biological relevance.  An edgeR 
adjusted p value < 0.05 was considered significant (Robinson et al. 2009).  
Comparison analysis was conducted between naïve (non-colitic) mice, colitic mice 
receiving PBS, colitic mice receiving αIL12/23, and colitic mice receiving Na-AIP-1.  
Volcano plots depicting DEGs were constructed in R using ggplot (Wickham 2016). 
 
5.1.5 Functional enrichment analysis 
Predicted protein-protein interaction (PPI) networks, gene ontology (GO) terms and 
KEGG pathways were determined using significantly DEGs.  Prediction and 
visualisation of PPIs was conducted using the STRINGdb package (Franceschini et 
al. 2013) and ggplot in R.  Scatter plots representing the top 20 GO terms, and KEGG 
pathways were created using STRINGdb and ggplot. Genes, ontology networks and 
pathway functions were defined using databases compiled by 
The Gene Ontology Consortium (2018), The UniProt Consortium (2018) and 





5.2.1 Principle component analysis shows a clear partitioning of treatment 
groups 
Firstly, a PCA was conducted in order to detect and display the expression mean 
(PC1) and random variation (PC2) both between and within treatment groups.  The 
PCA plot exhibits a clear separation between treatment groups, recognisable 
clustering of biological replicates within treatment groups, and a distinct separation 
between treatment groups and the naïve control (Figure 5.3A).   The greatest diversity 
in transcription measured was between the naïve control and the PBS-treated vehicle 
control, providing validation of model and a baseline for the intervention treatment 






















Figure 5.3:  PCA and volcano plots of differentially expressed genes.  Colitis was 
induced in RAG KO mice by adoptive transfer of CD4+ CD25- T cells on day 0.  Mice 
received PBS, αIL12/23 or Na-AIP-1 twice per week by intra-peritoneal injection.  
Naïve control mice did not receive T cells. Termination was conducted at day 27, when 
all vehicle control (PBS) mice displayed clinical indicators of colitis.  RNA-seq was 
conducted on distal colon sections and transcriptomic expression profiles compared. 
PCA indicates distinct separation between, but clustering within, treatment groups (A).  
Comparison of PBS-treated mice to naïve RAG KO control detected 5,664 significantly 
DEGs of which 69% were upregulated (B).  Comparison of αIL12/23 expression with 
the vehicle control identified 5,773 DEGs, of which 64% were downregulated (C).  
Prophylactic Na-AIP-1 administration induced 2,360 DEGs, of which 69% were 
downregulated in comparison to the PBS control.  Of these, 97 genes were not 
differentially expressed in the αIL12/23 group.  Data and images were generated using 
the consensusDE package in R (Waardenberg and Field 2019). 
 
 
5.2.2 Induction of CD4+ CD25- adoptive transfer colitis in RAG KO mice 
generates widespread transcriptional alterations in colonic tissue. 
In order to determine the magnitude of transcriptional alterations generated in CD4+ 
CD25- T cell transfer colitis, I measured the divergence in expression between naïve 
RAG KO mice and PBS-treated colitic RAG KO mice.  A total of 5,664 DEGs were 
identified, equating to 35% of genes assessed (Figure 5.3B).  Of these genes, the 
majority underwent upregulated expression in PBS-treated mice (n = 3,880, vs. 1,784 
downregulated).  Within the top ten upregulated genes (by edgeR p value), several 
genes correlate with immune signalling and trafficking (Lrp8, Ifitm1, Adam8), whereas 
downregulated genes largely correlated with drug and lipid metabolism (Cyp2c69, 
Hsd17b2, Ces2a, Ggh, Pck1) (Table 5.1).  This expression profile is utilised as the 









Table 5.1: Top 10 differentially expressed genes (ranked by edgeR adjusted p 
value). 
 
  upregulated DEGs downregulated DEGs 













) 1 Noc4l 2.2 7.37E-23 Gm5485 3.4 8.34E-19 
2 Tgm1 4.6 7.85E-21 Cyp2c69 6.5 1.37E-18 
3 Lrp8 3.5 1.93E-20 Hsd17b2 1.8 1.64E-18 
4 Fmnl1 3.5 6.35E-18 Ces2a 4.2 3.28E-17 
5 Apobr 4.1 3.44E-17 Ggh 3.4 5.67E-17 
6 Mthfd2 3.1 6.62E-17 Pdk2 2.3 1.76E-16 
7 Cars 2.1 1.32E-15 Pm20d1 3.9 4.83E-16 
8 Ifitm1 3.2 2.62E-15 Mep1a 4.2 6.93E-16 
9 Adam8 4.6 5.94E-15 Dio1 3.9 8.72E-16 











1 Hsd17b2 1.5 4.53E-24 Lrp8 2.9 7.18E-52 
2 Pdk2 1.9 8.27E-21 Noc4l 1.5 1.37E-40 
3 Gm5485 2.6 8.27E-21 Mthfd2 2.3 2.67E-33 
4 Ces2c 2.5 4.41E-18 Tgm1 2.6 4.31E-32 
5 H2bc7 1.8 9.80E-18 Cars 1.6 8.60E-31 
6 Ces2a 3.3 1.18E-17 Pak6 2.2 3.13E-30 
7 Dio1 3.1 5.52E-17 1700017B05Rik 1.4 1.73E-28 
8 Cyp2c69 4.9 9.15E-17 Ptpn1 1.4 8.96E-28 
9 Mep1a 3.4 1.16E-16 Tead4 2.9 1.32E-27 












1 Hsd17b2 1.0 1.39E-10 Tgm1 2.2 2.94E-22 
2 H2bc7 1.2 9.00E-09 Lrp8 1.4 1.44E-13 
3 H2bc6 1.1 7.18E-06 Mthfd2 1.4 3.28E-13 
4 Gstm1 1.2 8.89E-06 Tead4 2.0 3.53E-13 
5 Dio1 1.8 9.77E-06 Il1r2 2.8 8.02E-13 
6 Gstt3 0.8 9.96E-06 Adam8 2.1 1.22E-12 
7 Hist1h2br 1.2 1.02E-05 Bdkrb1 2.1 1.22E-12 
8 Pdk2 1.0 1.35E-05 Cd300lf 2.3 1.78E-12 
9 Slc26a2 1.3 1.54E-05 Gsap 1.6 6.40E-12 
10 Hist1h2bq 1.2 1.69E-05 Hmox1 1.6 1.18E-11 








Next, I compared the transcriptional profile of mice receiving αIL12/23p40 antibody, 
the benchmark for the induction of remission in the T cell transfer model of murine 
colitis (Lindebo Holm et al. 2012), to the PBS-treated control.  This comparison 
revealed 2,057 upregulated genes and 3,716 significantly downregulated genes in 
αIL12/23 mice compared to PBS treated mice (Figure 5.3C).  Two genes within the 
top ten upregulated were histone clusters associated with haematopoietic cell 
exosomes and immune disease (Hsd17b2, Hsbc7), whereas the ten most 
downregulated genes featured associations with immune signalling, interaction and 
trafficking (Lrp8, Pak6, Tead4). 
When comparing the transcriptional profile of mice treated with Na-AIP-1 to the PBS 
vehicle control, a total of 2,360 genes were differentially expressed.  Of these, 721 
genes were significantly upregulated and 1639 were significantly downregulated 
(Figure 5.3D).  The vast majority of genes within the top ten upregulated were 
associated with haematopoietic cell exosomes and the autoimmune disease systemic 
lupus erythematosus, similar to the profile of anti-IL-12/23 treated mice (H2bc7, 
H2bc6, Hist1h2br, Hist1h2bq).  This trend was mirrored when examining the ten most 
highly downregulated genes, of which seven were correlated with immune signalling, 
interaction and trafficking (Lrp8, Tead4, Il1r2, Adam8, Bdkrb1, Cd300lf, Hmox1).  The 
majority (n = 2264) of genes in which Na-AIP-1 initiated differential expression were 
similarly altered in the αIL12/23 group.  However, 97 of the DEGs were exclusive to 
Na-AIP-1; that is, not differentially expressed in mice receiving αIL12/23 when 
compared to colitic mice that received PBS.  These were dominated by 






Figure 5.4:  Venn diagrams comparing DEGs in mice treated with Na-AIP-1 to 
mice treated with αIL12/23.  Analysis identified 20 genes in which transcription is 
upregulated by Na-AIP-1, but not αIL12/23, administration (A) and 76 genes in which 
transcription is exclusively downregulated by Na-AIP-1 (B). 
 
Within the top ten most downregulated genes, those related to cytotoxic T cell and NK 
cell granulation (Gzmd, Gzmf) and T cell receptor alpha chain components (Trav9d-3, 
Trav9n-3).  Interestingly, the most highly upregulated gene transcription is associated 
with the T cell receptor beta chain (Table 5.2). 
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Table 5.2:  Top 10 differentially expressed genes exclusive to Na-AIP-1-treated 
mice (by edgeR adjusted p value). 
 upregulated DEGs^ downregulated DEGs^ 
 gene  LFC* p gene  LFC* p 
1 Trbv4 2.7 0.005 Gzmd 6.4 0.002 
2 Efnb2 0.6 0.009 Klk8 1.0 0.003 
3 Cmtm4 0.5 0.02 Gm4356 1.1 0.004 
4 Camkmt 0.5 0.02 Gzmf 5.5 0.004 
5 Gna11 0.6 0.02 Vmn1r181 2.4 0.005 
6 Ar 1.2 0.02 Nxf2 2.6 0.005 
7 Plpp6 0.5 0.02 Samd11 2.6 0.006 
8 Gm6710 0.7 0.02 Tnfrsf26 1.9 0.006 
9 Gm14403 0.9 0.02 Trav9d-3 3.6 0.006 
10 Emid1 0.8 0.02 Trav9n-3 3.6 0.006 
^vs. PBS, compared to αIL12/23 vs. PBS.  * vs. PBS.  p = edgeR adjusted p value.   
 
5.2.3 αIL12/23 and Na-AIP-1 treatment downregulate genes associated with 
the presence of multiple leukocyte subsets 
Previously, I described the effect of Na-AIP-1 administration on leukocyte proliferation 
in healthy BALB/c mice (section 4.24.2.6).  Whilst RNA-seq analysis will not allow the 
quantitation of cell numbers, one can assess whether expression of genes exclusive 
to specific immune cell subsets have been altered.  Accordingly, differential 
expression (in comparison to the vehicle control) was assessed in colitic RAG KO mice 
treated with αIL12/23 and Na-AIP-1 for genes in a list of genes corresponding to 
leukocyte-specific markers or receptors (Table 5.3).  Th1 exclusive genes (CD4, IFNγ) 
were significantly downregulated in both treatment groups. Th2 genes were not 
measured.  TREG (FoxP3) and macrophage-associated (F4/80) identifier expression 
levels were not found to be significantly different from the PBS control.  Of the Th17 
related genes, IL17A expression was found to be significantly downregulated in mice 
receiving αIL12/23 but not Na-AIP-1; conversely, IL17F expression was significantly 
downregulated only in mice receiving Na-AIP-1.  When assessing dendritic cell (DC) 
markers, αIL12/23 treatment was associated with a reduction in each of CD11b 
(Itgam), CD11c (Itgax) and H2-Eb1 expression, whereas treatment with Na-AIP-1 only 




Table 5.3: Differential expression of genes in RAG KO mice receiving adoptive 
transfer of CD4+ CD25- T cells treated with αIL12/23 and Na-AIP-1 (vs. PBS) 
phenotype gene 
αIL12/23 Na-AIP-1 
LFC* p LFC* p 
CD4+ T cells 
 
Cd4 -1.1 0.008 -1.0 0.008 
Ifng -4.2 < 0.0001 -2.4 0.003 
Il17a -2.1 0.02 -1.8 0.1 
Il17f -1.1 0.07 -1.6 0.02 
Foxp3 -1.7 0.06 -0.8 0.6 
Il10 -0.8 0.2 -0.2 0.7 
Txb21 -1.6 < 0.0001 -1.5 0.003 
Gata3 -1.7 0.002 -1.7 0.04 
Rorc 1.2 < 0.0001 0.7 0.02 
Dendritic cells 
Cd11b (Itgam) -1.7 < 0.0001 -1.5 0.007 
Cd11c (Itgax) -1.0 0.001 -1.0 0.06 
CD103 (Itgae) -0.7 0.1 -0.3 0.6 
H2-Eb1 -1.1 0.006 -0.8 0.1 
CD80 -2.3 < 0.0001 -1.6 < 0.0001 
CD86 -2.0 < 0.0001 -1.5 < 0.0001 
Aldh1a1 0.6 0.07 0.4 0.3 
Aldh1a2 1.0 0.1 0.6 0.4 
Macrophages 
F4/80 0.4 0.3 0.01 0.3 
Retnla 4.0 0.003 2.5 0.04 
Dhrs9 -1.4 < 0.0001 -0.4 0.4 
Arg1 1.7 0.2 -2.0 0.2 
Arg2 0.6 0.2 -0.7 0.3 
Cd206 (Mrc1) 0.4 0.6 0.5 0.5 
Cxcl9 -4.3 < 0.0001 -2.6 0.001 
Cxcl11 -4.0 < 0.0001 -2.1 0.01 
Ccl20 0.4 0.6 -0.4 0.8 
iNOS Nos2) -2.8 0.0009 -1.7 0.08 
Cox1 1.0 < 0.0001 0.5 0.1 
Cox2 0.8 0.0006 0.4 0.2 
Neutrophils Ly6g 0.4 0.4 -0.02 1.0 
*compared to PBS-treated colitic RAG KO mice. p = edgeR adj p value.  





5.2.4 Protein-protein interaction modelling displays an increase in pro-
inflammatory immune-related activity in colitic RAG KO mice 
Having determined the most highly upregulated and downregulated genes, I now 
wanted to examine what biological impact they may have.  In order to determine any 
functional relationships between the most highly DEGs, data modelling was conducted 
using the STRINGdb package in R.  The STRINGdb package enables the modelling 
of physical and functional relationships between proteins; each node representing a 
protein, with the lines between correlating to the strength of evidence towards the 
association.  The 25 most upregulated and downregulated genes (by p value) in colitic 








Figure 5.5:  STRING protein-protein analysis of differentially expressed genes in colitic RAG KO mice receiving PBS (vs. 
naïve RAG KO mice).  Highly DE genes were analysed for predicted interactions. Data and images were produced using the 
STRINGdb package in R (Franceschini et al. 2013). 
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In upregulated genes, strong hubs associated with the CD3 T cell receptor complex 
(Cd3d, Cd3e, Cd3g), NK cell and neutrophil granulation (Gzma, Gzmb) and pro-
inflammatory chemokine signalling (Cxcr2, Cxcl2, Cxcl5, Cxcl9) (Mariuzza et al. 2020).  
Hubs associated with fatty acid beta-oxidation (Hadhb, Acadvl, Acaa1a, Lvd) and 
mitochondrial respiration (Ndufb8, Ndufb11) were detected in downregulated genes 
(Diskin and Palsson-McDermott 2018, EMBL-EBI 2020a, EMBL-EBI 2020b). 
In comparison, mice treated with αIL12/23 had predicted network hubs associated with 
upregulated retinol metabolism (Hsd3b6, Hsd3b2, Cyp2c55, Ugt2b36) and DC-SIGN-
related proteins (CD209f, CD209g) (Powlesland et al. 2006, Kanehisa et al. 2019) 
(Figure 5.6).  Modelling of the most downregulated genes predicted a suppression of 
cytokine and chemokine signalling (Ptpn1, Il4ra, Myd88) and oxidoreductase activity 







Figure 5.6:  STRING protein-protein analysis of differentially expressed genes in 
colitic RAG KO mice receiving αIL12/23 (vs. PBS).  Highly DE genes were analysed 
for predicted interactions. Data and images were produced using the STRINGdb 
package in R (Franceschini et al. 2013). 
 
I previously determined that whilst a higher number of genes were differentially 
expressed in mice treated with αIL12/23 compared to mice treated with Na-AIP-1, 
there was a correlation between some of the more highly DEGs.  In order to test the 
hypothesis that that the same functional networks are being activated, STRING 
modelling was conducted on the 25 most upregulated and downregulated DEGs in 
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mice treated with Na-AIP-1 (vs. vehicle control).  The most highly predicted interaction 
networks that were affected were found to be distinct to αIL12/23-treated mice (Figure 
5.7).  When considering upregulated genes, a strong hub between MAPK-inhibiting 
glutathione S-transferase genes (Gstm1, Gstm2, Gstm3, Gstm6) is immediately 
apparent.  A hub related to tryptophan metabolism (Hadh, Aldh6a1) was also strongly 
predicted. Hubs within the downregulated network were indicative of a downregulation 
in interactions governing the MAPK signalling (Mapk11, Fgr, PLAUR, pak6) and 







Figure 5.7:  STRING protein-protein analysis of DEGs in RAG KO mice receiving 
CD4+ CD25- cells and treated with Na-AIP-1 (vs. PBS). Highly DEGs were analysed 
for predicted interactions. Data and images were produced using the STRINGdb 
package in R (Franceschini et al. 2013). 
 
Finally, the genes which were exclusively differentially expressed in Na-AIP-1-treated 
mice were also analysed to elucidate potential functional interactions (Figure 5.8).  
Despite there being less than 25 genes identified as upregulated, an interaction hub 
was detected which suppresses TGF-β signalling and innate immune responses 
(Smad6, Lefty2, Gna11, Gnaz) (Miyazawa and Miyazono 2017).  Interactions between 
the most highly downregulated genes suggests alterations in the functional 
governance of coagulation and fibrinolysis (Serpine1, Serpind1), a process known to 
also be intimately involved in inflammation (Weidmann et al. 2017).  Interactions 
between genes concerning cellular innate antiviral responses (Oas2, Oas3, Ifit1, 
Isg15) are also predicted to be reduced (Kanehisa et al. 2019).  Considered together, 
these data suggest that the most highly DEGs in Na-AIP-1-treated mice are exerting 
















Figure 5.8:  STRING protein-protein analysis of differentially expressed genes 
exclusive to colitic RAG KO mice receiving Na-AIP-1 compared with aIL12/23 
(vs. PBS).  Highly DE genes were analysed for predicted interactions.  Data and 
images were produced using the STRINGdb package in R (Franceschini et al. 2013). 
 
5.2.5 Functional analyses reflect changes in immune cell signalling and 
metabolic processes in colitic RAG KO mice 
Whilst a snapshot of functional associations between the most highly DEGs is 
valuable, it is important to note that in each of the treatment groups this represented 
< 1% of the significantly DEGs.  In order to therefore assess the cumulative effect of 
all significantly DEGs, further enrichment analyses were conducted.  For genes 
significantly upregulated and downregulated in PBS-treated colitic RAG KO mice (vs. 
naïve RAG KO), evaluation was conducted against GO terms, which classifies genes 
by their biological process, and KEGG pathways, which identifies genes that are part 
of known biological and disease pathways.  The top 20 affected processes and 
pathways were calculated and have been graphed by rank (Supplementary Figure 
5.2A-B, Supplementary Figure 5.3A-B). 
To facilitate an understanding of the factors driving the efficacy of αIL12/23 in CD4+ 
CD25- T cell transfer colitis, I next performed GO and KEGG enrichment on genes 
which were significantly differentially expressed in αIL12/23 mice compared to the 
vehicle control.  The top 20 affected processes and pathways were calculated and 
have been graphed by rank (Supplementary Figure 5.2C-D, Supplementary Figure 
5.3C-D).  When assessing upregulated pathways in αIL12/23 mice, 16 enriched GO 
terms and 15 of enriched KEGG pathways inversely correlated with downregulated 
terms in PBS-treated colitic mice.  When assessing downregulated genes, 15 GO 
terms and 18 KEGG pathways αIL12/23 mice inversely correlated with upregulated 
terms in PBS-treated colitic mice.  These data indicate that administration of αIL12/23 
instigates transcriptional modifications that prevent, or reverse, the enrichment of 
functional and biological pathways directly impacted by CD4+ CD25- adoptive transfer 




5.2.6 Prophylactic administration of Na-AIP-1 in RAG KO mice receiving CD4+ 
CD25- cells modulates functional pathways that largely correlate to αIL12/23-
treated mice 
Lastly, functional enrichment of Na-AIP-1-treated mice was conducted, and compared 
to αIL12/23-treated mice.  The top 20 affected GO terms (Figure 5.9A, C) and KEGG 
pathways (Figure 5.10A, C) have been graphed by rank.  Enrichment was also 
conducted on DEGs exclusive to Na-AIP-1 administration (vs. PBS, in comparison to 
αIL12/23-treated mice).  The top 20 affected GO terms (Figure 5.9B, D) and KEGG 
pathways (Figure 5.10B, D) have been graphed by rank.  A comparison of 
upregulated GO terms and KEGG pathways indicates a high correlation between Na-
AIP-1 and αIL12/23 groups, with 14 and 13 matches respectively.  Upregulated terms 
specific to Na-AIP-1 correlated with tryptophan and fatty acid metabolic processes, 
which are associated with a tolerogenic and regulatory immune environment (Švajger 
and Rožman 2018, Kempkes et al. 2019), whereas the αIL12/23 group instead 
showed an enhancement in ion transport processes, which in an immune context are 
more closely associated with signal transduction (Feske et al. 2015).  When comparing 
downregulated GO terms and KEGG pathways, a higher correlation between the two 
treatment groups is noted, with only 4 differences in GO terms and 3 differences in 
KEGG pathways.  Na-AIP-1 treatment appears to directly downregulate processes 
related to the development of inflammation such as NF-κB signal transduction, 
responses to cytokines and T cell activation.  These data indicate that administration 
of Na-AIP-1 broadly affects the same biological processes as αIL12/23 treatment in 
the alleviation of CD4+ CD25 T cell transfer-induced colitis.  However, Na-AIP-1 was 
able to enrich a cluster of functional and biological pathways which are not directly 





Figure 5.9:  Scatter plots of GO biological process terms enriched in Na-AIP-1-
treated mice.  Top 20 GO terms associated with genes differentially expressed in Na-
AIP-1-treated mice compared to PBS (A, C).  Top 20 GO terms associated with genes 
exclusively significantly DE in Na-AIP-1 mice (vs. PBS), compared to αIL12/23 (vs. 
PBS) (B, D).  Only processes with ≥ 2 hits have been included to ensure biological 
relevance.  Terms are listed by rank.  Frequency of all DEGs within the treatment 
group that are annotated to the respective term are represented as Hits (%).  Data 
was generated using the STRINGdb package in R (Franceschini et al. 2013).  Images 






Figure 5.10:  Scatter plots of KEGG pathway terms enriched in Na-AIP-1-treated 
mice.  Top 20 KEGG pathways associated with genes differentially expressed in Na-
AIP-1-treated mice compared to PBS (A, C).  Top 20 KEGG pathways associated with 
genes exclusively significantly DE in Na-AIP-1 mice (vs. PBS), compared to αIL12/23 
(vs. PBS) (B, D).  Only pathways with ≥ 2 hits have been included to ensure biological 
relevance.  Terms are listed by rank.  Frequency of all DEGs within the treatment 
group that are annotated to the respective term are represented as Hits (%).  Data 
was generated using the STRINGdb package in R (Franceschini et al. 2013).  Images 
were generated using the ggplot package in R (Wickham 2016). 
 
5.3 Discussion 
Whilst Na-AIP-1 displays potent anti-inflammatory activity in murine colitic models, as 
yet the mechanism driving this effect has not been elucidated.  Studies conducted to 
date have suggested a functional role for CD11c+ APCs in the mitigation of 
experimental murine colitis when Na-AIP-1 is administered, as well as mucosal TREG 
proliferation when administered to healthy mice.  This correlates with what is known 
about the mechanism of action of Ac-AIP-2, in which the suppression of murine 
asthma is dependent on CD11c+ cell-induced TREG proliferation (Navarro et al. 2016).  
However, a unique influence over multiple cellular subtypes has prevented the 
identification of a specific pathway or mechanism targeted by this Na-AIP-1 as yet.  In 
order to further understand what is driving the anti-colitic effect of prophylactic Na-AIP-
1 administration, modifications to the transcriptome of mice suffering from 
experimental colitis were assessed and compared to the gene expression profiles of 
positive and vehicle control treatments with known mechanisms of action. 
The adoptive transfer model of murine colitis is driven by a Th1 inflammatory 
response, instigated by donor CD4+ CD25- splenic T cells in recipient RAG KO mice, 
an immunocompromised engineered strain without B or T cells.  Production of IL-12 
by APCs is established, skewing T cell differentiation towards the pro-inflammatory 
Th1 phenotype (Castro-Mejía et al. 2016) and, in the absence of CD25+ TREG cells, 
chronic inflammation in response to intestinal commensal antigens occurs (Eri et al. 
2012).  This Th1-driven inflammation was verified by comparison of naïve RAG KO 
mouse gene expression with that of the PBS-treated mice, which revealed a great 
increase in IFNγ transcription in the colitic group (PBS: 7.7 LFC, p < 0.001, data not 
presented).  This was complimented by an upregulation in processes associated with 
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immune response induction and cell proliferation, and pathways involved in pro-
inflammatory immunity and T cell receptor signalling.  This was coupled with a 
downturn in metabolic and molecular processes involved in fatty acid metabolism.  
Prophylactic delivery of αIL12/23 inhibited the development of colitis by disrupting T 
cell differentiation and the subsequent downstream Th1 effector processes.  Mice 
treated with αIL12/23 displayed transcriptional upregulation of genes involved in retinol 
metabolism and DC-SIGN-related proteins, and suppression of TLR signalling and 
oxidoreductase activity (Lin et al. 2017, The Gene Ontology Consortium 2018).  These 
metabolic differences between the vehicle and positive control groups provide further 
insight into the mechanisms at play.  The induction and maintenance of immune 
response incurs a significant metabolic burden, however specific immune cell subsets 
will preferentially utilise alternate fuel sources.  During inflammation, activated effector 
T cells exclusively utilise glycolytic pathways, whereas TREG cells gain fuel from fatty 
acid uptake and oxidation (Michalek et al. 2011, Rothe et al. 2015).  Accordingly, the 
metabolic profile of αIL12/23-treated mice is suggestive of alignment with a regulatory, 
anti-inflammatory Th2-like paradigm.  This is strengthened by an upregulation of 
transcription of CD209f and CD209g, paralogues of the Homo sapiens CD209/DC-
SIGN receptor found on phagocytotic APCs (Ortiz et al. 2008).  DC-SIGN expression 
is traditionally induced by the Th2 hallmark cytokine IL4, and considered to be an 
identifier of tolerogenic APCs (Relloso et al. 2002, Powlesland et al. 2006, Kanehisa 
et al. 2019). 
When assessing the transcriptome of Na-AIP-1-treated mice, compared to that of 
αIL12/23-treated mice, some striking differences in DEGs become apparent.  A 
powerful network of upregulated functional interactions is apparent between four 
glutathione S-transferase genes (Gstm1, Gstm2, Gstm3, Gstm6).  These specific 
phase-II detoxification enzymes are recognised as MAPK pathway inhibitors, which 
are involved in immune regulation and are suppressed during gut inflammation 
(Townsend and Tew 2003, Fan et al. 2020).  Polymorphisms in the Gstm1 locus have 
also recently been identified as predisposing to both CD and UC (Moini et al. 2017, 
Zhou et al. 2019).  Furthermore, several genes which form part of the p38 MAPK 
pathway are downregulated (MAPK11, FGR, PLAUR, pak6) in Na-AIP-1-treated mice, 
suggestive of specific targeting of this pro-inflammatory intracellular signalling 
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pathway (Mohammad et al. 2018).  Enzymatic assays detecting and quantifying MAPK 
inhibition would be useful in verifying this effect. 
An upregulation in genes involved in tryptophan, glutathione, fatty acid and lipid 
metabolism pathways were also detected in mice receiving Na-AIP-1.  These 
metabolic pathways were not indicated to be in the top 20 pathways altered by 
αIL12/23 administration.  This metabolic signature, when considered holistically with 
the transcriptomic data, suggests that Na-AIP-1, similar to αIL12/23, is able to induce 
a state of intestinal immune tolerance, albeit by different mechanisms. 
APC tolerogenicity is heavily influenced by several of the metabolic pathways in which 
Na-AIP-1 appears to impact at the transcriptional level.  Expression levels of genes 
involved in tryptophan metabolism are increased, which is a process that is central to 
DC-driven intestinal tolerance and IBD activity (Nikolaus et al. 2017, Bosch et al. 2018, 
Gao et al. 2018).  Glutathione, an intracellular anti-oxidant that is downregulated in 
experimental murine colitis, also appears to undergo metabolic enhancement 
(Vassilyadi et al. 2016).  Interestingly, a recent study showed that Fasciola hepatica 
ES products are able to exert an anti-inflammatory effect in murine septic shock via 
glutathione-instigated NF-κB regulation (Aguayo et al. 2019); another signalling 
pathway that is transcriptionally downregulated exclusively in mice receiving Na-AIP-
1.  Whilst tolerogenic immune cells induce fatty acid metabolism for energy derivation, 
the process has also been shown to attenuate both DC and Th17 cell activation (Rothe 
et al. 2015).  This complements the transcriptional amendments indicative of immune 
cell phenotype.  Data presented here for mice receiving prophylactic Na-AIP-1, or 
indeed αIL12/23, are suggestive of a reduced transcription of CD4.  The reduction in 
IFNγ transcription is indicative of Th1 suppression.  Th17 cells also show 
transcriptional aberration in both treatment groups, although Il17f was only 
significantly downregulated in Na-AIP-1-treated mice.  This gene has been highly 
implicated in the development of IBD, and its suppression has been attributed to 
protection against colitis by way of induced TREG proliferation (Seiderer et al. 2007, 
Tang et al. 2018).  Expression levels of the DC and macrophage marker CD11c and 
TREG transcriptional factor FoxP3 did not differ significantly between the Na-AIP-1 and 
vehicle control groups, despite the disparity in CD4 expression.   This would suggest 
the frequency of these cells is potentially higher in Na-AIP1 treated mice than in colitic 
mice.  A similar study but with flow cytometric quantification of relevant immune cell 
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phenotypes would confirm if expansion in these lymphocytes also occurs in a disease 
setting; similarly, a loss of function study using this experimental model, but with the 
addition of anti-CD11c antibodies, can confirm the relevance of these phagocytotic 
APCs in the exertion of an anti-colitic effect. 
In conclusion, the data within has documented the transcriptional modifications 
induced in CD4+ CD25- adoptive transfer colitis in RAG KO mice.  Transcription of the 
colitic tissue indicated an upregulation in the metabolic, signalling and biological 
process pathways associated with Th1-driven inflammation.  Prophylactic treatment 
with αIL12/23 prevented the development of significant colitis, with a transcriptomic 
profile correlating with a pro-regulatory tolerogenic phenotype, including 
downregulation in transcription related to pro-inflammatory signalling pathways and 
energy metabolism.     Assessment of immune-cell specific genes and the metabolic 
environment similarly indicate prophylactic treatment with Na-AIP-1 induces APC-
driven FoxP3+ TREG proliferation, however this may be driven by disruption of the p38 
MAPK signalling pathway.  Further studies, including MAPK inhibition assays, should 
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Supplementary Figure 5.1:  MA plots utilised in the determination of LFC cut off.  Analysis of MA plots produced using 
consensusDE (Waardenberg and Field 2019).  As filtration and normalisation (FDR, Poisson correction, etc.) is conducted as part of 
the consensusDE analysis, a LogFC cut off between -0.5 to .05 was considered sufficient to remove genes with consistent but small 








Supplementary Figure 5.2:  Scatter plots of GO biological process terms 
enriched in PBS and αIL12/23-treated mice.  Top 20 GO terms associated with 
genes differentially expressed in PBS-treated mice compared to naïve RAG KO 
control mice (A-B).  Top 20 GO terms associated with genes differentially expressed 
in αIL12/23 mice compared to PBS mice (C-D).  Terms are listed by rank.  Frequency 
of all DEGs within the treatment group that are annotated to the respective term are 
represented as Hits (%).  Data was generated using the STRINGdb package in R 






Supplementary Figure 5.3:  Scatter plots of KEGG pathways enriched in PBS 
and αIL12/23-treated mice.  Top 20 KEGG pathways associated with genes 
differentially expressed in PBS-treated mice compared to naïve RAG KO control mice 
(A-B).  Top 20 KEGG pathways associated with genes differentially expressed in 
αIL12/23 mice compared to PBS mice (C-D).  Terms are listed by rank.  Frequency of 
all DEGs within the treatment group that are annotated to the respective term are 
represented as Hits (%).  Data was generated using the STRINGdb package in R 









6 GENERAL DISCUSSION 
 
6.1 Summary of study 
As the burden of conditions driven by inappropriate immune responses continues to 
grow, the need for effective therapeutic interventions has become more critical.  The 
unique symbiotic relationship shared between human and helminth has presented the 
opportunity for the discovery of pharmacopoeia of novel biologics, which come with 
the advantage of a favourable tolerability profile afforded by centuries of co-evolution.  
N. americanus, in particular, exhibits undeniable immunoevasive skill in its ability to 
reside within the human gut for several years, without instigating the inflammatory 
response anticipated against a typical pathogen.  My thesis project involved the 
identification of two TIMP-like proteins in the N. americanus secretome, both notable 
for their homology to molecules responsible for the regulation of inflammation in 
several mammalian species, including humans.  The studies contained within this 
thesis confirm that one of these proteins, subsequently named Na-AIP1, has displayed 
potent immunomodulatory properties in suppressing colitis in distinct murine models 
of disease.   
In the TNBS-induced model of acute chemically-induced colitis, prophylactic i.p. 
delivery of Na-AIP-1 protected against inflammatory pathology.  This was 
demonstrated across immunologically distinct murine strains, and appears dependent 
on the presence of CD11c+ cells.  In the T cell transfer model of murine colitis, 
prophylactic i.p. delivery similarly was able to curtail inflammation, reducing the 
presence of inflammatory CD4+ T cells in the colon.  After injection into mice, Na-AIP-
1 predominantly associates with CD11c-expressing antigen-presenting cells in the 
lung and colon, which was associated with FoxP3+ cell population expansion at these 
sites. Transcriptional profiling of the colon tissue-specific immunomodulatory response 
induced by Na-AIP-1 in the T cell transfer colitis model revealed multiple anti-
inflammatory biological pathways that are shared with anti-IL-12/23p40 mAb 
treatment.  However, Na-AIP-1 appeared to uniquely influence several biological 
processes, including the upregulation of fatty acid metabolism, the suppression of 
TGF-β signalling, and the downregulation of the coagulation cascade.  These studies 
have for the first time validated the immunomodulatory capabilities of a recombinant 
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human helminth-derived TIMP-like protein in suppressing inflammation in various 
murine strains and models of induced colitis. 
 
6.2 Discussion of findings 
The expectation driving the formation of my initial hypothesis was that Na-AIP-1 would 
act similarly to TIMP-like homologs isolated and cloned from the secretions of A. 
caninum, and induce a pro-regulatory immune environment.  Navarro et al. (2016) 
were able to clearly describe a mechanism by which i.p. administration of Ac-AIP-2 
led to an expansion in CD11c+ DC populations in mesenteric lymph nodes, correlating 
with an increase in tolerance-inducing retinaldehyde dehydrogenase activity.  
Treatment with Ac-AIP-2 was also associated with an increase in FoxP3+ TREG cell 
populations at mucosal sites, and a reduction in pro-inflammatory cytokines.  Similarly, 
Ferreira et al. (2017) were able to demonstrate suppression of Th1/Th17-associated 
cytokines in TNBS-induced colitis following Ac-AIP-1 treatment.  An upregulation in IL-
10, accompanying an increased proliferation of TREG cells, was detected in the colon 
at termination.  Na-AIP-1 was also able to potently suppress pro-inflammatory Th1 
cytokine IFNγ and minimise inflammatory pathology in the TNBS-induced colitis 
model; yet, some inconsistencies emerged in the effects of these two proteins on 
leukocyte populations.  Whilst TREG populations were not quantified in the TNBS-
induced colitis studies included within this thesis, FoxP3 transcription was not 
enhanced in the transcriptome of Na-AIP-1-treated RAG KO mice 27 days after 
receiving adoptive transfer of CD4+ CD25- T cells, despite their protection against 
colitis.  Superficially, this suggests that the anti-colitic influence of Na-AIP-1 may not 
be dependent on the presence of TREG cells.  Yet, this contrasts with the immunological 
studies that I have conducted, in which 5 days of i.p. administration of Na-AIP-1 to 
naïve FoxP3 reporter mice significantly enhanced TREG proliferation in the respiratory 
tract and peritoneal cavity, and trended towards the same in colonic tissue, which is 
remarkably consistent with results from a similar study conducted with Ac-AIP-2 
(Navarro et al. 2016).  This raises some interesting possibilities with regards to the 
mechanism of action of Na-AIP-1 potentially being dependent on the disease setting.  
However, the vast difference in the duration of the experimental period between the 
TNBS and adoptive transfer models must also be also considered.  The studies 
involving Ac-AIP-1 (Ferreira et al. 2017) and Ac-AIP-2 (Navarro et al. 2016), and 
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indeed Na-AIP-1, which reported enhanced FoxP3+ cell populations were conducted 
between 1- and 4-days post-administration of the respective molecules.  Termination 
of the CD4+ CD25- adoptive transfer study however, in which I did not detect 
significant upregulation of FoxP3 transcription at termination, came 27 days after 
experimental commencement.  It is therefore possible that TREG proliferation may have 
occurred earlier in the progression of the disease, which had since subsided.  
Alternatively, Na-AIP-1 may not be directly enhancing TREG proliferation or 
transcription, but rather promoting their inhibitory functionality.  Complementary co-
stimulation of ICOS, PD1 and CTLA-4 have been shown to positively influence the 
immunosuppressive capabilities of TREGS, both in vitro and in vivo (Redpath et al. 2013, 
Zhang et al. 2013, Kamada et al. 2019).  In order to determine more conclusively 
whether TREG induction is occurring, it is important that any future repetition of TNBS-
induced colitis studies involving Na-AIP-1 administration includes quantitation of CD4+ 
FoxP3+ cells at termination by flow cytometry.  Additionally, next generation 
sequencing conducted on samples harvested at various earlier timepoints during the 
development of T cell transfer-induced colitis would enable a greater characterisation 
of the mechanisms involved.  Murine loss of function studies utilising knock-out strains 
such as ICOS-/- mice, or via mAb-driven blockade of co-stimulatory molecules, would 
enable further elucidation of the potential influence of Na-AIP-1 on TREG co-stimulation. 
Further to above, the increased frequency of B cells detected in the colon of naïve 
mice during immunological studies (Table 4.1) initially raised the possibility of BREG-
driven immune suppression.  Whilst contribution to a pro-regulatory environment by 
this subset of leukocytes cannot be ruled out, the anti-colitic effect of Na-AIP-1 in the 
T cell transfer model of colitis - where B cells were absent – suggests that the presence 
of regulatory B cells is not critical for Na-AIP-1 to have an anti-inflammatory influence.   
Despite a lack of an increased presence of FoxP3+ TREGS implied by the transcriptional 
studies in the T cell transfer colitis model, a holistic analysis of all of the data presented 
within is highly suggestive of a mechanism that is aligned with A. caninum-derived 
TIMP-like proteins: induction of CD11c+ APC tolerogenicity, which in turn promotes 
the population expansion of FoxP3+ TREGS at mucosal sites.  Moving beyond the loss 
of function and cell uptake studies, there are several ways in which tolerogenicity may 
be measured.  The measurement of retinoic acid activity in peritoneal and colonic DCs 
isolated from Na-AIP-1-treated mice would indicate whether these cells have adopted 
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tolerogenic phenotype (Bakdash et al. 2015).  Alternatively, transcriptional analysis of 
sort-purified APCs isolated from mucosal sites in mice following Na-AIP-1 
administration enables a targeted characterisation of the cellular subsets implied in its 
activity.  Similar studies conducted on in vitro generated human APCs will attest to 
whether there is translational potential for this novel helminth molecule.  Causal 
influence of macrophages, which has similarly been implied in the results to date, can 
be evaluated in vivo via clodronate-induced depletion (Kozicky and Sly 2019).  
The potent effect of i.p. administration of Na-AIP-1 on leukocytes of the respiratory 
tract, whilst not the focus of these studies, was also intriguing.   Na-AIP-1 appears to 
exclusively bind to, or be internalised with, alveolar macrophages in the respiratory 
tract, in addition to promoting FoxP3+ cell population expansion.  This was associated 
with a reduction in the frequency of neutrophils in the lung BAL (Table 4.1).  The 
suppression of neutrophil function in ES-derived molecules has precedent, in the form 
of the Ancylostoma-derived NIF glycoprotein (Ali et al. 2001).  Given the high 
expression of Na-AIP-1 during the alveolar migratory stage of N. americanus life cycle, 
it may be that the lung, and not the gastrointestinal tract, is the target organ of this 
molecule.  Previously, FoxP3+ TREGS have been linked to neutrophil modulation in the 
lung during induced injury by inducing neutrophil apoptosis, inhibiting neutrophil 
recruitment, or promoting neutrophil clearance (D'Alessio et al. 2009, Mock et al. 2019, 
He et al. 2019).  Alternatively, the Na-AIP-1-induced MAPK signalling inhibition 
indicated in the transcriptional studies on colon tissue may be having a systemic effect.  
Disruption of MAPK signalling has been shown to selectively suppress neutrophil 
recruitment in murine models of LPS-induced, tobacco smoke-induced and house dust 
mite-induced lung injury (Nick et al. 2002, Martucci et al. 2017).  Preclinical 
investigations involving the glycosylflavonoid isovitexin in LPS-induced acute lung 
injury reported an association between MAPK and NF-κB downregulation and 
pulmonary neutropaenia (Lv et al. 2016); transcriptional pathways both shown to be 
downregulated in the colon tissue of Na-AIP-1-treated RAG KO mice at termination.    
Certainly, this data combined with the potent efficacy of Ac-AIP-2 in the OVA-induced 
model of murine asthma (Navarro et al. 2016) justifies further investigation into the 
potential of Na-AIP-1 as an effective intervention in pulmonary inflammatory disorders, 
such as asthma, COPD and cystic fibrosis.  Neutrophils perform an important “first-
responder” surveillance function in the lung, and it should be acknowledged that 
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neutropaenia may increase vulnerability to opportunistic bacterial and viral infection, 
and neoplastic expansion, particularly in individuals who already suffer from a chronic 
health condition such as IBD (Newburger and Dale 2013).  Longer term and more 
focused studies are encouraged to examine the clinical potential of Na-AIP-1 in the 
treatment of pulmonary disorders. 
In another point of interest, mRNA transcription of COX2, intimately involved in both 
inflammation and coagulation pathways, was downregulated in Ac-AIP-1-treated mice 
challenged with TNBS (Ferreira et al. 2017).  As blood-feeding parasites, there are 
distinct benefits to hookworms in inhibiting coagulation, and transcriptional data from 
Na-AIP-1 treated mice protected from colitis similarly suggested targeting of the 
complement and coagulation cascade.  However, COX2 transcription was not altered 
in Na-AIP-1-treated mice; instead, proteins of the serpin family were targeted.  
Specifically, Serpind1, is recognised as direct inhibitor of factor IIa (activated 
thrombin), a member of the intrinsic and extrinsic coagulation pathway which has 
become a target in the treatment of thromboembolisms (Moran et al. 2017).  This 
fascinating parallel in activity possibly implies that these unique helminth-derived 
TIMP-like proteins have evolved a complimentary bi-functional purpose.  If so, this 
presents an intriguing precedent.  A similar effect has been associated with helminth-
based molecule TPC (Blank et al. 2018).  TPC is able to suppress inflammation in 
several murine models of inflammatory disease, including DSS-induced colitis and 
collagen-induced rheumatoid arthritis, via concomitant TREG and BREG induction, whilst 
also displaying anticoagulant activity.  However, TPC is a constructed chimeric 
molecule, consisting of the coupling of macrophage-binding immunostimulatory 
peptide tuftsin with the phosphorylcholine moiety previously identified as driving the 
immunomodulatory activity of helminth-derived secretory molecule ES-62 (Harnett et 
al. 2008).  Accordingly, this does not correlate to any native helminth ES protein that 
has been described to date.  However, investigations utilising recombinant H. 
polygyrus-secreted protein HpAri revealed a novel ‘dual binding’ mechanism (Osbourn 
et al. 2017).  In inhibiting the development of murine allergic asthma, HpAri was 
demonstrated to bind directly to IL-33, whilst simultaneously binding to nucleic DNA 
within necrotic cells, via separate active domains.  Yet, this activity via two separate 
domains ultimately achieves the same endpoint of inhibiting IL-33 release.  As such, 
there is no evidence that can be presented at this point that gives indication of any 
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prior unmodified helminth ES-derived molecule which targets two functionally distinct 
biological processes (i.e. the induction of APC tolerogenicity and the inhibition of 
coagulation) via exclusive mechanisms.  Furthermore, it must be acknowledged that 
this thesis has not pursued any investigation of anti-coagulant activity and thus 
building a hypothesis of dual-functionality is premature at this time.  Nonetheless, 
coagulation assays utilising blood drawn from Na-AIP-1-treated mice are 
uncomplicated, and can assess whether and to what degree clot inhibition is indicated, 
and whether this is of any clinical relevance. 
 
6.3 Implications for practice 
The studies of Na-AIP-1 contained within were conducted with the intention of 
presenting a comprehensive pre-clinical portfolio attesting to the validity of this 
molecule as a therapy for human inflammatory disease.  Whilst the elucidation of the 
molecular mechanism remains elusive, Na-AIP-1 nonetheless presents as an 
excellent candidate for further clinical development and characterisation.  Efficient 
yeast-based recombinant production of the protein was achieved with no optimisation 
required, in the widely-utilised Pichia pastoris expression system, making scalability 
to commercial production uncomplicated.  Immunocompetent and 
immunocompromised mice receiving multiple administrations of both i.p. and orally 
delivered formulations of Na-AIP-1, at doses varying from 1 mg/kg to 25 mg/kg, did 
not display any signs or symptoms of toxicity.  Na-AIP-1 has proven tolerable and 
effective in distinct murine models of colitis, across several immunologically diverse 
mouse species.  The experimental data implicates Na-AIP-1 in the suppression of 
colitic conditions involving Th1 responses, suggesting it may be particularly effective 
in the management of the symptoms of Crohn’s Disease (Nemeth et al. 2017).  
Whilst in murine models of induced colitis Na-AIP-1 showed efficacy when delivered 
as a prophylactic intervention prior to the initial establishment of colitis, rather than as 
a rescue treatment in active inflammation, in a real world setting this of course is 
unrealistic; whilst several susceptible genetic loci and environmental factors have 
been identified in the development of IBDs, it is still not possible to predict with 
accuracy individuals in which this condition will actively emerge.  However, the 
relapsing-remitting nature of IBDs allows a unique advantage in treatment strategies.  
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In a clinical setting, for a diagnosis of IBD to be made, an individual must present with 
at least one active period of inflammatory disease (Maaser et al. 2018). I propose that 
this period of acute inflammation is brought into remission using methods based on 
current clinical guidelines, with therapy to be determined dependent on the anatomic 
distribution and severity of the disease (Lichtenstein et al. 2018). I envisage the 
optimal treatment window for Na-AIP-1 therapy would be after the resolution of acute 
disease activity.  I propose that during this time, Na-AIP-1 be utilised to redress the 
autoimmune hypersensitivity typified in CD, and other Th1-dominated IBDs, thereby 
extending the period of remission and reducing - potentially preventing - any further 
active periods of disease.   
One significant challenge to be overcome regarding Na-AIP-1 therapy involves the 
delivery method.  In murine colitis, Na-AIP-1 was potent when delivered via i.p. 
injection, but did not show anti-colitic activity when delivered by oral gavage.  
Furthermore, efficacy was potentiated by a multiple dose regimen.  In the development 
of novel therapeutics, formulations delivered orally are considered desirable, 
particularly for sustained therapies, as their ease of delivery and pain-free non-
invasive nature will usually result in heightened patient adherence (Homayun et al. 
2019).  Yet, the proteinaceous nature of Na-AIP-1 combined with the highly acidic and 
enzymatic environment inside the stomach means traditional oral delivery methods 
may result in the denaturing of the protein before absorption is able to occur.  Ideally, 
therapeutics utilised in the treatment of colitic inflammation should be delivered directly 
to the intestinal mucosa for maximal bioavailability at the site of inflammation; to this 
end, a variety of colon-specific drug delivery systems are currently under 
development, including pH sensitive nanoparticles, timed-release formulations and 
rectal gels (Amidon et al. 2015, Goyal et al. 2018).  One particularly novel and relevant 
delivery method which may be particularly suited to Na-AIP-1 therapy in CD is the use 
of ‘live therapeutics’ in the form of probiotic drug delivery.  This methodology involves 
the supplementation of intestinal microbiome with non-pathogenic bacteria which have 
been engineered to secrete immunomodulatory molecules (Mathipa and Thantsha 
2017); effectively, an in vivo inducible protein expression system similar to the P. 
pastoris system utilised in the lab-based production of recombinant Na-AIP-1.  A. 
vitae-derived immunosuppressive molecule AvCys has shown anti-colitic efficacy 
when delivered in this fashion (Whelan et al. 2014).  In this study, a strain of probiotic 
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Escherichia coli was modified to enable secretion of this recombinant protein, and 
delivered to mice during the onset of DSS colitis.  Terminal assessments confirmed a 
significant protection against inflammatory pathology, with evidence of TREG induction 
and a suppression of Th1 and Th17-related cytokines. Similarly, studies conducted by 
Allain et al. (2016) were able to induce effective delivery of recombinant murine IL-10 
directly to colonic mucosal surfaces by attenuated lactobacilli, generating a moderate 
suppression of pro-inflammatory cytokines during DNBS-induced colitis.  Intestinal 
dysbiosis has been correlated with the pathogenesis of IBDs, and as such probiotic 
supplementation, or more recently faecal transplantation, with formulations containing 
several beneficial bacteria including Lactobacillus, is often employed as an adjunct to 
traditional pharmaceutical based therapies to extend periods of remission (Gevers et 
al. 2014, Nishida et al. 2018).  Probiotic expression of Na-AIP-1 using this platform 
could accordingly eventually enable treatment to be delivered via innovative food-
based probiotic formulations, such as yoghurts or fermented drinks. 
 
6.4 Further directions of research 
Over the past decade, the field of molecular immunoparasitology has evolved 
immeasurably.  The continued characterisation of the remarkably sophisticated 
interaction between human and helminth has brought us the opportunity to exploit the 
evolutionary advantages afforded to these “old friends” and utilise them in the fight 
against human disease.  The identification, isolation and recombinant production of 
hookworm-derived TIMP-like proteins may prove to be the greatest legacy of our 
coevolution yet.  Several critical avenues for further exploration have arisen from the 
studies contained within. 
The potent efficacy of Na-AIP-1 certainly warrants further examination in both murine 
and human inflammatory conditions.  The identification of binding partners and the 
characterisation of the pharmacokinetics involved in Na-AIP-1 metabolism are 
fundamental in the determination of its potential for development as a druggable 
compound.  Indeed, to date the effect of Na-AIP-1 on human cells is yet to be explored, 
although in vitro studies have indicated the tolerogenic impact of Ac-AIP-2 does 
translate to human PBMCs (Navarro et al. 2016).  The high level of homology between 
Ac-AIP-2 and Na-AIP-1, combined with the anthropophilic nature of N. americanus, 
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leads to the hypothesis that Na-AIP-1 will similarly exert an anti-inflammatory effect on 
human cells; in fact, it is not unreasonable to expect that Na-AIP-1 may be more suited 
to biopharmaceutical development.  In vitro human PBMC and gut biopsy tissue 
studies including analysis of inflammatory cytokine responses and mRNA sequencing 
will give indication as to the translatability of Na-AIP-1 as a therapeutic for human 
development. 
What little is understood regarding this family of unique molecules seemingly 
confounds expectations based on current knowledge; they remain the only N-terminal 
netrin domain bearing protein which has been identified outside of mammalian TIMPs, 
to which they display a high level of sequence conservation, and similarly modulate 
inflammation.  Yet, helminth-derived TIMP-like proteins show no evidence of MMP 
specificity or inhibition in the exertion of their anti-inflammatory effect.  A 
comprehensive characterisation of the structure of Ancylostoma ceylanicum ES 
protein AceES-2 confirmed the TIMP-like homology of the N-terminal netrin domain, 
but was unable to induce inhibition against the 10 most abundant human MMPs 
(Kucera et al. 2011).  Studies in animal models of inflammatory disease instead 
suggest immune modulation by way of APC tolerogenicity.  An additional level of 
complexity is added when considering NECAME_13168; despite a high level of 
homology with Na-AIP-1 and a similar heightened transcription during the infectious 
stage of the parasitic life cycle, this molecule displayed no anti-inflammatory 
properties, suggesting either no immunomodulatory influence, or a potential lack of 
suitability for recombinant production in the P. pastoris system.  The likely 
physiological role of NECAME_13168 remains unclear at this stage, and potentially in 
contradiction to other TIMP-like proteins.  However, identification of sequential or 
morphological divergences from Na-AIP-1, Ac-AIP-1 and Ac-AIP-2 may assist on the 
determination of regions contributing to anti-inflammatory activity.  Furthermore, 
definitive structural determination using nuclear magnetic resonance or X-ray 
crystallography should be conducted in order to solve the structures of these three 
unique proteins.  
Finally, the potential efficacy of Na-AIP-1 therapy should be explored in other 
inflammatory conditions.  Immunological studies indicated that Na-AIP-1 
administration may induce a proliferation of TREGS and a suppression of neutrophils in 
the respiratory tract.  Therefore, the hypothesis that Na-AIP-1 will suppress human 
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pulmonary inflammation or fibrosis, potentially to a greater degree than canine 
hookworm-derived Ac-AIP-2, presents as logical.  Pilot studies conducted in the 
murine collagen-induced arthritis model (Haleagrahara et al., unpublished) have also 
indicated a role for Na-AIP-1 therapy in the suppression of this condition. 
 
6.5 Conclusions 
I have demonstrated within the prophylactic efficacy of recombinantly produced 
hookworm-derived ES molecule Na-AIP-1 in the amelioration of clinical and 
histological indicators of colitis in two distinct murine models of IBD.  In the chemically-
induced TNBS model of acute colitis, this effect is dependent on the presence of 
CD11c+ APCs.  In the CD4+ CD25- adoptive transfer-induced model of chronic colitis, 
where inflammation is instigated by a disruption in T cell homeostasis, prophylactic 
administration of Na-AIP-1 induced a transcriptomic profile which correlates with a 
downregulation in metabolic and signalling pathways associated with Th1 
inflammation.  Furthermore, I have established that administration of Na-AIP-1 in 
healthy, immunocompetent mice induces FoxP3+ cell proliferation at mucosal tissue 
sites.   
Various studies have documented the alleviation of the symptoms of inflammatory 
disease associated with live helminth infection.  Previously, Navarro et al. (2016) and 
Ferreira et al. (2017) were able to demonstrate the potent anti-inflammatory influence 
of canine helminth derived TIMP-like proteins in murine models of induced asthma 
and colitis, driven by the instigation of a pro-regulatory immune environment.  
However, this thesis for the first time presents the effect of a similar TIMP-like homolog 
isolated from the secretome of the human hookworm N. americanus.  I have also for 
the first time described the transcriptional profile of colon tissue in RAG KO mice with 
CD4+ CD25- adoptive transfer-induced colitis that have received either prophylactic 
administration of PBS or anti-IL-12/23 (p40) monoclonal antibodies.   
I have validated that Na-AIP-1 is safely tolerated following multiple administrations of 
concentrations varying from 1 mg/kg to 25 mg/kg.  Efficient formulation of the 
recombinant protein was achieved with no optimisation, in a system which can be 
scaled up for commercial production.  Significant abatement of inflammatory pathology 
was evidenced in distinct models of murine colitis, across varying experimental 
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conditions and in several immunologically diverse murine strains.  Whilst the immune 
environment induced by exposure to this unique immunomodulatory molecule has 
been relatively well characterised, the active site of the protein, binding partners and 
molecular mechanism of action driving this effect remains elusive.  It is my hope that 
the research presented here validates the suitably of Na-AIP-1 for further development 
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